WO2007021982A2 - Modulators of cystic fibrosis transmembrane conductance regulator - Google Patents

Modulators of cystic fibrosis transmembrane conductance regulator Download PDF

Info

Publication number
WO2007021982A2
WO2007021982A2 PCT/US2006/031457 US2006031457W WO2007021982A2 WO 2007021982 A2 WO2007021982 A2 WO 2007021982A2 US 2006031457 W US2006031457 W US 2006031457W WO 2007021982 A2 WO2007021982 A2 WO 2007021982A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
methyl
dioxol
thiazol
Prior art date
Application number
PCT/US2006/031457
Other languages
French (fr)
Other versions
WO2007021982A3 (en
Inventor
Ruah Sara Hadida
Jingaln ZHOU
Frederick F. Vangoor
Mark T. Miller
Jason Mccartney
Vijayalaksmi Arumugam
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to AT06801307T priority Critical patent/ATE512145T1/en
Priority to NZ566208A priority patent/NZ566208A/en
Priority to JP2008526246A priority patent/JP5143738B2/en
Priority to EP06801307A priority patent/EP1912983B1/en
Priority to AU2006279810A priority patent/AU2006279810B2/en
Priority to CA002618057A priority patent/CA2618057A1/en
Priority to MX2008002019A priority patent/MX2008002019A/en
Publication of WO2007021982A2 publication Critical patent/WO2007021982A2/en
Publication of WO2007021982A3 publication Critical patent/WO2007021982A3/en
Priority to IL189178A priority patent/IL189178A0/en
Priority to NO20081280A priority patent/NO20081280L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus

Definitions

  • the present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof, and methods therewith.
  • CFTR cystic fibrosis Transmembrane Conductance Regulator
  • the present invention also relates to methods of treating CFTR mediated diseases using such modulators.
  • ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions.
  • ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities.
  • Some of these transporters were discovered as multidrug resistance proteins (like the MDRl-P glycoprotein, or the multidrug resistance protein, MRPl), defending malignant cancer cells against chemotherapeutic agents.
  • MRPl multidrug resistance protein
  • 48 ABC Transporters have been identified and grouped into 7 families based on their sequence identity and function.
  • ABC transporters regulate a variety of important physiological roles within the body and provide defense against harmful environmental compounds. Because of this, they represent important potential drug targets for the treatment of diseases associated with defects in the transporter, prevention of drug transport out of the target cell, and intervention in other diseases in which modulation of ABC transporter activity may be beneficial.
  • CFTR cAMP/ ATP -mediated anion channel
  • CFTR is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
  • CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeate of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • cystic fibrosis hi patients with cystic fibrosis, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in cystic fibrosis patients, hi addition to respiratory disease, cystic fibrosis patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death, hi addition, the majority of males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis.
  • cystic fibrosis associated gene In contrast to the severe effects of two copies of the cystic fibrosis associated gene, individuals with a single copy of the cystic fibrosis associated gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea - perhaps explaining the relatively high frequency of the cystic fibrosis gene within the population.
  • the most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as ⁇ F508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease .
  • CFTR transports a variety of molecules in addition to anions
  • this role represents one element in an important mechanism of transporting ions and water across the epithelium.
  • the other elements include the epithelial Na + channel, ENaC, Na + /2C17K + co-transporter, Na + -K + - ATPase pump and the basolateral membrane K + channels, that are responsible for the uptake of chloride into the cell.
  • CFTR Arrangement of Na + /2C17K + co-transporter, Na + -K + -ATPase pump and the basolateral membrane K + channels on the basolateral surface and CFTR on the luminal side coordinate the secretion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia depends on tiny transepithelial osmotic gradients generated by the bulk flow of sodium and chloride. [0011] In addition to cystic fibrosis, modulation of CFTR activity may be beneficial for other diseases not directly caused by mutations in CFTR, such as secretory diseases and other protein folding diseases mediated by CFTR. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • dry eye disease dry eye disease
  • Sjogren's Syndrome Sjogren's Syndrome.
  • COPD is characterized by airflow limitation that is progressive and not fully reversible.
  • the airflow limitation is due to mucus hypersecretion, emphysema, and bronchiolitis.
  • Activators of mutant or wild-type CFTR offer a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD.
  • increasing anion secretion across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimized periciliary fluid viscosity. This would lead to enhanced mucociliary clearance and a reduction in the symptoms associated with COPD.
  • Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles.
  • Sjogrens's syndrome is an autoimmune disease in which the immune system attacks moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as well as lung disease.
  • the disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Modulators of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.
  • the diseases associated with the first class of ER malfunction are cystic fibrosis (due to misfolded ⁇ F508-CFTR as discussed above), hereditary emphysema (due to al -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to ⁇ -hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl- sialyc-transferase), polyendoc
  • the diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to ⁇ l -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to ⁇ l-antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasopvessin hormone/V2-receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to ⁇ APP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy,
  • CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport.
  • the mechanism involves elevation of cAMP and stimulation of CFTR.
  • Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old.
  • Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement, as well as in response to a variety of bacterial or viral infections and generally occurs within the first few hours of the animal's life.
  • ETEC enterotoxogenic E-coli
  • Common viral causes of diarrhea include rotavirus and coronavirus.
  • Other infectious agents include Cryptosporidium, giardia lamblia, and salmonella, among others.
  • Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus causes a more severe illness in the newborn animals, and has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease. IDU21] Accordingly, there is a need for modulators of CFTR activity, and compositions thereof, that can be used to modulate the activity of the CFTR in the cell membrane of a mammal.
  • compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, diabetes mellitus, laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1,
  • each R x is independently hydrogen, halo, CF 3 , C1-C4 alkyl, or -OC1-C4 alkyl; provided that both R x are not simultaneously hydrogen; or the two R x , taken together form ring (a):
  • X is CH 2 , CF 2 , CH 2 -CH 2 , or CF 2 -CF 2 ;
  • ring A is 3-7 membered monocyclic cycloalkyl ring;
  • R' is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO 2 -, -NR-, -SO 2 NR-, NRSO 2 -, or -NRSO 2 NR-;
  • R is hydrogen or C1-C6 aliphatic; Z is an electron withdrawing substituent; and q is 0-3.
  • CFTR cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, ⁇ F508 CFTR and G551D CFTR (see, e.g., https://www.genet.sickkids.on.ca/cftr/. for CFTR mutations).
  • modulating means increasing or decreasing by a measurable amount.
  • correction means increasing the number of CFTR in a membrane of a cell.
  • potentiator means a compound that increases the gating activity of CFTR in a membrane of a cell.
  • electronegative substituent means an atom or a group that is electronegative relative to hydrogen. See, e.g., “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," Jerry March, 4 th Ed., John Wiley & Sons (1992), e.g., pp. 14-16, 18-19, etc. Exemplary such substituents include halo, CN, COOH, CF 3 , etc.
  • aliphatic or "aliphatic group” by itself, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” "cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-20 aliphatic carbon atoms.
  • aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms, hi still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms.
  • cycloaliphatic refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers, including mixtures containing an excess of one enantiomer relative to the other enantiomer or an excess of one diastereomer relative to another.
  • single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention.
  • each R x is independently hydrogen, halo, or CF 3 ; provided that both R x are not simultaneously hydrogen.
  • one R x is hydrogen and the other R x is halo or CF 3 .
  • both R x are halo.
  • X is CH 2 . In other embodiments, X is CF 2 . Or, X is CH 2 -CH 2 . In certain other embodiments, X is CF 2 -CF 2 ;
  • ring A is cyclopropyl, cyclopentyl, or cyclohexyl. In another embodiment, ring A is cyclopropyl or cyclopentyl. In certain embodiments, ring A is cyclopropyl.
  • R is hydrogen. Or, R is C1-C6 alkyl. Exemplary R includes methyl, ethyl, or propyl.
  • R' is hydrogen. Or, R' is Cl -C6 alkyl. Exemplary R' include methyl, ethyl, propyl, or C(O)Me.
  • R AA and R BB taken together, form a pyrrolidinyl with an OH substituent.
  • Z is selected from halo, CF 3 , or difluoromethylenedioxy.
  • q is 0. Or, q is 1-2. hi certain embodiments, q is 1. Or, q is 2.
  • compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two R x are taken together to form ring (a);
  • X is CH 2 ; ring A is cyclopropyl;
  • R' is hydrogen; q is 1 or 2;
  • Z is halo, CF 3 , or difluoromethylenedioxy.
  • compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two R x are taken together to form ring (a);
  • X is CH 2 ;
  • R is hydrogen; ring A is cyclopropyl;
  • R' is hydrogen; q is 1 or 2;
  • compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two R x are taken together to form ring (a);
  • ring A is cyclopropyl
  • R' is hydrogen; q is 1 or 2;
  • Z is halo, CF 3 , or difluoromethylenedioxy.
  • compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two R x are taken together to form ring (a);
  • X is CF 2 ;
  • R is hydrogen; ring A is cyclopropyl;
  • R' is hydrogen; q is 1 or 2;
  • Z is halo, CF 3 , or difluoromethylenedioxy.
  • R AA and R BB taken together with the nitrogen atom, form the following ring (ii):
  • the present invention provides intermediates having formula I' or formula II':
  • R , R, ring A, Z, and q are as defined above; L is a linker selected from C(O) , SO 2 ; p is 0 or 1 ; and CA is a suitable chiral auxiliary.
  • chiral auxiliary as used herein means an asymmetric molecule or molecular fragment that is used to achieve the chemical resolution of a racemic or diastereomeric mixture.
  • Such chiral auxiliaries may possess one chiral center such as methylbenzylamine or several chiral centers such as menthol.
  • the purpose of a chiral auxiliary, once built into the starting material, is to allow simple separation of the resulting diastereomeric mixture. See, for example, J. Jacques et al., “Enantiomers, Racemates And Resolutions, ' " pp. 251-369, John Wiley & Sons, New York (1981); E. L. Eliel & S. H. Wilen, "Stereochemistry of Organic Compounds:' pp. 868-870, John Wiley & Sons (1994).
  • Suitable chiral auxiliaries useful in the present invention include those that are amenable to attachment to the linker L above (i.e., p is 1) or directly to the oxygen atom (i.e., p is 0). Exemplary such chiral auxiliaries are found in, e.g., E. L. Eliel & S. H. Wilen, ibid, pp. 337-340.
  • CA, L, p, and the oxygen atom linked thereto, taken together is (+)-10-camphorsulfonate, (IS, 4i?)-(-)- ⁇ -camphanic ester, (Ii?, 2S, 5i?)-(-) mentholcarbonate, (IS, 2R, 55)-(+)-mentholcarbonate, (Ii?, 2i?)-l ⁇ phenyl-2-cyclopropylester, or (3i?)-tetrahydrofuran-3 -carbonate.
  • the present invention provides a method for producing a compound of formula I or formula II:
  • each R >x A is independently hydrogen, halo, CF 3 , C1-C4 alkyl, or -OC1-C4 alkyl; provided that both R x are not simultaneously hydrogen; or the two R >x ⁇ , taken together form ring (a):
  • X is CH 2 , CF 2 , CH 2 -CH 2 , or CF 2 -CF 2 ;
  • ring A is 3-7 membered monocyclic cycloalkyl ring;
  • R' is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO 2 -, -OCO-, -NRCO 2 -, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO 2 -, -NR-, -SO 2 NR-, NRSO 2 -, or -NRSO 2 NR-;
  • R is hydrogen or C1-C6 aliphatic;
  • Z is an electron withdrawing substituent; and q is 0-3; and LG 1 is a first suitable leaving group
  • first suitable conditions means conditions suitable to effectuate the reaction between compound of formula I-A and compound of formula R-I or between compound of formula II-A and compound of formula R-I.
  • suitable conditions include, e.g., a first suitable solvent, a first suitable temperature, and a suitable reducing agent.
  • suitable conditions include, e.g., a first suitable solvent, a first suitable temperature, and a suitable reducing agent.
  • the first suitable solvent is a polar aprotic, a polar protic solvent, an apolar solvent, or a suitable combination thereof.
  • Exemplary solvents useful as first suitable solvent include methanol, ethanol, propanol, isopropanol, t-butanol, dichloromethane, dichloroethane, toluene, tetrahydrofuran, dioxane, diethylether, dimethylether, acetonitrile, dimethylformamide, DMAC, or NMP.
  • the first suitable temperature is a temperature that is sufficient to effectuate the reaction between compound of formula I-A and compound of formula R-I in the first suitable solvent. In another embodiment, the first suitable temperature is a temperature that is sufficient to effectuate the reaction between compound of formula II-A and compound of formula R-I in the first suitable solvent. Exemplary first suitable temperature includes between about 0 °C to about 110 °C. In one embodiment, the first suitable temperature is between about 0 0 C to about 25 0 C.
  • the suitable reducing agent is a reducing agent that is capable effectuating the reaction between compound of formula I-A and compound of formula R-I.
  • the suitable reducing agent is a reducing agent that is capable effectuating the reaction between compound of formula H-A and compound of formula R-I.
  • Agents suitable for the present invention include a metallo-borohydride or a reagent capable of catalytic hydrogenation.
  • Exemplary such suitable reducing agents include sodium borohydride, sodium cyanoborohydride, lithium borohydride, sodium triacetoxyborohydride, calcium borohydride, hydrogene in the presence of a suitable metal catalyst such as Pd/C.
  • LG 1 is a first suitable leaving group that is capable of displacement to produce compound of formula I. or compound of formula II. See, "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,” pp. 339-357, Jerry March, 4 th Ed., John Wiley & Sons (1992).
  • LG 1 is selected from alkysulfonate, arylsulfonate, halide, alkyl carboxylate.
  • a "suitable chiral auxiliary" above in compound of formula H-B or formula I-B is a chiral auxiliary that is capable of attachment to an amino group.
  • An isomeric mixture of a compound containing such an amino group with a suitable chiral auxiliary attached thereto is readily separated into its individual isomers by suitable separation means. See, for example, J. Jacques et al., "Enantiomers, Racemates And Resolutions," pp. 251-369, John Wiley & Sons, New York (1981); E. L. Eliel & S. H. Wilen, "Stereochemistry of Organic Compounds," pp. 868-870, John Wiley & Sons (1994).
  • said suitable chiral auxiliary is an alkylsulfoxyl group.
  • said suitable second conditions comprises a suitable protic acid and a suitable second solvent.
  • said suitable second solvent is selected from a polar aprotic solvent or a protic solvent.
  • polar aprotic solvents include dioxane, tetrahydrofurane, diethyl ethez * , dichloromethane, etc.
  • protic solvents include methanol, ethanol, z-propanaol, ⁇ -butanol, etc.
  • said suitable second solvent is a polar aprotic solvent.
  • said compound of formula I-B and compound of formula H-B is produced by reacting, respectively, a compound of formula I-C or formula II- C with a compound of formula R-2 under a third suitable conditions:
  • R is hydrogen or C1-C6 aliphatic
  • R 1 is hydrogen or a first suitable protecting group
  • [CA] is a suitable chiral auxiliary
  • LG 2 is a second suitable leaving group.
  • LG 2 is selected from halide, OC(O)(Cl-Co alkyl), pentafluorophenoxy, C1-C6 alkoxy, OCO 2 (C 1-C6 alkyl) or hydroxy.
  • R 1 is hydrogen
  • said third suitable conditions comprises a third suitable coupling agent and a third suitable solvent.
  • said suitable coupling agent is selected from DCC 5 DCI, HATU, TCPH, or HBTU.
  • said third suitable solvent is selected from dichloromethane, dioxane, acetonitrile, DMF, dichloroethane, or tetrahydrofuran.
  • said compound of formula I-C or formula H-C is produced from an isomeric mixture of a compound of formula R-3:
  • R, Z, and q are as defined above;
  • PGj is a second suitable protecting group; and [CA] is a suitable chiral auxiliary; said method comprising two steps, wherein one of said two steps is separating said isomeric mixture using suitable separation means, and the other of said two steps is the conversion OfPG 1 to R 1 in a fourth suitable conditions.
  • said suitable separation means comprises suitable chromatographic means.
  • suitable chromatographic means include column chromatography or thin layer chromatography.
  • said suitable separation means comprises suitable crystallization means.
  • said fourth suitable conditions comprises a suitable deprotecting reagent and a fourth suitable solvent.
  • An exemplary suitable deprotecting reagent is trifluoroacetic acid.
  • said fourth suitable solvent is a polar aprotic solvent.
  • exemplary solvents include dichloromethane, tetrahydrofuran, dioxane, diethyl ether, etc.
  • said compound of formula R-3 is produced from a compound of formula R-4 and a compound of formula R-5:
  • PG 1 is a second suitable protecting group; M is a suitable metal cation; and [CA] is a suitable chiral auxiliary; said method comprising the steps of reacting said compound of formula R-4 with said compound of formula R-5 in a fifth suitable conditions.
  • said M is selected from Li + , Na + , or Mg +"1" .
  • said PG 1 is selected from an alkylcarbamate, trifluoroacetyl, trialkylsilyl, or pivaloyl. Or, said PG 1 is BOC or trimethylsilyl.
  • said fifth suitable conditions comprises a fifth suitable solvent and a fifth suitable temperature. In one embodiment, said suitable temperature is about -78 degrees C.
  • said fifth suitable solvent is tetrahydrofuran.
  • said compound of formula R-I is:
  • said compound of formula I or formula II are selected from Table 1.
  • Scheme I-B illustrates a process for producing intermediate B.
  • Scheme I-B a) Br 2 ; b) thiourea, (Me) 2 NCH(OMe) 2 ; c) HCl
  • Scheme H-A illustrates another exemplary process for preparing compounds of the present invention using a chiral auxiliary.
  • Scheme II-B illustrates a process for preparing an exemplary compound of the present invention using a chiral auxiliary.
  • Scheme III illustrates another process for preparing a compound of the present invention.
  • the present invention provides compounds that are useful as modulators of CFTR and thus are useful in the treatment of disease, disorders or conditions such as Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary
  • compositions comprising any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • these compositions optionally further comprise one or more additional therapeutic agents.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term “inhibitorily active metabolite or residue thereof means that a metabolite or residue thereof is also an inhibitor of an ATP -Binding Cassette Transporters.
  • compositions of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fo ⁇ nate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pec
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C i-4alkyl)4 salts.
  • This invention also envisions the quaternization of any basic nitrogen- containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxyniethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; ge
  • the present invention provides a method of treating a condition, disease, or disorder implicated by CFTR.
  • the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of CFTR, the method comprising administering a composition comprising a compound of formula (I) to a subject, preferably a mammal, in need thereof.
  • the present invention provides a method of treating cystic fibrosis, hereditary emphysema (due to al -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to ⁇ -hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), polyendocrinopathy/hyperinsulemia, diabetes mell
  • the diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to ⁇ l -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to ⁇ l- antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasopvessin hormone/V2- receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to ⁇ APP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick'
  • the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
  • an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of cystic fibrosis, hereditary emphysema (due to al -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to ⁇ -hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transfer
  • the diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to ⁇ l -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to ⁇ l- antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasopvessin hormone/V2- receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to ⁇ APP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick'
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of cystic fibrosis, hereditary emphysema (due to a 1 -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to ⁇ - hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl
  • the diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to ⁇ l -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to ⁇ l-antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasop ' vessin hormone/V2 -receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus- Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to ⁇ APP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emu ⁇ sif ⁇ ers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can contain inert diluents commonly used in the art such as,
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • a compound of the present invention hi order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by fo ⁇ ning microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as. sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absoiption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical fonnulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. Pn such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the compounds of the invention are useful as modulators of CFTR.
  • the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of CFTR is implicated in the disease, condition, or disorder.
  • the disease, condition, or disorder may also be referred to as a "CFTR-mediated disease, condition or disorder".
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of an CFTR is implicated in the disease state.
  • the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility .of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition are known as "appropriate for the disease, or condition, being treated".
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the present invention in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to modulating CFTR activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Modulation of CFTR activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such memeposes include, but are not limited to, the study of CFTR in biological and pathological phenomena; and the comparative evaluation of new modulators of CFTR.
  • a method of modulating activity of an anion channel in vitro or in vivo comprising the step of contacting said channel with a compound of formula (I).
  • the anion channel is a chloride channel or a bicarbonate channel, hi other preferred embodiments, the anion channel is a chloride channel.
  • the present invention provides a method of increasing the number of functional CFTR in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (T).
  • a compound of formula (T) as used herein means an CFTR that is capable of transport activity.
  • the activity of the CFTR is measured by measuring the transmembrane voltage potential.
  • Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
  • the optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (Sea, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (Se ⁇ 1 Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIP Voltage/Ion Probe Reader
  • These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC 2 (3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor.
  • FRET fluorescence resonant energy transfer
  • Changes in membrane potential (V 1n ) cause the negatively charged DiSBAC 2 (3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly.
  • the changes in fluorescence emission can be monitored using VIPRTM II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
  • the present invention provides a kit for use in measuring the activity of a CFTR or a fragment thereof in a biological sample in vitro or in vivo comprising (i) a composition comprising a compound of formula (I) or any of the above embodiments; and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said CFTR or a fragment thereof.
  • the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the CFTR in the presence of the additional compound with the density of the CFTR in the presence of a composition of formula (I).
  • the kit is used to measure the density of CFTR.
  • the dark brown/black reaction mixture was diluted with water (400 mL) and extracted twice with equal volumes ethyl acetate and dichloromethane.
  • the basic aqueous solution was acidified with concentrated hydrochloric acid to pH less than one and the precipitate was filtered and washed with 1 M hydrochloric acid.
  • the solid material was dissolved in dichloromethane (400 mL) and extracted twice with equal volumes of 1 M hydrochloric acid and once with a saturated aqueous solution of sodium chloride.
  • the organic solution was dried over sodium sulfate and evaporated to dryness to give a white to slightly off- white solid (5.23 g, 25.4 mmol, 80.1 %).
  • ESI-MS m/z calc.
  • the first eluting product under these conditions had a retention time of 8.2 min (Chiralpak AS-H column). This product had a retention time 14.5 min. on a Chiralpak OJ- H 4.6 mm x 250 mm column (25% of a 50/50 (v/v) mixture of ethanol and methanol in hexanes at 1.0 mL/min.)
  • the second eluting product (( ⁇ )-l-((R)-(2-(l-(benzo[ ⁇ /][l,3]dioxol-6- yl)cyclopropanecarboxamido)thiazoI-5-yl)(2-chlorophenyI)methyI)pyrroIidin-3-yI (liS',2i?,5S)-2-isopropyl-5-methylcyclohexyl carbonate) had a retention time of 28.6 min (Chiralpak AD column). ESI-MS m/z calc. 679.3, found; 680.5 (M+l) + ; Retention time 3.86 minutes.
  • reaction mixture was allowed to warm up to 25 0 C, stirred at 25 0 C for 18 h, quenched with NaHCO 3 and then filtered through a short plug of Celite using EtOAc. The organic layer was separated from the aqueous layer and dried over Na 2 SO 4 and concentrated. The crude product was purified by column chromatography (0-25% EtOAc/Hexane) to provide (i?)-N-(2-chlorobenzylidene)-l,l-dimethylethylsulfinamide as a yellow liquid (45.1 g, 75%).
  • the crude product was purified by column chromatography (0- 80% EtOAc/Hexane) to provide a diastereomeric mixture of (i?)-N-(l-((2-t- butoxylcarbonylamino)thiazol-5-yl)- 1 -(2-chlorophenyl)-methyl)- 1 , 1 -dimethyl ethylsulf ⁇ namide as a yellow solid (15.1 g, 83%) that was used directly in the next step.
  • the crude product was purified by column chromatography (0- 5% EtOH/EtOAc) to provide (i?)-N-(,S)-l-(2-aminothiazol-5-yl)-l-(2-chlorophenyl)methyl)-l,l- dimethylethylsulfmamide and (RyN-(R)- 1 -(2-aminothiazol-5-yl)- 1 -(2-chlorophenyl)methyl)- 1.1- dimethylethylsulfinamide.
  • reaction mixture was stirred at 25 0 C for 18 h, diluted with CH 2 Cl 2 and washed with 1 N HCl (50 mL X 2), NaHCO 3 (50 mL X 1) and brine (50 mL X 1).
  • the organic layer was separated from the aqueous layer, dried over Na 2 SO 4 and concentrated.
  • the dark brown/black reaction mixture was diluted with water (400 mL) and extracted twice with equal volumes of ethyl acetate and dichloromethane.
  • the basic aqueous solution was acidified with concentrated hydrochloric acid to pH less than one and the precipitate was filtered and washed with 1 M hydrochloric acid.
  • the solid material was dissolved in dichloromethane (400 mL) and washed twice with equal volumes of 1 M hydrochloric acid and once with brine.
  • the organic solution was dried over sodium sulfate and evaporated to dryness to give a white to slightly off-white solid (5.23 g, 80.1 %).
  • Method A Methyl 2,2-difluorobenzo[ ⁇ f][l,3]dioxole-5-carboxylate from previous step (11.5 g) dissolved in anhydrous tetrahydrofuran (20 mL) was slowly added to a suspension of lithium aluminum hydride (4.10 g, 106 mmol) in anhydrous THF (100 mL) at 0 0 C. The mixture was then warmed to room temperature and stirred at for 1 h. The reaction mixture was cooled to 0 °C and treated with water (4.1 g), followed by sodium hydroxide (10% aqueous solution, 4.1 mL). The resulting slurry was filtered and washed with THF.
  • l-(2,2-difluorobenzo[ ⁇ i][l,3]dioxol-5-yl)cyclopropanecarboxylic acid was made by the procedure used for l-(benzo[ ⁇ f][l,3]dioxol-5-yi)cyclopropanecarboxylic acid, starting from 2-(2,2- difluorobenzo[ ⁇ i][l,3]dioxol-5-yl)acetonitrile. Yield (86%) of a white solid.
  • (R)-N-(3,4-Dichlorobenzylidene)-2-methylpropane-2-sulfinamide was made by the procedure used for (R)-N-(2-chlorobenzylidene)-2-methylpropane-2-sulfinamide, starting from 3,4-dichlorobenzaldehyde and (i?)-2-methylpropanesulfmamide. Yield (93%) of a yellow oil that crystallizes upon standing.
  • the crude product was purified by column chromatography to provide a diasteriomeric mixture of (S)-tert-butyl 5-((2-chloiO-4-fluorophenyi)(l,l- dimethylethylsulfinamido)methyl) thiazol-2-ylcarbamate as an orange-yellow solid (95%) that was used without further purification.
  • the cmde product was purified by column chromatography to provide a diasteriomeric mixture of (R)-tert-butyl 5-((4-chloro-2-fluorophenyl)(l,l- dimethylethylsulfinamido)methyl) thiazol-2-ylcarbamate (78%) that was used without further purification.
  • (R)-ferf-Butyl 5-((3 ,4-dichlorophenyl)( 1 , 1 -dimethylethylsulfmamido) methyl)thiazol-2-ylcarbamate was made by the procedure used for (R)-fert-butyl 5-((2-chloro- 4-fluorophenyl)(l,l-dimethylethylsulfinamido)methyl)thiazol-2-ylcarbamate, starting from tert-butyl thiazol-2-ylcarbamate and (R)-N-(3,4-dichlorobenzylidene)-2-methylpropane-2- sulfinamide.
  • the crude product was purified by column chromatography (excess tert-butyl thiazol-2-ylcarbamate is eluted at 70% EtOAc/hexane, the desired product follows at 0-15% MeOH/EtOAc) to provide a diasteriomeric mixture of (R)-te/t-butyl 5-((3,4- dichlorophenyl)( 1,1 -dimethyl ethylsulfinamido)methyl)thiazol-2-ylcarbamate as a yellow solid (92%) that was used without further purification.
  • N-(5-((S)-(2-Chloro-4-fluorophenyl)((R)- 1,1- dimethylethylsulfinamido)methyl) thiazol-2-yl)-l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)- 1 , 1 -dimethylethylsulfmamido)methyl)thiazol-2- yl)cyclopropanecarboxamide, starting from l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (R)-N
  • N-(5 ⁇ ((R)-(2-Chloro-4-fluorophenyr ⁇ (S)-l,l- dimethylethylsulfinamido)methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo[ ⁇ /] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-1 , 1 -dimethylethylsulfmamido)methyl)thiazol-2- yl) cyclopropanecarboxamide, starting from l-(2,2-difluorobenzo[(i][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (S)-(
  • N-(5-((S)-((R)-3-(ter ⁇ butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro ⁇ 4- fluorophenyl) methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo[ ⁇ (][ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[ ⁇ f
  • N-(5-((R)-((R)-3-(tert-butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro-4- fluorophenyl) methyl)thiazol-2-yl)-l -(2,2-difluorobenzo[ ⁇ fj [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-((R)-3 -(te ⁇ butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl) cyclopropanecarboxamide, starting from (R)-N-(5-(amino(2- chloro-4-fluorophenyl)
  • N-(5-((S)-(2-chloro-4-fluorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[J][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5-yl) ⁇ N-(5-((S)-(2-chloro-4- fluorophenyl) ((R)-3-hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from N-(5-((S)-((R)-3-(tert-butyldimethylsilyloxy)pynOlidin-l-yl)(2-chloro-4- fluoiOphenyl)methyl)thiazol-2
  • N-(5-((R)-(2-Chloro-4-fluorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[ ⁇ i][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4- fluorophenyl) ((R)-3-hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclo ⁇ ropanecarboxamide, stalling from N-(5-((R)-((R)-3 -(te7 ⁇ -butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro-4- fluorophenyl)
  • N-(5-((S)-(4-chloro-2-fluorophenyl)((R)-3-hydroxypyrrolidin- 1 - yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol ⁇ 5-yl)-N-(5-((S) ⁇ (2-chloro-4- fluorophenyl) ((R)-3-hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from N-(5-((S)-((R)-3-(tert-butyldimethylsilyloxy)pyrrolidin-l-yl)(4-chloro-2- fluorophenyl)methyl)thia
  • the crude product was adsorbed onto silica gel and purified by column chromatography (70 - 100 % EtOAc/ hexanes.
  • the EtOAc contained 2% NH 4 OH and was stirred to maintain the mixture) to provide (R)-N-((R)-(2-amino-4-methylthiazol-5-yl)(2- chlorophenyl)methyl)-2-methylpropane-2-sulfinamide and (R)-N-((S)-(2-amino-4- methylthiazol-5-yl)(2-chlorophenyl)methyl)-2-methylpropane-2-sulfinamide and a mixture of both diastereomers (7.1 g, 47 %).
  • [l,3]dioxol-5-yi)cyclopropanecarboxamide (Isomer A) was made by the procedure used for N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(benzo[(f][l,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer A) starting from l-(benzo[ ⁇ /][l,3]dioxol-5-yl)-N-(5- ((3 ,4-dichlorophenyl)((R)- 1 , 1 -dimethylethylsulf ⁇ namido)methyl)thiazol-2- yl)cyclopropanecarboxamide (Isomer A).
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, . Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR Voltage/Ion Probe Reader
  • NIH3T3 mouse fibroblasts stably expressing ⁇ F508-CFTR are used for optical measurements of membrane potential.
  • the cells are maintained at 37 0 C in 5% CO 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, ⁇ -ME, 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • the cells were seeded at 30,000/well in 384- well matrigel-coated plates and cultured for 2 hrs at 37 0 C before culturing at 27 0 C for 24 hrs.
  • Ussing chamber experiments were performed on polarized epithelial cells expressing ⁇ F508-CFTR to further characterize the ⁇ F508-CFTR modulators identified in the optical assays.
  • pR r p ⁇ F508 - CFTR epithelial cells grown on Costar Snapwell cell culture inserts were mounted in an Ussing chamber (Physiologic Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a Voltage-clamp System (Department of Bioengineering, University of Iowa, IA, and, Physiologic Instruments, Inc., San Diego, CA). Transepithelial resistance was measured by applying a 2-mV pulse.
  • the FRT epithelia demonstrated resistances of 4 K ⁇ / cm 2 or more.
  • the solutions were maintained at 27 0 C and bubbled with air.
  • the electrode offset potential and fluid resistance were corrected using a cell-free insert.
  • the current reflects the flow of Cl " through ⁇ F508-CFTR expressed in the apical membrane.
  • the Isc was digitally acquired using an MPlOOA-CE interface and AcqKnowledge software (V3.2.6; BIOPAC Systems, Santa Barbara, CA).
  • Typical protocol utilized a basolateral to apical membrane Cl " concentration gradient.
  • normal ringer was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl " concentration gradient across the epithelium.
  • AU experiments were performed with intact monolayers.
  • forskolin (10 ⁇ M) and the PDE inhibitor, IBMX (100 ⁇ M) were applied followed by the addition of the CFTR potentiator, genistein (50 ⁇ M).
  • the cells were incubated with 10 ⁇ M of the test compound for 24 hours at 37°C and the current density was compared to the 27°C and 37°C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 ⁇ M of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37°C controls.
  • Table 3 illustrates the EC50 and relative efficacy of exemplary embodiments of the present invention.
  • Table 3 the following meanings apply:
  • the compounds of the present invention exhibit unexpectedly better correction activity as measured by the assays above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator ('CFTR'), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators.

Description

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE
REGULATOR
TECHNICAL FIELD OF THE INVENTION
[001] The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators.
BACKGROUND OF THE INVENTION
[002] ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions. ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were discovered as multidrug resistance proteins (like the MDRl-P glycoprotein, or the multidrug resistance protein, MRPl), defending malignant cancer cells against chemotherapeutic agents. To date, 48 ABC Transporters have been identified and grouped into 7 families based on their sequence identity and function.
[003] ABC transporters regulate a variety of important physiological roles within the body and provide defense against harmful environmental compounds. Because of this, they represent important potential drug targets for the treatment of diseases associated with defects in the transporter, prevention of drug transport out of the target cell, and intervention in other diseases in which modulation of ABC transporter activity may be beneficial.
[004] One member of the ABC transporter family commonly associated with disease is the cAMP/ ATP -mediated anion channel, CFTR. CFTR is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeate of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
[005] The gene encoding CFTR has been identified and sequenced (See Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P. et al. (1990) Nature 347:358-362), (Riordan, J. R. et al. (1989) Science 245:1066-1073). A defect in this gene causes mutations in CFTR resulting in cystic fibrosis, the most common fatal genetic disease in humans. Cystic fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people cany a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the cystic fibrosis associated gene suffer from the debilitating and fatal effects of cystic fibrosis, including chronic lung disease.
[006] hi patients with cystic fibrosis, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in cystic fibrosis patients, hi addition to respiratory disease, cystic fibrosis patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death, hi addition, the majority of males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis. In contrast to the severe effects of two copies of the cystic fibrosis associated gene, individuals with a single copy of the cystic fibrosis associated gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea - perhaps explaining the relatively high frequency of the cystic fibrosis gene within the population.
[007] Sequence analysis of the CFTR gene of cystic fibrosischromosomes has revealed a variety of disease causing mutations (Cutting, G. R. et al. (1990) Nature 346:366- 369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, B-S. et al. (1989) Science 245:1073- 1080; Kerem, B-S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, > 1000 disease causing mutations in the cystic fibrosis gene have been identified (https://www.genet.sickkids.on.ca/cftr/). The most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as ΔF508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease .
[008] The deletion of residue 508 in ΔF508-CFTR prevents the nascent protein from folding correctly. This results in the inability of the mutant protein to exit the endoplasmic reticulum ("ER"), and traffic to the plasma membrane. As a result, the number of channels present in the membrane is far less than observed in cells expressing wild-type CFTR. In addition to impaired trafficking, the mutation results in defective channel gating. Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion transport across epithelia leading to defective ion and fluid transport. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). Studies have shown, however, that the reduced numbers of ΔF508- CFTR in the membrane are functional, albeit less than wild-type CFTR. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al., supra; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to ΔF508-CFTR, other disease causing mutations in CFTR that result in defective trafficking, synthesis, and/or channel gating could be up- or down-regulated to alter anion secretion and modify disease progression and/or severity.
[009] Although CFTR transports a variety of molecules in addition to anions, it is clear that this role (the transport of anions) represents one element in an important mechanism of transporting ions and water across the epithelium. The other elements include the epithelial Na+ channel, ENaC, Na+/2C17K+ co-transporter, Na+-K+- ATPase pump and the basolateral membrane K+ channels, that are responsible for the uptake of chloride into the cell.
[0010] These elements work together to achieve directional transport across the epithelium via their selective expression and localization within the cell. Chloride absorption takes place by the coordinated activity of ENaC and CFTR present on the apical membrane and the Na+-K+-ATPase pump and Cl- channels expressed on the basolateral surface of the cell. Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then passively leave the cell via Cl" channels, resulting in a vectorial transport. Arrangement of Na+/2C17K+ co-transporter, Na+-K+-ATPase pump and the basolateral membrane K+ channels on the basolateral surface and CFTR on the luminal side coordinate the secretion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia depends on tiny transepithelial osmotic gradients generated by the bulk flow of sodium and chloride. [0011] In addition to cystic fibrosis, modulation of CFTR activity may be beneficial for other diseases not directly caused by mutations in CFTR, such as secretory diseases and other protein folding diseases mediated by CFTR. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
[0012] COPD is characterized by airflow limitation that is progressive and not fully reversible. The airflow limitation is due to mucus hypersecretion, emphysema, and bronchiolitis. Activators of mutant or wild-type CFTR offer a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD. Specifically, increasing anion secretion across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimized periciliary fluid viscosity. This would lead to enhanced mucociliary clearance and a reduction in the symptoms associated with COPD. Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles. There are many causes of dry eye, some of which include age, Lasik eye surgery, arthritis, medications, chemical/thermal burns, allergies, and diseases, such as cystic fibrosis and Sjόgrens's syndrome. Increasing anion secretion via CFTR would enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help to alleviate the symptoms associated with dry eye disease. Sjogrens's syndrome is an autoimmune disease in which the immune system attacks moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as well as lung disease. The disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Modulators of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.
[0013] As discussed above, it is believed that the deletion of residue 508 in ΔF508- CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane. As a result, insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced. In fact, this cellular phenomenon of defective ER processing of ABC transporters by the ER machinery, has been shown to be the underlying basis not only for cystic fibrosis disease, but for a wide range of other isolated and inherited diseases. The two ways that the ER machinery can malfunction is either by loss of coupling to ER export of the proteins leading to degradation, or by the ER accumulation of these defective/misfolded proteins (Aridor M, et al, Nature Med., 5(7), pp 745- 751 (1999); Shastry, B. S., et al, Neurochem. International, 43, pp 1-7 (2003); Rutishauser, J., et al, Swiss Med WkIy, 132, pp 211-222 (2002); Morello, JP et al, TIPS, 21, pp. 466- 469 (2000); Bross P., et al, Human Mut, ,14, PP- 186-198 (1999)). The diseases associated with the first class of ER malfunction are cystic fibrosis (due to misfolded ΔF508-CFTR as discussed above), hereditary emphysema (due to al -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to β-hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl- sialyc-transferase), polyendocrinopathy/hyperinsulemia, diabetes mellitus (due to insulin receptor), Laron dwarfism (due to growth hormone receptor), myleoperoxidase deficiency, primary hypoparathyroidism (due to preproparathyroid hormone), melanoma (due to tyrosinase). The diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to αl -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to αl-antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasopvessin hormone/V2-receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to βAPP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to prion protein processing defect), Fabry disease (due to lysosomal α-galactosidase A), Straussler-Scheinker syndrome, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome. [0014] In addition to up-regulation of CFTR activity, reducing anion secretion by CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport. The mechanism involves elevation of cAMP and stimulation of CFTR.
[0015] Although there are numerous causes of diarrhea, the major consequences of diarrheal diseases, resulting from excessive chloride transport are common to all, and include dehydration, acidosis, impaired growth and death.
[0016] Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old.
[0017] Secretory diarrheas are also a dangerous condition in patients of acquired immunodeficiency syndrome (AIDS) and chronic inflammatory bowel disease (IBD). Sixteen million travelers to developing countries from industrialized nations every year develop diarrhea, with the severity and number of cases of diarrhea varying depending on the country and area of travel.
[0018] Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement, as well as in response to a variety of bacterial or viral infections and generally occurs within the first few hours of the animal's life.
[0019] The most common diarrheal causing bacteria is enterotoxogenic E-coli (ETEC) having the K99 pilus antigen. Common viral causes of diarrhea include rotavirus and coronavirus. Other infectious agents include Cryptosporidium, giardia lamblia, and salmonella, among others.
[0020] Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus causes a more severe illness in the newborn animals, and has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease. IDU21] Accordingly, there is a need for modulators of CFTR activity, and compositions thereof, that can be used to modulate the activity of the CFTR in the cell membrane of a mammal.
[0022] There is a need for methods of treating CFTR-mediated diseases using such modulators of CFTR activity.
[0023] There is a need for methods of modulating CFTR activity in an ex vivo cell membrane of a mammal.
SUMMARY OF THE INVENTION
[0024] It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of CFTR activity. These formula I or formula II:
Figure imgf000008_0001
I II or a pharmaceutically acceptable salt thereof, wherein Rx, ring A, RAA, RBB, Z, and q are described below.
[0025] These compounds and pharmaceutically acceptable compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, diabetes mellitus, laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, hereditary emphysema, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, diabetes insipidus (di), neurophyseal di, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, spinocerebuUar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, and Sjogren's disease.
DETAILED DESCRIPTION OF THE INVENTION [0026] /. General Description of Compounds of the Invention: [0027] The present invention provides compounds of formula I or formula II:
Figure imgf000009_0001
or a pharmaceutically acceptable salt thereof, wherein: each Rx is independently hydrogen, halo, CF3, C1-C4 alkyl, or -OC1-C4 alkyl; provided that both Rx are not simultaneously hydrogen; or the two Rx, taken together form ring (a):
Figure imgf000009_0002
X is CH2, CF2, CH2-CH2, or CF2-CF2; ring A is 3-7 membered monocyclic cycloalkyl ring;
RAA and RBB, taken together with the nitrogen atom, form a pyrrolidinyl ring substituted with OR';
R' is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, NRSO2-, or -NRSO2NR-;
R is hydrogen or C1-C6 aliphatic; Z is an electron withdrawing substituent; and q is 0-3.
[0028] As used herein, the following definitions shall apply unless otherwise indicated.
[0029] The term "CFTR" as used herein means cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, ΔF508 CFTR and G551D CFTR (see, e.g., https://www.genet.sickkids.on.ca/cftr/. for CFTR mutations).
[0030] The term "modulating" as used herein means increasing or decreasing by a measurable amount.
[0031] The term "correction" as used herein means increasing the number of CFTR in a membrane of a cell.
[0032] The term "potentiator" as used herein means a compound that increases the gating activity of CFTR in a membrane of a cell.
[0033] The term "electron withdrawing substituent", as used herein means an atom or a group that is electronegative relative to hydrogen. See, e.g., "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," Jerry March, 4th Ed., John Wiley & Sons (1992), e.g., pp. 14-16, 18-19, etc. Exemplary such substituents include halo, CN, COOH, CF3, etc.
[0034] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0035] Unless otherwise specified, the term "aliphatic" or "aliphatic group" by itself, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" "cycloaliphatic" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. Ih some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms, hi still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0036] The term "unsaturated", as used herein, means that a moiety has one or more units of unsaturation.
[0037] Unless stereochemically specified, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers, including mixtures containing an excess of one enantiomer relative to the other enantiomer or an excess of one diastereomer relative to another. Unless otherwise specified, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
[0038] hi one embodiment, each Rx is independently hydrogen, halo, or CF3; provided that both Rx are not simultaneously hydrogen. Li another embodiment, one Rx is hydrogen and the other Rx is halo or CF3. hi another embodiment, both Rx are halo.
[0039] hi one embodiment, the two Rx groups taken together form ring (a). [0040] In certain embodiments, X is CH2. In other embodiments, X is CF2. Or, X is CH2-CH2. In certain other embodiments, X is CF2-CF2;
[0041] In one embodiment, ring A is cyclopropyl, cyclopentyl, or cyclohexyl. In another embodiment, ring A is cyclopropyl or cyclopentyl. In certain embodiments, ring A is cyclopropyl.
[0042] In one embodiment, R is hydrogen. Or, R is C1-C6 alkyl. Exemplary R includes methyl, ethyl, or propyl.
[0043] In one embodiment, R' is hydrogen. Or, R' is Cl -C6 alkyl. Exemplary R' include methyl, ethyl, propyl, or C(O)Me.
[0044] hi one embodiment, RAA and RBB, taken together, form a pyrrolidinyl with an OH substituent.
[0045] hi one embodiment, Z is selected from halo, CF3, or difluoromethylenedioxy.
[0046] hi one embodiment, q is 0. Or, q is 1-2. hi certain embodiments, q is 1. Or, q is 2.
[0047] hi another embodiment, compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two Rx are taken together to form ring (a);
X is CH2; ring A is cyclopropyl;
R' is hydrogen; q is 1 or 2; and
Z is halo, CF3, or difluoromethylenedioxy.
[0048] In another embodiment, compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two Rx are taken together to form ring (a);
X is CH2;
R is hydrogen; ring A is cyclopropyl;
R' is hydrogen; q is 1 or 2; and
Z is halo, CF3, or difluoromethylenedioxy. [0049] In another embodiment, compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two Rx are taken together to form ring (a);
X Is CF2; ring A is cyclopropyl;
R' is hydrogen; q is 1 or 2; and
Z is halo, CF3, or difluoromethylenedioxy.
[0050] In another embodiment, compounds of formula I or formula II comprise one or more, and preferably all, of the following features: the two Rx are taken together to form ring (a);
X is CF2;
R is hydrogen; ring A is cyclopropyl;
R' is hydrogen; q is 1 or 2; and
Z is halo, CF3, or difluoromethylenedioxy.
[0051] In one embodiment of compounds of formula I, RAA and RBB, taken together with the nitrogen atom, form the following ring (i):
/rx
,N.
O
OH (i).
[0052] In one embodiment of compounds of formula II, RAA and RBB, taken together with the nitrogen atom, form the following ring (ii):
Figure imgf000014_0001
[0053] In one embodiment of compounds of formula I, RAA and RBB, taken together with the nitrogen atom, form the following ring (iii):
Figure imgf000014_0002
[0054] In one embodiment of compounds of formula II, R^ and RBB, taken together with the nitrogen atom, form the following ring (iv):
Figure imgf000014_0003
[0055] In an alternative embodiment, the present invention provides intermediates having formula I' or formula II':
Figure imgf000014_0004
wherein:
R , R, ring A, Z, and q are as defined above; L is a linker selected from C(O) , SO2; p is 0 or 1 ; and CA is a suitable chiral auxiliary.
[0056] The term "chiral auxiliary" as used herein means an asymmetric molecule or molecular fragment that is used to achieve the chemical resolution of a racemic or diastereomeric mixture. Such chiral auxiliaries may possess one chiral center such as methylbenzylamine or several chiral centers such as menthol. The purpose of a chiral auxiliary, once built into the starting material, is to allow simple separation of the resulting diastereomeric mixture. See, for example, J. Jacques et al., "Enantiomers, Racemates And Resolutions,'" pp. 251-369, John Wiley & Sons, New York (1981); E. L. Eliel & S. H. Wilen, "Stereochemistry of Organic Compounds:' pp. 868-870, John Wiley & Sons (1994).
[0057] Suitable chiral auxiliaries useful in the present invention include those that are amenable to attachment to the linker L above (i.e., p is 1) or directly to the oxygen atom (i.e., p is 0). Exemplary such chiral auxiliaries are found in, e.g., E. L. Eliel & S. H. Wilen, ibid, pp. 337-340.
[0058] In one embodiment, CA, L, p, and the oxygen atom linked thereto, taken together, is (+)-10-camphorsulfonate, (IS, 4i?)-(-)-ω-camphanic ester, (Ii?, 2S, 5i?)-(-) mentholcarbonate, (IS, 2R, 55)-(+)-mentholcarbonate, (Ii?, 2i?)-l~phenyl-2-cyclopropylester, or (3i?)-tetrahydrofuran-3 -carbonate.
[0059] Exemplary compounds of the present invention are shown below in Table 1.
[0060] Table 1
Figure imgf000016_0001
Figure imgf000016_0002
7
Figure imgf000016_0003
Figure imgf000016_0004
Figure imgf000017_0001
[0061] In one embodiment, the present invention provides a method for producing a compound of formula I or formula II:
Figure imgf000017_0002
I II; comprising the step of reacting under a first suitable conditions a compound of formula R-I with either a compound of formula I-A to produce said compound of formula I, or a compound of formula II-A to produce said compound of formula II:
R-I; wherein: each R >xA is independently hydrogen, halo, CF3, C1-C4 alkyl, or -OC1-C4 alkyl; provided that both Rx are not simultaneously hydrogen; or the two R >xΛ, taken together form ring (a):
Figure imgf000018_0001
X is CH2, CF2, CH2-CH2, or CF2-CF2; ring A is 3-7 membered monocyclic cycloalkyl ring;
RAA and RBB, taken together with the nitrogen atom, form a pyrrolidinyl ring substituted with OR';
R' is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, NRSO2-, or -NRSO2NR-; R is hydrogen or C1-C6 aliphatic; Z is an electron withdrawing substituent; and q is 0-3; and LG1 is a first suitable leaving group
[0062] As used herein, the term "first suitable conditions" means conditions suitable to effectuate the reaction between compound of formula I-A and compound of formula R-I or between compound of formula II-A and compound of formula R-I. Such suitable conditions include, e.g., a first suitable solvent, a first suitable temperature, and a suitable reducing agent. One of skill in the art will be well aware of various such suitable conditions that effectuate the reaction between compound of formula I-A and compound of formula R-I or between compound of formula II-A and compound of formula R-I.
[0063] In one embodiment, the first suitable solvent is a polar aprotic, a polar protic solvent, an apolar solvent, or a suitable combination thereof. Exemplary solvents useful as first suitable solvent include methanol, ethanol, propanol, isopropanol, t-butanol, dichloromethane, dichloroethane, toluene, tetrahydrofuran, dioxane, diethylether, dimethylether, acetonitrile, dimethylformamide, DMAC, or NMP.
[0064] In one embodiment, the first suitable temperature is a temperature that is sufficient to effectuate the reaction between compound of formula I-A and compound of formula R-I in the first suitable solvent. In another embodiment, the first suitable temperature is a temperature that is sufficient to effectuate the reaction between compound of formula II-A and compound of formula R-I in the first suitable solvent. Exemplary first suitable temperature includes between about 0 °C to about 110 °C. In one embodiment, the first suitable temperature is between about 0 0C to about 25 0C.
[0065] In one embodiment, the suitable reducing agent is a reducing agent that is capable effectuating the reaction between compound of formula I-A and compound of formula R-I. In another embodiment, the suitable reducing agent is a reducing agent that is capable effectuating the reaction between compound of formula H-A and compound of formula R-I. One of skill in the art will be well aware of suitable reducing agents for that reaction. Agents suitable for the present invention include a metallo-borohydride or a reagent capable of catalytic hydrogenation. Exemplary such suitable reducing agents include sodium borohydride, sodium cyanoborohydride, lithium borohydride, sodium triacetoxyborohydride, calcium borohydride, hydrogene in the presence of a suitable metal catalyst such as Pd/C.
[0066] Pn another embodiment, LG1 is a first suitable leaving group that is capable of displacement to produce compound of formula I. or compound of formula II. See, "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," pp. 339-357, Jerry March, 4th Ed., John Wiley & Sons (1992).
[0067] The method according to claim 1, wherein LG1 is selected from alkysulfonate, arylsulfonate, halide, alkyl carboxylate.
[0068] hi one embodiment, the compound of formula I-A is produced from formula I- B:
Figure imgf000019_0001
I B; wherein [CA] is a suitable chiral auxiliary; said method comprising the step of removing said chiral auxilary under a second suitable conditions.
[0069] hi an alternative embodiment, the compound of formula H-A is produced from formula H-B:
Figure imgf000020_0001
H-B; wherein [CA] is a suitable chiral auxiliary; said method comprising the step of removing said chiral auxilary under a second suitable conditions.
[0070] A "suitable chiral auxiliary" above in compound of formula H-B or formula I-B is a chiral auxiliary that is capable of attachment to an amino group. An isomeric mixture of a compound containing such an amino group with a suitable chiral auxiliary attached thereto is readily separated into its individual isomers by suitable separation means. See, for example, J. Jacques et al., "Enantiomers, Racemates And Resolutions," pp. 251-369, John Wiley & Sons, New York (1981); E. L. Eliel & S. H. Wilen, "Stereochemistry of Organic Compounds," pp. 868-870, John Wiley & Sons (1994).
[0071] In one embodiment, said suitable chiral auxiliary is an alkylsulfoxyl group.
[0072] In another embodiment, said suitable second conditions comprises a suitable protic acid and a suitable second solvent.
[0073] In one embodiment, said suitable second solvent is selected from a polar aprotic solvent or a protic solvent. Exemplary polar aprotic solvents include dioxane, tetrahydrofurane, diethyl ethez*, dichloromethane, etc. Exemplary protic solvents include methanol, ethanol, z-propanaol, ^-butanol, etc.
[0074] In one embodiment, said suitable second solvent is a polar aprotic solvent.
[0075] In another embodiment, said compound of formula I-B and compound of formula H-B is produced by reacting, respectively, a compound of formula I-C or formula II- C with a compound of formula R-2 under a third suitable conditions:
Figure imgf000020_0002
Figure imgf000021_0001
R-2 wherein:
R is hydrogen or C1-C6 aliphatic;
R1 is hydrogen or a first suitable protecting group;
[CA] is a suitable chiral auxiliary; and
LG2 is a second suitable leaving group.
[0076] In one embodiment, LG2 is selected from halide, OC(O)(Cl-Co alkyl), pentafluorophenoxy, C1-C6 alkoxy, OCO2(C 1-C6 alkyl) or hydroxy.
[0077] In one embodiment, R1 is hydrogen.
[0078] In another embodiment, said third suitable conditions comprises a third suitable coupling agent and a third suitable solvent.
[0079] In another embodiment, said suitable coupling agent is selected from DCC5 DCI, HATU, TCPH, or HBTU.
[0080] In one embodiment, said third suitable solvent is selected from dichloromethane, dioxane, acetonitrile, DMF, dichloroethane, or tetrahydrofuran.
[0081] hi another embodiment, said compound of formula I-C or formula H-C is produced from an isomeric mixture of a compound of formula R-3:
Figure imgf000021_0002
R-3; wherein:
R, Z, and q are as defined above;
PGj is a second suitable protecting group; and [CA] is a suitable chiral auxiliary; said method comprising two steps, wherein one of said two steps is separating said isomeric mixture using suitable separation means, and the other of said two steps is the conversion OfPG1 to R1 in a fourth suitable conditions.
[0082] In one embodiment, said suitable separation means comprises suitable chromatographic means. Exemplary such means include column chromatography or thin layer chromatography.
[0083] In another embodiment, said suitable separation means comprises suitable crystallization means.
[0084] In another embodiment, said fourth suitable conditions comprises a suitable deprotecting reagent and a fourth suitable solvent. An exemplary suitable deprotecting reagent is trifluoroacetic acid.
[0085] In one embodiment, said fourth suitable solvent is a polar aprotic solvent. Exemplary solvents include dichloromethane, tetrahydrofuran, dioxane, diethyl ether, etc. [0086] In another embodiment, said compound of formula R-3 is produced from a compound of formula R-4 and a compound of formula R-5:
Figure imgf000022_0001
R-4 R-5; wherein:
PG1 is a second suitable protecting group; M is a suitable metal cation; and [CA] is a suitable chiral auxiliary; said method comprising the steps of reacting said compound of formula R-4 with said compound of formula R-5 in a fifth suitable conditions.
[0087] In one embodiment, said M is selected from Li+, Na+, or Mg+"1". [0088] In another embodiment, said PG1 is selected from an alkylcarbamate, trifluoroacetyl, trialkylsilyl, or pivaloyl. Or, said PG1 is BOC or trimethylsilyl. [0089] In one embodiment, said fifth suitable conditions comprises a fifth suitable solvent and a fifth suitable temperature. In one embodiment, said suitable temperature is about -78 degrees C.
[0090] hi another embodiment, said fifth suitable solvent is tetrahydrofuran.
[0091] hi an alternative embodiment, said compound of formula R-I is:
Figure imgf000023_0001
[0092] Or, said compound of formula R-I is:
R1- \
"O
O
[0093] In another embodiment, said compound of formula I or formula II are selected from Table 1.
[0094] 4. General Synthetic Schemes
[0095] The compounds of this invention may be prepared by methods known in the art. Exemplary synthetic routes to prepare compounds of this invention are illustrated below. [0096] Scheme I-A below illustrates a process for producing intermediate A: [0097] Scheme I-A:
Figure imgf000023_0002
A; a) 50% NaOH, Y(CH2)nY, BTEAC (benzyl triethyl ammonium chloride); Y= suitable leaving group.
[0098] Scheme I-B below illustrates a process for producing intermediate B. [0099] Scheme I-B:
Figure imgf000024_0001
a) Br2; b) thiourea, (Me)2NCH(OMe)2; c) HCl
[00100] Scheme I-C below illustrates a process for producing compounds of formula I or formula II:
[00101] Scheme I-C:
Figure imgf000024_0002
Figure imgf000024_0003
a) SOCl2, DMF; b) 1,4-dioxane, Et3N; c) NaBH4, MeOH; d) i) CH3SO2Cl, DCM, Et3N; ii) R AA R BB NH. e) chiral chromatography [00102] Scheme I-D illustrates the synthesis of an exemplary compound of the present invention.
[00103] Scheme I-D:
Figure imgf000025_0001
a) 50% aqueous NaOH, 1,2-chlorobromoethane, BTEAC
Figure imgf000025_0002
a) Br2; b) thiourea, (Me)2NCH(OMe)2; c) HCl
Figure imgf000025_0003
Figure imgf000026_0002
Figure imgf000026_0001
Figure imgf000026_0003
Figure imgf000026_0004
Figure imgf000026_0005
1 2 a) SOCl2, DMF; b) 1,4-dioxane, Et3N; c) NaBH4, MeOH; d) i) CH3SO2Cl, DCM, Et3N; ii) (R)- pyrrolidinol; e) chiral chromatography
[00104] Scheme H-A below illustrates another exemplary process for preparing compounds of the present invention using a chiral auxiliary.
[00105] Scheme H-A:
Figure imgf000027_0001
Removal of CA-L Removal of CA-L
Figure imgf000027_0002
Figure imgf000028_0001
Figure imgf000028_0002
Removal of CA-(L)p
Figure imgf000028_0004
Figure imgf000028_0003
[00106] Scheme II-B below illustrates a process for preparing an exemplary compound of the present invention using a chiral auxiliary. [00107] Scheme II-B:
Figure imgf000029_0001
Chiral Chromatography
Figure imgf000029_0002
Chiral Chromatography
Figure imgf000030_0001
[00108] Scheme III below illustrates another process for preparing a compound of the present invention.
[00109] Scheme III, Step A:
NH,
W -N 'I
Figure imgf000031_0001
b) Ti(OPr)4, dioxane; b) (Boc)2O, Et3N, DMAP, THF; c) n-BuLi, -780C, THF; d) 50% TFA, CH2Cl2. [00104] Scheme III, Step B:
Figure imgf000031_0002
R'- \
O O
Figure imgf000031_0003
a) SOCl2, DMF, 6O0C; b) Et3N, CH2Cl2; c) HCl in dioxane, CH3OH; d) NaBH4 (LG= leaving group). [00110] Scheme III, Step C:
Figure imgf000032_0001
a) SOCl2, DMF, 600C; b) Et3N, CH2Cl2; c) HCl in dioxane, CH3OH; d) NaBH4 (LG= leaving group).
[00111] Further illustrative examples for preparing compounds of the present invention are recited below.
[00112] J. Uses, Formulation and Administration
[00113] Pharmaceutically acceptable compositions
[00114] As discussed above, the present invention provides compounds that are useful as modulators of CFTR and thus are useful in the treatment of disease, disorders or conditions such as Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI)5 Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease (due to Prion protein processing defect), Fabry disease and Straussler-Scheinker syndrome.
[00115] Accordingly, in another aspect of the present invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
[00116] It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
[00117] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A "pharmaceutically acceptable salt" means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof means that a metabolite or residue thereof is also an inhibitor of an ATP -Binding Cassette Transporters.
[00118] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, foπnate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C i-4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen- containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[00119] As described above, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxyniethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
[00120] Uses of Compounds and Pharmaceutically Acceptable Compositions [00121] hi yet another aspect, the present invention provides a method of treating a condition, disease, or disorder implicated by CFTR. hi certain embodiments, the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of CFTR, the method comprising administering a composition comprising a compound of formula (I) to a subject, preferably a mammal, in need thereof.
[00122] hi certain preferred embodiments, the present invention provides a method of treating cystic fibrosis, hereditary emphysema (due to al -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to β-hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), polyendocrinopathy/hyperinsulemia, diabetes mellitus (due to insulin receptor), Laron dwarfism (due to growth hormone receptor), myleoperoxidase deficiency, primary hypoparathyroidism (due to preproparathyroid hormone), melanoma (due to tyrosinase). The diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to αl -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to αl- antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasopvessin hormone/V2- receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to βAPP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to prion protein processing defect), Fabry disease (due to lysosomal α-galactosidase A), Straussler-Scheinker syndrome, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome, comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
[00123] According to an alternative preferred embodiment, the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
[00124] According to the invention an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of cystic fibrosis, hereditary emphysema (due to al -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to β-hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), polyendocrinopathy/hyperinsulemia, diabetes mellitus (due to insulin receptor), Laron dwarfism (due to growth hormone receptor), myleoperoxidase deficiency, primary hypoparathyroidism (due to preproparathyroid hormone), melanoma (due to tyrosinase). The diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to αl -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to αl- antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasopvessin hormone/V2- receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to βAPP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to prion protein processing defect), Fabry disease (due to lysosomal α-galactosidase A), Straussler-Scheinker syndrome, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome. [00125] The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of cystic fibrosis, hereditary emphysema (due to a 1 -antitrypsin; non Piz variants), hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses (due to lysosomal processing enzymes), Sandhof/Tay-Sachs (due to β- hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), polyendocrinopathy/hyperinsulemia, diabetes mellitus (due to insulin receptor), Laron dwarfism (due to growth hormone receptor), myleoperoxidase deficiency, primary hypoparathyroidism (due to preproparathyroid hormone), melanoma (due to tyrosinase). The diseases associated with the latter class of ER malfunction are glycanosis CDG type 1, hereditary emphysema (due to αl -antitrypsin (PiZ variant), congenital hyperthyroidism, osteogenesis imperfecta (due to Type I, II, IV procollagen), hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency (due to αl-antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (due to vasop'vessin hormone/V2 -receptor), neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome (due to peripheral myelin protein 22), Perlizaeus- Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to βAPP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to prion protein processing defect), Fabry disease (due to lysosomal α-galactosidase A), Straussler-Scheinker syndrome, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
[00126] The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[00127] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00128] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emuϊsifϊers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[00129] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. [00130] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00131] hi order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by foπning microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[00132] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00133] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as. sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absoiption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00134] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical fonnulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
[00135] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. Pn such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00136] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[00137] As described generally above, the compounds of the invention are useful as modulators of CFTR. Thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of CFTR is implicated in the disease, condition, or disorder. When hyperactivity or inactivity of an CFTR is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a "CFTR-mediated disease, condition or disorder". Accordingly, in another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of an CFTR is implicated in the disease state.
[00138] The activity of a compound utilized in this invention as a modulator of an CFTR may be assayed according to methods described generally in the art and in the Examples herein.
[00139] It will also be appreciated that the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility .of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated".
[00140] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[00141] The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
[00142] Another aspect of the invention relates to modulating CFTR activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound. The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[00143] Modulation of CFTR activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such puiposes include, but are not limited to, the study of CFTR in biological and pathological phenomena; and the comparative evaluation of new modulators of CFTR.
[00144] hi yet another embodiment, a method of modulating activity of an anion channel in vitro or in vivo, is provided comprising the step of contacting said channel with a compound of formula (I). In preferred embodiments, the anion channel is a chloride channel or a bicarbonate channel, hi other preferred embodiments, the anion channel is a chloride channel.
[00145] According to an alternative embodiment, the present invention provides a method of increasing the number of functional CFTR in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (T). The term "functional ABC transporter" as used herein means an CFTR that is capable of transport activity.
[00146] According to another preferred embodiment, the activity of the CFTR is measured by measuring the transmembrane voltage potential. Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
[00147] The optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (Sea, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (Se^1 Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00148] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (V1n) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission can be monitored using VIPR™ II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
[00149] In another aspect the present invention provides a kit for use in measuring the activity of a CFTR or a fragment thereof in a biological sample in vitro or in vivo comprising (i) a composition comprising a compound of formula (I) or any of the above embodiments; and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said CFTR or a fragment thereof. In one embodiment, the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the CFTR in the presence of the additional compound with the density of the CFTR in the presence of a composition of formula (I). In preferred embodiments, the kit is used to measure the density of CFTR.
[00150] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXAMPLES
[00151] Example 1:
[00152] l-(Benzo[d][l,3]dioxol-6-yl)-N-(5-((JR)-(2-chlorophenyl)((R)-3- hydroxypyrroIidin-l-vDmethyDthiazol^-yDcyclopropanecarboxamide (2) hydrochloride and l-(benzo[d][l,3]dioxol-6-yl)-N-(5-((Λ)-(2-chlorophenyl)((i?)-3-hydroxypyrrolidin-l- vDmethvDthiazol^-vDcyclopropanecarboxamide fl) hydrochloride
Figure imgf000046_0001
[00153] l-Benzo[l,3]dioxol-5-yl-cyclopropanecarboxylic acid
Figure imgf000046_0002
A mixture of benzo[l,3]dioxole-5-carbonitrile (5.10 g 31.7 mmol), l-bromo-2-chloro- ethane (9.000 niL 108.6 mmol), and benzyltriethylammonium chloride (BTEAC, 0.181 g 0.795 mmol) was heated to 70 0C and then 50% (wt./wt.) aqueous sodium hydroxide (26 mL) was slowly added. The reaction was stirred at 70 0C for 24 hours and then heated to reflux (130 °C bath temperature) for 72 hours. The dark brown/black reaction mixture was diluted with water (400 mL) and extracted twice with equal volumes ethyl acetate and dichloromethane. The basic aqueous solution was acidified with concentrated hydrochloric acid to pH less than one and the precipitate was filtered and washed with 1 M hydrochloric acid. The solid material was dissolved in dichloromethane (400 mL) and extracted twice with equal volumes of 1 M hydrochloric acid and once with a saturated aqueous solution of sodium chloride. The organic solution was dried over sodium sulfate and evaporated to dryness to give a white to slightly off- white solid (5.23 g, 25.4 mmol, 80.1 %). ESI-MS m/z calc. 206.1, found 207.1 (M+l)+. Retention time of 2.37 minutes. 1R NMR (400 MHz, DMSO-d6) δ 1.07-1.11 (m, 2H), 1.38-1.42 (m, 2H), 5.98 (s, 2H), 6.79 (m, 2H), 6.88 (m, IH), 12.26 (s, IH). [00154] 2-Bromo-l-(chloro-phenyl)-ethanone
Figure imgf000046_0003
Bromine (3.8 mL, 65 mmol) was added dropwise to a solution of l-(2-chloro-phenyl)- ethanone (10 g, 65 mmol) in acetic acid (75 mL) at 0 °C. The mixture was then warmed to room temperature and stirred overnight. The mixture was evaporated to dryness and used in the next step without further purification.
[00155] iV'-[5-(2-Chloro-benzoyl)-thiazol-2-yl]-iVr/V-dimethyl-formamidine
Figure imgf000047_0001
A mixture of thiourea (4.95 g, 65.0 mmol) and dimethoxymethyl-dimethyl-amine (23.2 g, 195 mmol) in methanol (80 mL) was heated to reflux for 30 minutes. After allowing the mixture to cool, triethylamine (19.8 g, 195 mmol) and a solution of 2-bromo-l-(chloro-phenyl)-ethanone (crude from last step) in methanol (50 mL) were added. The mixture was heated to reflux for 4 hours. The solvent was removed and the residue was used directly in the next procedure.
[00156] (2-Amino-thiazol-5-yl)-(2-chloro-phenyl)-methanone
Figure imgf000047_0002
The crude N'-[5-(2-chloro-benzoyl)-thiazol-2-yl]-N,N-dimethyl-formamidine was dissolved in 10% HCl (150 mL) and heated to 70 °C for 4 hours. The precipitate was filtered, washed with ether, and then suspended in a 10% sodium carbonate solution (250 mL). The suspension was stirred for 1 hour and the precipitate was filtered, washed with ether, and dried in air to give (2-amino-thiazol-5-yl)-(2-chloro-phenyl)-methanone as a brown solid (8.5 g, 36 mmol, 55% from l-(2-chloro-phenyl)-ethanone). 1H NMR (400 MHz, DMSO-d6) δ 7.27 (s, IH), 7.41-7.58 (m, 4H), 8.37 (s, 2H). ESI-MS m/z calc. 238.0, found; 239.3 (M+l)+' [00157] l-Benzo[l,3]dioxol-5-yl-cyclopropanecarboxylic acid [5-(2-chloro- benzoyl)-thiazol-2-yl]-amide
Figure imgf000048_0001
l-Benzo[l,3]dioxol-5-yl-cyclopropanecarboxylic acid (1.29 g, 6.28 mmol) was placed in an oven-dried flask under nitrogen. Thionyl chloride (3mL) and N,N~dimethylformamide (0.3 rnL) were added and the solution was allowed to stir for 2 hours. The excess thionyl chloride was removed under vacuum and the resulting solid was suspended in 30 niL of anhydrous 1,4- dioxane containing triethylamine (1.77 mL, 12.6 mmol). (2-Amino-thiazol-5~yl)-(2-chloro- phenyl)-methanone (1.50 g, 6.28 mmol) suspended in 10 mL of anhydrous 1,4-dioxane was slowly added to this suspension. The resulting suspension was allowed to stir for 20 minutes. The mixture was filtered and then the filtrate was evaporated to dryness. The crude product was dissolved in 50 mL of dichloromethane and washed three times with 50 mL of IN HCl, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer was then dried over sodium sulfate and evaporated to dryness to yield the product as a beige solid (1.51 g, 3.54 mmol, 56.4 %). 1H NMR (400 MHz, DMSO-d6) δ 1.20-1.24 (m, 2H), 1.54-1.57 (m, 2H), 6.01 (s, 2H), 6.88 (d, J= 1.3 Hz, 2H), 6.98 (s, IH), 7.48-7.52 (m, IH), 7.56-7.60 (m, 3H), 7.77 (s, IH), 11.98 (s, IH). ESI-MS m/z calc. 426.0, found; 427.3 (M+l)+; Retention time 3.46 minutes.
[00158] l-(Benzo[</] [l,3]dioxol-6-yl)-N-(5-((2- chlorophenyl)(hydroxy)methyI)thiazoI-2-yl)cyclopropanecarboxamide
Figure imgf000048_0002
1 -Benzo[ 1 ,3]dioxol-5-yl-cyclopropanecarboxylic acid [5-(2-chloro-benzoyl)-thiazol-2- yl]-amide (1.0 g, 2.3 mmol) was suspended in 150 mL of anhydrous methanol. Sodium borohydride (1.3 g, 35 mmol) was slowly added and the resulting pale yellow solution was allowed to stir for 1 hour at room temperature. The crude product was evaporated to dryness and then dissolved in a minimum of ethyl acetate. The organic was washed three times with an equal volume of IN hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer was then dried over sodium sulfate, filtered, and evaporated to dryness to yield the product as a beige solid (0.64 g, 1.5 mmol, 63 %). 1H NMR (400 MHz, DMSO-d6) δ 1.10-1.14 (m, 2H), 1.41-1.45 (m, 2H), 6.00 (s, 2H), 6.14 (s, IH), 6.86 (d, J= 1.0 Hz, 2H), 6.95 (t, J= 1.0 Hz, IH), 7.14 (d, J= 0.6 Hz, IH)5, 7.29-7.34 (m, IH), 7.38-7.43 (m, 2H), 7.71 (d, J= 7.5 Hz, IH), 10.93 (s, IH) ESI-MS m/z calc. 428.1, found; 429.5 (M+l)+ Retention time 3.17 minutes.
[00159] l-(Benzo[rf][l,3]dioxol-5-yl)-Λ?-(5-((2-chlorophenyl)((iJ)-3- hydroxypyrrolidin-l-ytymethytythiazol-l-ytycyclopropanecarboxamide
Figure imgf000049_0001
1 -Benzo[ 1 ,3]dioxol-5-yl-cycloproρanecarboxylic acid [5-[(2-chloro-phenyl)-hydroxy- methyl]-thiazol-2-yl] -amide (0.500 g, 1.17 mmol) was placed in 10 mL of anhydrous dichloromethane containing triethylamine (984 μL, 7.02 mmol). The mixture was cooled to 0 0C and methanesulfonyl chloride (364 μL, 4.68 mmol) was added, immediately followed by (R)- pyrrolidin-3-ol (945 μL, 11.7 mmol) and the solution was allowed to stir for 10 minutes at room temperature. The crude product was washed three times with an equal volume of a saturated aqueous solution of sodium bicarbonate, followed by a saturated aqueous solution of sodium chloride. The organic layer was then dried over sodium sulfate and evaporated to dryness. The crude mixture was purified by column chromatography (20-90% ethyl acetate in hexanes on silica gel) to yield the product as a white solid (194.2 mg, 0.390 mol, 33.3 %). 1H NMR (400 MHz, DMSOd6) δ 1.09-1.15 (m, 2H), 1.41-1.44 (m, 2H), 1.54-1.63 (m, IH), 1.93-2.77 (m, 5H), 4.20 (s, IH), 4.72-4.77 (m, IH), 4.96 (d, J= 7.0 Hz, IH), 6.00 (s, 2H), 6.85 (d, J= 0.9 Hz, 2H), 6.95 (s, IH), 7.24-7.29 (m, IH), 7.37-7.43 (m, 3H), 7.76-7.80 (m, IH), 11.03 (s, IH). ESI-MS m/z calc. 497.1, found; 498.1 (M+l)+; Retention time 2.36 minutes.
[00160] l-(Benzo[(/I[l,3]dioxol-5-yl)-iV-(5-((2-chlorophenyl)((R)-3- hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide hydrochloride
Figure imgf000050_0001
A solution of HCl in ether (0.1556 mL, 0.3112 mmol, IM) was slowly added to a stirred solution of l-(benzo[(f|[l,3]dioxol-5-yl)-iV-(5-((2-chlorophenyl)((i?)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)cyclopropanecarboxamide (0.1550 g, 0.3112 mmol) in 100 mL of anhydrous dichloromethane. The solution was evaporated to dryness to give the pure product (0.1654 g, 0.3095, 99.45%). ESI-MS m/z calc. 497.1, found; 498.1 (M+l)+; Retention time 5.74 minutes.
[00161] l-(Benzo[</] [l,3]dioxol-6-yl)-N-(5-((5)-(2-chlorophenyl)((Λ)-3- hydroxypyrrolidin-l-yl)methyI)thiazol-2-yl)cyclopropanecarboxamide (1) hydrochloride and l-(Benzo[ώf][l,3]dioxol-6-yI)-Λ'-(5-((i?)-(2-chlorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)cyclopropanecarboxamide (2) hydrochloride
Figure imgf000050_0002
[00162] l-(Benzo[d][l,3]dioxol-6-yl)-N-(5-((2-chlorophenyl)((i?)-3- hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide hydrochloride prepared above was separated using utilizing a Chiralpak AS-H 4.6mm x 250mm column from Chiral Technologies.
[00163] 20-25μL of a 2 mg/mL solution of l~(benzo[d][l,3]dioxol-6-yl)-N-(5-((2- chlorophenyl)((i?)-3 -hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide hydrochloride in methanol was injected onto the Chiralpak AS-H column and was eluted with a mixture of 10% of a 50/50 (v/v) mixture of ethanol and methanol in hexanes at 1.5 mL/min.
[00164] The first eluting product under these conditions had a retention time of 8.2 min (Chiralpak AS-H column). This product had a retention time 14.5 min. on a Chiralpak OJ- H 4.6 mm x 250 mm column (25% of a 50/50 (v/v) mixture of ethanol and methanol in hexanes at 1.0 mL/min.)
[00165] The second product eluted at 9.6 min using a Chiralpak AS-H column. This second product had a retention time of 10.9 min. on a Chiralpak OJ-H 4.6 mm x 250 mm column (25% of a 50/50 (v/v) mixture of ethanol and methanol in hexanes at 1.0 mL/min.)
[00166] Example 2
[00167] (i?)-l-((2-(l-(Benzo[^l[l,3]dioxol-6-yl)cyclopropanecarboxamido)thiazol- 5-yl)(2-chlorophenyl)methyl)pyrrolidin-3-yl (liS^iϊ^^-l-isopropyl-S-methylcyclohexyl carbonate
Figure imgf000051_0001
[00168] l-(Benzo[rf][l,3]dioxol-5-yl)-N-(5-((2-chlorophenyl)((i?)-3- hydroxypyiτolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide (3.00 g, 6.02 mmol) was suspended in 200 mL of anhydrous dichloromethane containing ΛζiV-dimethylpyridin-4- amine (2.20 g, 18.0 mmol). (l£,2i?,55)-2-Isopropyl-5-metriylcyclohexyl chloroformate (1.91 mL, 9.00 mmol) was slowly added to the suspension and the resulting mixture was heated to reflux for 16 hours. The resulting pale yellow solution was allowed to cool to room temperature, diluted with 20 mL of methanol, and then evaporated to dryness. The crude reaction mixture was separated on 330 g of silica gel utilizing a gradient of 0-5% methanol in dicholoromethane to yield the pure product as a pale yellow solid (2.0087 g, 2.9529 mmol, 49.1%). ESI-MS m/z calc. 679.3, found; 680.5 (M+l)+; Retention time 3.88 minutes.
[00169] (i?)-l-«3>(2-(l-(Benzo[tfI [l,3]dioxol-6- yl)cyclopropanecarboxamido)thiazol-5-yl)(2-chlorophenyl)methyl)pyrrolidin-3-yl (lS,2i?,5S)-2-isopropyl-5-methylcyclohexyl carbonate and (2?)-l-((2?)-(2-(l- (benzo[rf][l,3]dioxol-6-yl)cyclopropanecarboxamido)thiazol-5-yl)(2- chlorophenyl)methyl)pyrrolidin-3-yl (li-»,2iϊ,5S)-2-isopropyl-5-methylcyclohexyl carbonate
Figure imgf000052_0001
(i?)-l-(2-(l-(Benzo [d] [1,3] dioxol-6-yl)cyclopropanecarboxamido)thiazol-5-yl)(2- chlorophenyI)methyl)pyrrolidin-3-yl (liS',2i?,5iS)-2-isopropyl-5-methylcyclohexyl carbonate prepared above was separated utilizing a Chiralpak AD 21mm x 250mm column from Chiral Technologies. ImL of a 30 mg/mL solution of compound prepared above in isopropanol was injected onto the Chiralpak AD column and was eluted with a mixture of 7.5% isopropanol in heptane at 15 mL/min. The first eluting product ((iϋ)-l-((Λ)-(2-(l-(benzo[</][l,3]dioxol-6- yl)cyclopropanecarboxamido)thiazoI-5-yl)(2-chlorophenyl)methyl)pyrrolidin-3-yl (l>S,2i?,5iS)-2-isopropyl-5-methylcyclohexyl carbonate ) had a retention time of 14.4 min.(Chiralpak AD column); 1H NMR (400 MHz, CD3OD) δ 0.79 (d, J= 7.0 Hz, 3H), 0.85-1.84 (m, 18H), 1.86-2.04 (m, 3H), 2.23-2.34 (m, IH), 2.43-2.51 (m, IH), 2.62-2.69 (m, IH), 2.73-2.78 (m, 2H), 4.45-4.54 (m, IH), 5.04-5.08 (m, IH), 5.12 (s, IH), 5.99 (s, 2H), 6.82 (d, J= 8.5 Hz, IH), 6.93-6.97 (m, 2H), 7.25 (t, J= 6.8 Hz, IH), 7.32 (s, IH), 7.34-7.40 (m, 2H), 7.85 (dd, J- 8.1, 1.6 Hz, IH). ESI-MS m/z calc. 679.3, found; 680.5 (M+l)+; Retention time 3.91 minutes.
The second eluting product ((Λ)-l-((R)-(2-(l-(benzo[</][l,3]dioxol-6- yl)cyclopropanecarboxamido)thiazoI-5-yl)(2-chlorophenyI)methyI)pyrroIidin-3-yI (liS',2i?,5S)-2-isopropyl-5-methylcyclohexyl carbonate) had a retention time of 28.6 min (Chiralpak AD column). ESI-MS m/z calc. 679.3, found; 680.5 (M+l)+; Retention time 3.86 minutes. [00170] l-(Benzo[rf][l,3]dioxol-6-yl)-iV-(5-((5)-(2-chlorophenyl)((i?)-3- hydroxypyrrolidin-l-yI)methyl)thiazol-2-yl)cyclopropanecarboxamide (1) hydrochloride and l-(Benzo[rf][l,3]dioxol-6-yl)-iV-(5-((i?)-(2-chlorophenyl)((i?)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yI)cyclopropanecarboxamide (2) hydrochloride
Figure imgf000053_0001
[00171] The first eluting product from previous step (1.20 g, 1.76 mmol) was stirred at room temperature in 182 mL of methanol containing (0.9153 g, 16.31 mmol) of potassium hydroxide for 4 days. The solution was then cooled to 0 0C and 16.31 mL of IN HCl was slowly added to the reaction mixture. The resulting solution was evaporated to near dryness and then partitioned between 100 mL of dichloromethane and 100 mL of a saturated aqueous solution of sodium bicarbonate. The layers were separated and the organic layer was washed twice with and equal volume of a saturated aqueous solution of sodium bicarbonate followed by three washes with a saturated aqueous solution of sodium chloride. The organic layer was then dried over anhydrous sodium sulfate, concentrated, and purified on 12O g of silica gel utilizing a gradient of 20-100% ethyl acetate in hexanes over 40 minutes to yield the pure product 1 as a white solid (0.70 g, 1.4 mmol). This material was then dissolved in a minimum of dichloromethane and 1.4 mL of IM HCl in ether was added to the solution. The solution was evaporated to dryness to yield the HCl salt as a white solid (0.7818 g, 1.463 mmol, 83.1%). ESI-MS m/z calc. 497.1, found; 498.3 (M+l)+; Retention time 2.36 minutes. Retention time of this product was 14.5 min. on a Chiralpak OJ-H 4.6 mm x 250 mm column (25% of a 50/50 (v/v) mixture of ethanol and methanol in hexanes at 1.0 mL/min). 1H NMR (400 MHz, DMSOd6) δ (free base )1.07-1.15 (m, 2H), 1.40-1.44 (m, 2H), 1.51-1.65 (m, IH), 1.95-2.08 (m, IH), 2.32-2.58 (m, 4H), 4.10-4.31 (m, IH), 4.76 (d, J= 4.3 Hz, IH), 4.95 (s, IH), 6.00 (s, 2H), 6.85 (s, 2H), 6.95 (d, J= 0.9 Hz, IH), 7.26 (t, J= 7.6 Hz, IH), 7.34-7.44 (m, 3H), 7.78 (d, J= 7.7 Hz, IH), 11.02 (s, IH) [00172] The second eluting product from previous step (0.1018 g, 0.1497 mmol) was stirred at room temperature in 15 mL of methanol containing (9.5 mg, 0.17 mmol) of potassium hydroxide for 3 days. An additional aliquot of potassium hydroxide was added (64.8 mg, 1.15 mmol) and the solution was allowed to stir for and additional 3 days. The solution was then cooled to 0 0C and 1.319 mL of IN HCl was slowly added to the reaction mixture. The resulting solution was evaporated to near dryness and then partitioned between 10 mL of dichloromethane and 10 mL of a saturated aqueous solution of sodium chloride. The organic layer was then dried over anhydrous sodium sulfate, concentrated, and purified on 12 g of silica gel utilizing a gradient of 20-100% ethyl acetate in hexanes over 40 minutes. The column was then flushed with ethylacetate containing 2.5% triethylamine. The pure fractions were combined and evaporated to dryness to yield the pure product 2 as a white solid (15.7 mg, 0.0315 mmol). This material was then dissolved in a minimum of dichloromethane and 0.0315 mL of IM HCl in ether was added to the solution. The solution was evaporated to dryness to yield the HCl salt as a white solid (16.8 g, 0.0315 mmol, 21.0%). ESI-MS m/z calc. 497.1, found; 498.3 (M+l)+; Retention time 2.42 minutes. Retention time 10.9 minutes on a Chiralpak OJ-H 4.6 mm x 250 mm column (25% of a 50/50 (v/v) mixture of ethanol and methanol in hexanes at 1.0 mL/min.)
[00173] (R)-iV-(2-Chlorobenzylidene)-l,l-dimethylethylsulfmamide
Figure imgf000054_0001
To a stirred anhydrous dioxane (500 mL) was added 2-chlorobenzaldehyde (34.8 g, 247.5 mmol) and the solution was cooled down to O0C in an ice bath. A solution of (R)-2- methylpropanesulfmarnide (30.0 g, 247.5 mmol) in anhydrous dioxane (100 mL) was added to the aldehyde solution. Ti(OPr)4 (105.5 g, 371.3 mmol) was then slowly added to the solution while stirring at O0C. The reaction mixture was allowed to warm up to 250C, stirred at 250C for 18 h, quenched with NaHCO3 and then filtered through a short plug of Celite using EtOAc. The organic layer was separated from the aqueous layer and dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0-25% EtOAc/Hexane) to provide (i?)-N-(2-chlorobenzylidene)-l,l-dimethylethylsulfinamide as a yellow liquid (45.1 g, 75%). 1H- NMR (400 MHz, CDC13) δ 9.05 (s, IH), 8.06 (dd, J = 7.9, 1.1 Hz, IH), 7.47-7.41 (m, 2H), 7.37- 7.33 (m, IH), 1.28 (s, 9H). HPLC ret. time 3.45 rain, 10-99%CH3CN, 5 min run; ESI-MS 244.3 m/z (MH4).
[00174] tert-Butyl thiazol-2-ylcarbamate
/sV-NHBoc
To a solution of 2-aminothiazole (20.0 g, 199.7 mmol) and (Boc)2O (48.0 g, 219.7 mmol) in anhydrous THF (100 mL) were added DMAP (20 mg) and Et3N (36.0 mL, 260.0 mmol). The reaction mixture was stirred at 250C for 18 h, diluted with CH2Cl2 and washed with 0.1 N HCl (X 1), brine (X 1) and H2O (X 1). The organic layer was separated from the aqueous layer, dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0- 40% EtOAc/Hexane) to provide tert-butyl thiazol-2-ylcarbamate as a white solid (20.7 g, 72%). 1H-NMR (400 MHz, CDCl3) δ 11.44 (s, IH), 7.38 (d, J = 3.6 Hz, IH), 6.89 (d, J = 3.6 Hz, IH), 1.58 (s, 9H). HPLC ret. time 2.61 min, 10-99%CH3CN, 5 min run; ESI-MS 145.1 m/z (MH+).
[00175] (i?)-iV-(l-((2-^-butoxylcarbonylainino)thiazoI-5-yl)-l-(2-chIorophenyl)- methyl)-l,l-dimethylethylsulfϊnamide
Figure imgf000055_0001
A solution of tert-butyl thiazol-2-ylcarbamate (15.0 g, 75.0 mmol) in anhydrous THF (175 mL) was stirred and cooled down to -780C. To this solution was slowly added M-BuLi (2.5 M in hexane: 60.0 mL, 150.0 mmol). Upon completion of 7?-BuLi addition, the mixture was allowed to warm up to -4O0C, maintained at -4O0C for 1 h and then cooled down to -780C. A solution of (iϋ)-N-(2-chlorobenzylidene)- 1,1 -dimethyl ethylsulfinamide (10.0 g, 41.0 mmol) in anhydrous THF (175 mL) previously cooled to -780C was slowly added to the above solution via canulation. The reaction was kept at -780C for 0.5 h, allowed to warm up to room temperature and stirred at room temperature for 2 h. The reaction was then quenched with aqueous NH4Cl, and the crude product was extracted with EtOAC (X 3). The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0- 80% EtOAc/Hexane) to provide a diastereomeric mixture of (i?)-N-(l-((2-t- butoxylcarbonylamino)thiazol-5-yl)- 1 -(2-chlorophenyl)-methyl)- 1 , 1 -dimethyl ethylsulfϊnamide as a yellow solid (15.1 g, 83%) that was used directly in the next step.
[00176] (R)-iV-(S)-l-(2-Aminothiazol-5-yl)-l-(2-chlorophenyl)methyl)-l,l- dimethylethylsuIfinamide and (i?)-iV-(Λ)-l-(2-aπiinothiazol-5-yl)-l-(2- chlorophenyl)methyl)-l,l-dimethylethylsulfinamide
Figure imgf000056_0001
To a solution of of (i?)-N-(l-((2-t-butoxylcarbonylamino)thiazol-5-yl)-l-(2- chlorophenyl)-methyl)-l,l-dimethylethylsulfinamide (7.0 g, 15.8 mmol) in CH2Cl2 (28 mL) was added trifluoroacetic acid (28 mL). The reaction was stirred at room temperature for 3.5 h. The trifluoroacetic acid and CH2Cl2 were removed under vacuum. The crude product was re- dissolved in CH2Cl2, washed with aqueous NaHCO3 (20 mL X 2) and water (20 mL X l), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0- 5% EtOH/EtOAc) to provide (i?)-N-(,S)-l-(2-aminothiazol-5-yl)-l-(2-chlorophenyl)methyl)-l,l- dimethylethylsulfmamide and (RyN-(R)- 1 -(2-aminothiazol-5-yl)- 1 -(2-chlorophenyl)methyl)- 1.1- dimethylethylsulfinamide.
[00177] (i?)-iV-(5)-l-(2-aminothiazol-5-yl)-l-(2-chlorophenyl)methyl)-l,l- dimethylethylsulfinamide: yellow solid, 4.3 g (79%). 1H-NMR (400 MHz, CDCl3) δ 7.53 (dd, J = 7.6, 1.8 Hz, IH), 7.38 (dd, J = 7.7, 1.5 Hz, IH), 7.32 (td, J = 7.5, 1.6 Hz, IH), 7.27 (td, J = 7.5, 1.8 Hz, IH), 6.84 (d, J = 0.7 Hz, IH), 6.17 (s, 2H), 6.07 (d, J = 4.5 Hz, IH), 4.17 (d, J = 4.6 Hz, IH), 1.26 (s, 9H). HPLC ret. time 2.11 min, 10-99%CH3CN, 5 min run; ESI-MS 344.0 m/z (MH+).
[00178] (i?)-iV-(i?)-l-(2-Aminothiazol-5-yl)-l-(2-chlorophenyl)methyl)-l,l- dimethylethylsulfϊnamide: yellow solid, 596 mg, (11%). HPLC ret. time 2.35 min, 10- 99%CH3CN, 5 min run; ESI-MS 344.0 m/z (MH+).
[00179] (5)-7V-(5-((R)-t-butylsulfinylaraino(2-chIorophenyI)methyl)thiazol-2- yty-l-φenzoIdπijSJdioxol-S-yOcyclopropanecarboxamide
Figure imgf000057_0001
To l-(benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxylic acid (2.16 g, 10.5 mmol) was slowly added SOCl2 (2.3 mL, 31.5 mmol) followed by DMF (3 drops). The reaction mixture was heated at 6O0C for 0.5 h. The excess SOCl2 was removed under vacuum. The acid chloride (10.5 mmol) was then dissolved in anhydrous CH2Cl2 (16 mL) and was slowly added to a cold (temperature ~ O0C) solution of (i?)-iV-(5)-l-(2-ammothiazol-5-yl)-l-(2-chlorophenyl)methyl)- 1,1-dimethylethylsulfϊnamide (3.6 g, 10.5 mmol) and Et3N (7.33 mL, 52.6 mmol) in anhydrous CH2Cl2 (16 mL). The reaction mixture was stirred at 250C for 18 h, diluted with CH2Cl2 and washed with 1 N HCl (50 mL X 2), NaHCO3 (50 mL X 1) and brine (50 mL X 1). The organic layer was separated from the aqueous layer, dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0-80% EtOAc/Hexane) to provide (6)-iV-(5- ((i?)-^-butylsulfinylamino-(2-chlorophenyl)methyl)thiazol-2-yl)-l -(benzo[d] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide as a yellow solid (4.7 g, 84%). 1H-NMR (400 MHz, CDCl3) δ 8.52 (s, IH), 7.60 (dd, J = 7.7, 1.7 Hz, IH), 7.35 (dd, J = 7.8, 1.4 Hz, IH), 7.32 (dd, J = 7.5, 1.4 Hz, IH), 7.29 (d, J = 0.7 Hz, IH), 7.23 (dd, J = 7.6, 1.7 Hz, IH), 6.89 (dd, J = 7.9, 1.8 Hz, IH), 6.86 (d, J = 1.6 Hz, IH), 6.81 (d, J = 7.9 Hz, , , 6.21 (d, J = 4.0 Hz, IH), 6.01 (s, 2H), 3.93 (d, J = 4.0 Hz, , IH), 1.75-1.66 (m, 2H), 1.27 (s, 9H), 1.22 (t, J = 3.3 Hz, 2H).. HPLC ret. time 3.52 min, 10-99%CH3CN, 5 min run; ESI-MS 532.0 m/z (MH4).
[00180] (S)-N-(5-(Amino(2-chIorophenyl)methyl)thiazol-2-yl)-l- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamide
Figure imgf000057_0002
To a solution of (jS)-N-(5-((i?)-/-butylsulfinylamino-(2-chlorophenyl)methyl)thiazol-2-yl)- l-(benzo[d][l,3]dioxol-5-yl)cyclopropane- carboxamide (11.25 g, 21.19 mmol) in MeOH (100 mL) was added 4 M HCl in dioxane (32 mL,128 mmol). The reaction mixture was stirred at 25°C for 1.5 h and evaporated to dryness. The crude product was dissolved in CH2Cl2. The organic layer was washed with aqueous NaHCO3 (50 mL X 2), brine (50 mL X l), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0-2.5% Et3N- EtOAc) to provide (5)-N-(5-(amino(2-chlorophenyl)methyl)thiazol-2-yl)-l-(benzo[d][l,3]dioxol- 5-yl)cyclopropanecarboxamide (6.5 g, 72%, >99% ee). 1H-NMR (400 MHz, CDCl3) δ 8.51 (s, IH), 7.60 (dd, J = 7.7, 1.7 Hz, IH), 7.33 (dd, J = 7.9, 1.3 Hz, IH), 7.29-7.25 (m, IH), 7.20 (td, J = 7.6, 1.7 Hz, IH), 7.16 (d, J = 1.0 Hz, IH), 6.89 (td, J = 7.8, 1.7 Hz, 2H), 6.80 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 5.79 (s, IH), 1.86 (bs, 2H), 1.72-1.69 (m, 2H), 1.22-1.19 (m, 2H). HPLC ret. time 2.66 min, 10-99%CH3CN, 5 min run; ESI-MS 428.1 m/z (MH+).
[00181] l-(Benzo[d][l,3]dioxol-5-yl)-iV-(5-((S)-(2-chlorophenyl)((i?)-3- dimethyl-f-butylsilyIhydroxypyrroIidin-l-yl)methyl)thiazol-2- yl)cyclopropanecarboxamide
Figure imgf000058_0001
To a solution of (lS)-N-(5-(amino(2-chlorophenyl)methyl)thiazol-2-yl)-l- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamide (214 mg, 0.5 mmol) in MeOH (2.5 mL) was added (i?)-4-chloro-3-dimethyl-t-butylhydroxybutanal (142 mg, 0.6 mmol). The reaction mixture was stirred at 250C for 5 min before NaBH4 (28 mg, 0.75 mmol) was added. Stirring was continued at 25°C for 1 h. The reaction was diluted with H2O and extracted with EtOAc. The combined organic layers was washed with brine and dried over MgSO4. After the removal of solvent, the residue was purified by column chromatography (10-20% EtOAc-Hexane) to afford l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((5}-(2-chlorophenyl)((i?)-3-dimethyl-t- butylsilylhydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide (162 mg, 53%). 1H-NMR (400 MHz, CDCl3) δ 8.45 (s, IH), 7.81 (dd, J = 8.1, 1.6 Hz, IH), 7.28 (s, IH), 7.25- 7.22 (m, 2H), 7.13-7.09 (m, IH), 6.85 (td, J = 7.7, 1.7 Hz, 2H), 6.77 (d, J = 7.9 Hz, IH), 5.98 (s, 2H), 5.05 (s, IH), 4.36-4.31 (m, IH), 2.81 (dd, J = 9.8, 6.2 Hz, IH), 2.57-2.46 (m, 2H), 2.37 (dd, J = 9.8, 4.5 Hz, IH), 2.08-1.99 (m, IH), 1.73-1.62 (m, 3H), 1.17 (t, J = 3.9 Hz, 2H), 0.85 (s, 9H), -0.01 (d, J = 6.9 Hz, 6H). HPLC ret. time 3.51 min, 10-99%CH3CN, 5 min run; ESI-MS 612.41 m/z (MH+). [00182] l-(Benzo[d][l,3]dioxoI-5-yl)-iV-(5-((5)-(2-chlorophenyl)((i?)- hydroxypyrrolidin-l-ytymethytythiazol^-y^cyclopropanecarboxamide (1)
Figure imgf000059_0001
A mixture of l-(benzo[d][l,3]dioxol-5-yl)-iV-(5-((ly)-(2-chlorophenyl)((i?)-3-dimethyl-^- butylsilylhydroxypyrrolidin-l-y^methyl^liiazol-l-y^cyclopropanecarboxamide (61 mg, 0.1 mmol) and TBAF (1 M in THF, 0.6 mL, 0.6 mmol) was stirred at 250C for 3 h. The reaction was diluted with H2O and extracted with EtOAc. The combined organic layers was washed with brine and dried over MgSO4. After the removal of solvent, the residue was purified by column chromatography (10-20% EtOAc-Hexane) to afford l-(benzo[d][l,3]dioxol-5-yl)-iV-(5-((5)-(2- chlorophenyi)((i?)- hydroxypyrrolidin- 1 -y^methy^thiazol-l-y^cyclopropanecai'boxamide (1) (30 mg, 62%, >99% ee). 1H-NMR (400 MHz, DMSO-d6) δ 11.00 (s, IH), 7.79 (dd, J = 7.8, 1.5 Hz, IH), 7.43-7.37 (m, 3H), 7.26 (td, J = 7.6, 1.4 Hz, IH), 6.95 (s, IH), 6.86 (d, J = 0.7 Hz, 2H), 6.00 (s, 2H), 4.96 (s, IH), 4.76 (d, J = 4.4 Hz, IH), 4.20 (ddd, J = 6.6, 3.4 Hz, IH), 2.56-2.45 (m, 2H), 2.43-2.36 (m, 2H), 2.06-1.97 (m, IH), 1.62-1.54 (m, IH), 1.43 (q, J = 3.7 Hz, 2H), 1.14-1.09 (m, 2H). HPLC ret. time 2.85 min, 10-99%CH3CN, 5 man run; ESI-MS 498.0 m/z (MH+).
[00183] (i?)-iV-(5-((J?)-/-butylsulfmylamino(2-chlorophenyl)methyl)thiazol-2- yO-l-φenzofdπi^dioxol-S-ytycyclopropanecarboxamide
Figure imgf000059_0002
(i?)-7V-(5-((i?)^-butylsulfmylamino(2-chlorophenyl)methyl)thiazol-2-yl)-l- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamide was prepared from (R)-N-(R)-I -(2- aminotliiazol-5-yl)-l-(2-chloiOphenyl)methyl)-l,l-dimethylethylsulfinamide and 1- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxylic acid using the same protocol for (JS)-JV-(5- ((/?)-ϊ-butylsulfinylamino(2-chlorophenyl)methyl)thiazol-2-yl)- 1 -(benzo[d] [ 1 ,3]dioxol-5- yljcyclopropanecarboxamide. 1H-NMR (400 MHz, CDCl3) δ 8.55 (s, IH), 7.62 (dd, J = 7.7, 1.7 Hz, IH), 7.37 (d, J = 0.7 Hz, IH)3 7.34 (dd, J = 7.8, 1.4 Hz, IH), 7.31-7.20 (m, 2H), 6.87 (td, J = 8.4, 1.7 Hz, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.30 (d, J = 2.8 Hz, IH), , 6.01 (s, 2H), 3.74 (d, J = 2.8 Hz, IH), 1.71-1.68 (m, 2H), 1.24 (s, 9H), 0.88 (t, J = 6.9 Hz, 2H). HPLC ret. time 3.59 min, 10- 99%CH3CN, 5 min run; ESI-MS 532.1 m/z (MH+).
[00184] (2?)-iV-(5-(Amino(2-chlorophenyl)niethyl)thiazol-2-yl)-l- (benzofdπi^dioxol-S-yrjcyclopropanecarboxamide
Figure imgf000060_0001
(i?)-N-(5-(Amino(2-chlorophenyl)methyl)thiazol-2-yl)-l-(benzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamide was prepared from (i?)-N-(5-((i?)-^butylsulfinylamino(2- chlorophenyl)methyl)thiazol-2-yl)- 1 -(benzo[d][ 1 ,3]dioxol-5-yl)cyclopropanecarboxamide using the same protocol described for (5)-N-(5-(amino(2-chlorophenyl)methyl)thiazol-2-yl)-l- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamide.1H-ΝMR (400 MHz, CDCl3) δ 8.47 (s, IH), 7.60 (dd, J = 7.7, 1.7 Hz, IH), 7.33 (dd, J = 7.9, 1.3 Hz, IH), 7.27 (td, J = 7.4, 1.5 Hz, IH), 7.20 (td, J = 7.6, 1.8 Hz, IH), 7.16 (d, J = 1.0 Hz, IH), 6.89 (td, J = 8.2, 1.7 Hz, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 5.79 (s, IH), 1.89 (s, 2H), 1.72-1.70 (m, 2H), 1.22-1.19 (m, 2H). HPLC ret. time 2.52 min, 10-99%CH3CΝ, 5 min run; ESI-MS 428.2 m/z (MH+).
[00185] l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-((if)-(2-chlorophenyl)((i?)-3- dimethyl-^butylsilylhydroxypyrrolidin-l-yI)methyl)thiazol-2- yl)cyclopropanecarboxamide
Figure imgf000060_0002
l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-((i?)-(2-chlorophenyl)((i?)-3-dimethyl-t- butylsilylhydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide was prepared from (JR)-N-(5-(amino(2-chlorophenyl)methyl)thiazol-2-yl)- 1 -(benzo[d] [ 1 ,3 ]dioxol-5- yl)cyclopropanecarboxamide using the same protocol for l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((6)- (2-chlorophenyl)((i?)-3 -dimemyl^butylsilylhydroxypyrrolidin- 1 -yl)methyl)thiazol-2- yl)cyclopropanecarboxamide. 1H-ΝMR (400 MHz, CDCl3) δ 8.45 (s, IH), 7.79 (dd, J = 8.1, 1.5 Hz, IH), 7.28-7.23 (m, 3H), 7.14-7.10 (m, IH), 6.85 (td, J = 8.1, 1.7 Hz, 2H), 6.78 (d, J = 7.9 Hz, IH), 5.99 (s, 2H), 5.08 (s, IH), 4.36-4.31 (m, IH), 2.94 (dd, J = 9.9, 6.3 Hz, IH), 2.65 (td, J = 8.4, 3.9 Hz, IH), 2.56 (q, J = 8.3 Hz, IH), 2.16 (dd, J = 9.9, 4.6 Hz, IH), 2.06-1.97 (m, IH), 1.73-1.62 (m, 3H), 1.20-1.15 (m, 2H), 0.84 (s, 9H), -0.01 (d, J = 7.9 Hz, 6H). HPLC ret. time 3.51 min, 10-99%CH3CΝ, 5 min run; ESI-MS 612.41 m/z (MH+).
[00186] l-(Benzo[d][l,3]dioxol-5-yl)-iV-(5-((R)-(2-clilorophenyl)((if)- hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cydopropanecarboxamide (2)
Figure imgf000061_0001
1 -(Benzo[d][ 1 ,3]dioxol-5-yl)-iV-(5-((i?)-(2-chlorophenyl)((i?)-hydroxypyrrolidm- 1 - yl)methyl)thiazol-2-yl)cyclopropanecarboxamide was prepared from l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((i?)-(2-chloroprienyl)((i?)-3-dimethyl-?-butylsilylhydroxypyrrolidm-l- yl)methyl)thiazol-2-yl)cyclopropanecarboxamide using the same protocol described for 1 - (benzo[d][ 1 ,3]dioxol-5-yl)-N-(5-((1S)-(2-chlorophenyl)((i?)-hydroxypyrrolidin- 1 - yl)methyl)thiazol-2-yl)cyclopropanecarboxamide. 1H-NMR (400 MHz, DMSO-d6) δ 11.01 (s, IH), 7.79 (dd, J = 7.8, 1.6 Hz, IH), 7.45-7.39 (m, 3H), 7.30-7.26 (m, IH), 6.97 (s, IH), 6.87 (d, J = 0.9 Hz, 2H), 6.02 (s, 2H), 4.99 (s, IH), 4.73 (d, J = 4.3 Hz, IH), 4.24-4.18 (m, IH), 2.72 (dd, J = 9.9, 6.1 Hz, IH), 2.62 (q, J = 7.8 Hz, IH), 2.37-2.32 (m, IH), 2.22 (dd, J = 9.9, 3.2 Hz, IH), 2.04-1.96 (m, IH), 1.64-1.57 (m, IH), 1.44 (q, J = 3.8 Hz, 2H), 1.13 (t, J = 3.8 Hz, 2H). HPLC ret. time 2.56 min, 10-99%CH3CN, 5 min run; ESI-MS 498.3 m/z (MH+). [00187] The methods outlined in Scheme A, Scheme B, and Scheme C below were used to make representative compounds of this invention as recited below. [00188] Scheme A:
Figure imgf000062_0001
Figure imgf000062_0002
a) Ti(OPr)4, dioxane or THF; b) (Boc)2O, Et3N, DMAP, THF; c) n-BuLi, -780C, THF; d) 50% TFA, CH2Cl2.
[00189] Scheme B:
Figure imgf000063_0001
a) SOCl2, DMF, 600C; b) Et3N, CH2Cl2; c) HCl in dioxane, CH3OH; d) NaBH4 (LG= leaving group).
[00190] Scheme C:
Figure imgf000063_0002
Figure imgf000063_0003
a) SOCl2, DMF, 60°C; b) Et3N, CH2Cl2; c) HCl in dioxane, CH3OH; d) NaBH4 (LG= leaving group). [00191] l-(Benzo[</|[l,3]dioxoI-5-yl)cyclopropanecarboxylic acid
Figure imgf000064_0001
A mixture of 2-(benzo[<f][l,3]dioxol-5-yl)acetonitrile (5.10 g, 31.7 mmol), l-bromo-2-chloro- ethane (9.000 niL 108.6 mmol), and benzyltriethylammonium chloride (BTEAC, 0.181 g, 0.795 mmol) was heated to 7O0C and then 50% (wt./wt.) aqueous sodium hydroxide (26 mL) was slowly added. The reaction was stirred at 70 0C for 88 hours and then heated to reflux (130 °C bath temperature) for 24 hours. The dark brown/black reaction mixture was diluted with water (400 mL) and extracted twice with equal volumes of ethyl acetate and dichloromethane. The basic aqueous solution was acidified with concentrated hydrochloric acid to pH less than one and the precipitate was filtered and washed with 1 M hydrochloric acid. The solid material was dissolved in dichloromethane (400 mL) and washed twice with equal volumes of 1 M hydrochloric acid and once with brine. The organic solution was dried over sodium sulfate and evaporated to dryness to give a white to slightly off-white solid (5.23 g, 80.1 %). 1H NMR (400 MHz, DMSOd6) δ 1.07-1.11 (m, 2H), 1.38-1.42 (m, 2H), 5.98 (s, 2H), 6.79 (m, 2H), 6.88 (m, IH), 12.26 (s, IH); HPLC ret. time 2.37 min, 10-99% CH3CN, 5 min run; ESI-MS 206.1 m/z (MH+).
Figure imgf000064_0002
R=Me or H
Figure imgf000064_0003
[00192] Methyl 2,2-difluorobenzo[</][l,3]dioxole~5-carboxylate
Figure imgf000065_0001
A solution of 5-bromo-2,2-difluorobenzo[rf][l,3]dioxole (11.8 g, 50.0 mmol) and tetrakis(triphenylphosphine)palladium (0) [5.78 g, 5.00 mmol] in methanol (20 mL) containing acetonitrile (30 mL) and triethylamine (10 mL) was stirred under a carbon monoxide atmosphere (55 psi) at 75 °C (oil bath temperature) for 15 h. The cooled reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was purified by silica gel column chromatography to give methyl 2,2-difluorobenzo [d][l,3]dioxole-5-carboxylate (11.5 g), which was used directly in the next step.
[00193] (2,2-Difluorobenzo[d] [l,3]dioxol-5-yl)methanol
Figure imgf000065_0002
Method A: Methyl 2,2-difluorobenzo[<f][l,3]dioxole-5-carboxylate from previous step (11.5 g) dissolved in anhydrous tetrahydrofuran (20 mL) was slowly added to a suspension of lithium aluminum hydride (4.10 g, 106 mmol) in anhydrous THF (100 mL) at 0 0C. The mixture was then warmed to room temperature and stirred at for 1 h. The reaction mixture was cooled to 0 °C and treated with water (4.1 g), followed by sodium hydroxide (10% aqueous solution, 4.1 mL). The resulting slurry was filtered and washed with THF. The combined filtrate was evaporated to dryness and the residue was purified by silica gel column chromatography to give (2,2- difluorobenzo[J][l,3]dioxol-5-yl)methanol as a colorless oil (7.2 g, 76% over two steps).
Method B: To a solution of 2,2-difluorobenzo[J][l,3]dioxole-5-carbaldehyde (125 g, 0.67 mol) in anhydrous THF (400 mL) was added NaBH4 (28 g, 0.74 mol) in portions at 0 0C. The mixture was stirred for 1 h at 0 0C, then poured into 500 mL of water. The mixture was extracted with ethyl acetate (200 mL x 3). The organic phase was dried over Na2SO4 and concentrated in vacuo to give (2,2-difluorobenzo[<f|[l,3]dioxol-5-yl)methanol as colorless oil (120 g, 95%).
[00194] 5-(ChloiOmethyl)-2,2-difluorobenzo[</| [l,3]dioxole
Figure imgf000066_0001
A solution of (2,2-difluorobenzo[</][l,3]dioxol-5-yl)methanol (12O g, 0.64 mol) in neat thionyl chloride (500 niL) was stirred for 2 h at 25 0C. The excess thionyl chloride was distilled off in vacuo. The residue was partitioned between saturated NaHCO3 (400 mL) and dichloromethane (200 mL). The separated aqueous layer was extracted with dichloromethane (300 mL x 3). The combined organic layers were dried, filtered and concentrated in vacuo to give 5-(chloromethyl)- 2,2-difluorobenzo[XJ[l,3]dioxole (117.6 g, 89%), which was directly used in the next step.
[00195] 2-(2,2-difluorobenzo[rf] [l,3]dioxol-5-yl)acetonitrile
Figure imgf000066_0002
A mixture of 5-(chloromemyl)-2,2-difluorobenzo[<J][l,3]dioxole (117.6 g, crude from last step) and NaCN (84 g, 1.7 mmol) in DMSO (800 mL) was stirred for 2 h at 25 0C. The reaction mixture was poured into ice and extracted with EtOAc (500 mL x 3). The combined organic layers were dried with anhydrous Na2SO4 and concentrated in vacuo to give crude product which was purified by column chromatography (P.E./EtOAc 10:1) to give 2-(2,2- difluorobenzo[φ,3]dioxol-5-yl)acetonitrile (77.8 g, 66%). 1H NMR (300 MHz , CDCl3) δ 7.06-7.07 (m, 3 H), 3.75 (s, 2 H).
[00196] l-(2,2-Difluorobenzo[</[ [l,3]dioxol-5-yl)cyclopropanecarboxylic acid
Figure imgf000066_0003
l-(2,2-difluorobenzo[<i][l,3]dioxol-5-yl)cyclopropanecarboxylic acid was made by the procedure used for l-(benzo[<f][l,3]dioxol-5-yi)cyclopropanecarboxylic acid, starting from 2-(2,2- difluorobenzo[<i][l,3]dioxol-5-yl)acetonitrile. Yield (86%) of a white solid. 1H NMR (400 MHz, CDCl3) δ 7.14-7.04 (m, 2 H), 6.98-6.96 (m, 1 H), 1.74- 1.64 (m, 2 H), 1.26- 1.08 (m, 2 H); ESI-MS m/z calc. 242.04, found 241.58 (M-I). [00197] tert-Butyl thiazol-2-ylcarbamate
Figure imgf000067_0001
To a solution of aminothiazole (20.0 g, 199.7 mmol) and (Boc)2O (48.0 g, 219.7 mmol) in anhydrous THF (100 mL) were added DMAP (20 mg) and Et3N (36.0 mL, 260.0 mmol). The reaction mixture was stirred at room temperature for 18 h, diluted with DCM and washed with 0.1 N HCl, H2O and brine. The organic layer was separated from the aqueous layer, dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0-40% EtOAc/Hexane) to provide tert-butyl thiazol-2-ylcarbamate as a white solid (20.7 g, 72%). 1H- NMR (400 MHz, CDCl3) δ 11.44 (s, IH), 7.38 (d, J = 3.6 Hz, IH), 6.89 (d, J = 3.6 Hz, IH), 1.58 (s, 9H); HPLC ret. time 2.61 min, 10-99%CH3CN, 5 min run; ESI-MS 145.1 m/z (MH+).
[00198] tert-Butyl 4-methylthiazol-2-ylcarbamate
Figure imgf000067_0002
To a solution of 4-methylthiazol-2-amine (25 g, 219 mmol) and (Boc)2O (53 g, 241 mmol) in anhydrous THF (110 mL) were added DMAP (250 mg) and Et3N (39.6 mL, 285 mmol). The reaction mixture was stirred at room temperature for 18 h. Then the reaction was heated to reflux for 5 h, until no more starting material was detected by LC-MS. The reaction was cooled to room temperature and filtered to remove the precipitate. The filtrate was concentrated, then dissolved in CH2Cl2 and washed with 0.1 N aqueous HCl, H2O and brine. The organic layer was dried over MgSO4 and concentrated. The residue was suspended in hexane and then filtered to obtain tert-butyl 4-methylthiazol-2-ylcarbamate as a cream colored solid (30.9 g, 66 %). 1H- NMR (400 MHz, DMS(W6) δ 11.30 (s, IH), 6.68 (d, J= 1.0 Hz, IH), 2.20 (d, J= 0.9 Hz, 3H), 1.47 (s, 9H); HPLC ret. time 2.68 min, 10-99 % CH3CN, 5 min run; ESI-MS 215.3 m/z (MH+).
Figure imgf000068_0001
PPh3, NCS^ 9H TBSC|i DMAp ψBSD D|BAL OTBS
CH2CI2 CI^^^CHO imidazole
[00199] (R)-Dimethyl 2-hydroxysuccinate
Figure imgf000068_0002
To a solution of (R)-2-hydroxysuccinic acid (134 g, 1 mol) in CH3OH (500 niL) was added toluene-4-sulfonic acid (9.5 g, 0.05 mol). The mixture was heated to reflux overnight. Methanol was evaporated, and then water (250 mL) was added to the residue. The mixture was basified with sat. NaHCO3 solution to pH 7-8 and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give (R)-dimethyl 2-hydroxysuccinate (140 g, 86%). 1HNMR (300 MHz, CDCl3) δ 4.46 (dd, J= 6 Hz, 4.8 Hz, 1 H), 3.74 (s, 3 H), 3.64 (s, 3 H), 3.42 (s, 1 H), 2.69-2.85 (m, 2 H).
[00200] (R)-Methyl 3,4-dihydroxybutanoate
OH O HO.
O
To a solution of (R)-dimethyl 2-hydroxysuccinate (140 g, 0.86 mol) in THF (1400 mL) was added dropwise Me2S*BH3 (86 mL, 10 M) at 20 0C over 30 min. The mixture was stirred at 20 0C for 30 min. NaBH4 (1.63g, 42.9 mmol) was added at 100C and stirred at 100C for 30 min. The mixture was warmed to room temperature and stirred for 1 h. CH3OH (200 mL) was slowly added to the mixture while cooling in an ice- water bath. The resulting mixture was evaporated to give (R)-methyl 3,4-dihydroxybutanoate (130 g, crude).
[00201] (R)-Methyl 4-chloro-3-hydroxybutanoate OH Q
-o'
To a solution of (R)-methyl 3,4-dihydroxybutanoate (125.1 g, 0.93 mol) in CH2Cl2 (1.8 L) was added PPh3 (244.5 g, 0.93 mol) and slowly added NCS (124.2g, 0.93 mol) under ice water cooling. The mixture was stirred at 5 0C for 20 min and then stirred for 18 h at room temperature. After evaporating the solvent, the residue was purified by column chromatography (P.E\E.A 20:1-5:1, gradient) to give (R)-methyl 4-chloro-3-hydroxybutanoate (33 g, 26% over 3 steps). 1H NMR (300MHz, CDCl3) δ 4.18-4.25 (m, 1 H), 3.68 (s, 3 H), 3.55-3.60 (m, 2 H), 3.32- 3.33 (d, J= 4.2 Hz, 1 H), 2.52-2.68 (m, 2 H).
[00202] (R)-Methyl 3-(tert-butyldimethylsilyloxy)-4-chlorobutanoate
QTBSO
A solution of (R)-methyl 4-chloro-3-hydroxybutanoate (15 g, 98.7 mmol) in CH2Cl2 (240 mL) was stirred overnight with te/^-butyl-chloro-dimethyl-silane (17.82 g, 118.2 mmol), imidazole (33.6 g, 493.5 mmol) and a catalytic amount of DMAP (0.6 g, 4.92 mmol) at room temperature under N2. The reaction mixture was poured into water (150 mL) and acidified to pH 6-7 by dropwise addition of cold aqueous HCl (0.5 M). The aqueous phase was extracted with CH2Cl2 (3 x 60 mL). The combined organic phases were washed with sat. Na2CO3 solution, brine, dried over anhydrous Na2SO4 and concentrated to give (R)-methyl 3-(fe?t-butyldimethylsilyloxy)-4- chlorobutanoate (30 g, crude).
[00203] (R)-3-(fe^-Butyldimethylsilyloxy)-4-chlorobutanal
QTBS
To a solution of (R)-methyl 3-(ter^-butyldimethylsilyloxy)-4-chlorobutanoate (27.9 g, 104.7 mmol) in CH2Cl2 was added dropwise DIBAL-H (120 mL, 1 M in toluene, 120 mmol) at -78 0C under N2 atmosphere. The mixture was stirred at -78 0C for 4 h. CH3OH (80 mL) was added slowly to the reaction mixture at -78 0C. Then the temperature was warmed to room temperature gradually. The mixture was filtered and the cake was washed with CH2Cl2. The combined filtrates were concentrated under reduced pressure and purified by column chromatography (PE) to give (R)-3-(tert-butyldimethylsilyloxy)-4-chlorobutanal (13 g, 60% over 2 steps). 1H NMR (300 MHz, CDCl3) δ 9.80 (t, J= 1.6 Hz, 1 H), 4.35-4.42 (m, 1 H), 3.53 (dd, J= 1 LlHz, 4.8 Hz, 1 H), 3.46 (dd, J= 12 Hz, 6.3 Hz, 1 H), 2.63-2.82 (m, 2 H), 0.87 (s, 9 H), 0.12 (s, 3 H), 0.08 (s, 3 H).
[00204] (S)-3-(tert-Butyldimethylsilyloxy)-4-chIorobutanal
OTBS
[00205] (S)-3-(teι ^-Butyldimethylsilyloxy)-4-chlorobutanal was prepared by the same route as (R)-3-(te/t-butyldimethylsilyloxy)-4-chlorobutanal starting from (S)-2- hydroxysuccinic acid. 1HNMR (400 MHz, CDCl3) δ 9.72 (dd, J = 1.6, 2.2 Hz, IH), 4.33 - 4.28 (m, IH), 3.46 (dd, J = 4.7, 11.1 Hz, IH), 3.39 (dd, J = 6.4, 11.1 Hz, IH), 2.68 (dd, J = 1.5, 4.7 Hz, IH), 2.62 (dd, J = 2.3, 6.8 Hz, IH), 0.79 (s, 9H), 0.04 (s, 3H), 0.01 (s, 3H).
[00206] (R)-N-(2-Chlorobenzylidene)-2-methylpropane-2-suIfϊnamide
Figure imgf000070_0001
[00208] To a stirred anhydrous dioxane (500 niL) was added 2- chlorobenzaldehyde (34.8 g, 247.5 mmol) and the solution was cooled down to O0C in an ice bath. A solution of (i?)-2-methylpropanesulfinamide (30.0 g, 247.5 mmol) in anhydrous dioxane (100 mL) was added to the aldehyde solution. Ti(OPr)4 (105.5 g, 371.3 mmol) was then slowly added to the solution while stirring at O0C. The reaction mixture was allowed to warm up to room temperature and stirred for 18 h, then quenched with saturated aqueous NaHCO3 solution and filtered through a short plug of Celite using EtOAc. The organic layer was separated from the aqueous layer and dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (0-25% EtOAc/Hexane) to provide (R)-N-(2- chlorobenzylidene)-2-methylproρane-2-sulfinamide as a yellow liquid (45.1 g, 75%). 1H- NMR (400 MHz, CDCl3) δ 9.05 (s, IH), 8.06 (dd, J = 7.9, 1.1 Hz, IH), 7.47-7.41 (m, 2H), 7.37-7.33 (m, IH), 1.28 (s, 9H); HPLC ret. time 3.45 min, 10-99% CH3CN, 5 min run; ESI-MS 244.3 m/z (MH+).
[00209] (R)-N-(3,4-Dichlorobenzylidene)-2-methylpropane-2-sulfinamide
Figure imgf000071_0001
[00211] (R)-N-(3,4-Dichlorobenzylidene)-2-methylpropane-2-sulfinamide was made by the procedure used for (R)-N-(2-chlorobenzylidene)-2-methylpropane-2-sulfinamide, starting from 3,4-dichlorobenzaldehyde and (i?)-2-methylpropanesulfmamide. Yield (93%) of a yellow oil that crystallizes upon standing. 1H-NMR (400 MHz, CDCl3) D 8.51 (s, IH), 7.96 (d, J = 1.9 Hz, IH), 7.66 (dd, J = 1.9, 8.3 Hz, IH), 7.57 (d, J = 8.3 Hz, IH), 1.27 (s, 9H); HPLC ret. time 3.72 min, 10-99% CH3CN, 5 min run; ESI-MS 278.1 m/z (MH+).
[00212] (R)-N-(2-Chloro-4-fluorobenzylidene)-2-methylpropane-2-sulflnamide
Figure imgf000071_0002
[00214] (R)-N-(2-Chloro-4-fluorobenzylidene)-2-methylpropane-2-sulfinamide was made by the procedure used for (R)-N-(2-chlorobenzylidene)-2-methylpropane-2- sulfinamide, starting from 2-chloro-4-fluorobenzaldehyde and (R)-2- methylpropanesulfmamide. Yield (74%) of a colorless solid. 1H-NMR (400 MHz, CDCl3) δ 9.00 (s, IH), 8.11 (dd, J = 8.8, 6.2 Hz, IH), 7.23 (dd, J = 8.4, 2.5 Hz, IH), 7.13-7.08 (m, IH), 1.29 (s, 9H); HPLC ret. time 3.46 min, 10-99% CH3CN, 5 min run; ESI-MS 262.1 m/z (MH+).
[00215] (S)-N-(2-Chloro-4-fluorobenzylidene)-2-methylpropane-2-sulfinamide
[00217] (S)-N-(2-Chloro-4-fluorobenzylidene)-2-methylpropane-2-sulfinamide was made by the procedure used for (R)-N-(2-chlorobenzylidene)-2-methylpropane-2- sulfinamide, starting from 2-chloro-4-fluorobenzaldehyde and (8)-2- methylpropanesulfmamide. Yield (78%) of a colorless solid. 1H-NMR (400 MHz, CDCl3) δ 9.00 (s, IH), 8.11 (dd, J = 6.2, 8.8 Hz, IH), 7.23 (dd, J = 2.5, 8.4 Hz, IH), 7.13 - 7.08 (m, IH), 1.29 (s, 9H); HPLC ret. time 3.49 min, 10-99% CH3CN, 5 min run; ESI-MS 262.1 m/z (MH+).
[00218] (R)-N-(4-Chloro-2-fluorobenzylidene)-2-methylpropane-2-suIflnamide
Figure imgf000072_0002
[00220] (R)-N-(4-Chloro-2-fluorobenzylidene)-2-methylpropane-2-sulfmamide was made by the procedure used for (R)-N~(2-chlorobenzylidene)-2-methylpropane-2- sulfinamide, starting from 4-chloro-2-fluorobenzaldehyde and (R)-2- methylpropanesulfmamide. Yield (65%) of a colorless solid. 1H-NMR (400 MHz, CDCl3) δ 8.84 (s, IH), 7.97 - 7.93 (m, IH), 7.28 - 7.19 (m, 2H), 1.27 (s, 9H); HPLC ret. time 3.53 min, 10-99% CH3CN, 5 min run; ESI-MS 262.0 m/z (MH+).
[00221] (R)-fert-Butyl5-((2-chloro-4-fluorophenyl)(l,l- dimethylethylsulfinamido) methyl) thiazoI-2-ylcarbamate
Figure imgf000073_0001
[00223] A solution of tert-butyl thiazol-2-ylcarbamate (2.0 g, 10.0 mmol) in anhydrous THF (25 rnL) was stirred and cooled down to -78 0C. To this solution was slowly added «-BuLi (2.5 M in hexane: 8.0 mL, 20.0 mmol). Upon completion of /z-BuLi addition, the mixture was maintained at -78 0C for I h. A solution of (R,E)-N-(2-chloro-4- fluorobenzylidene)-2-methylpropane-2-sulfϊnamide (1.4 g, 5.4 mmol) in anhydrous THF (25 mL) previously cooled to -78 0C was slowly added to the above solution via canulation. The reaction was kept at -78 0C for 0.5 h, allowed to warm up to room temperature, quenched with aqueous NH4CI solution, and extracted with EtOAC (x 3). The combined organic layers were dried over MgSO4 and concentrated. The crude product was purified by column chromatography (0-80% EtOAc/Hexane) to provide a diasteriomeric mixture of (R)-tert-butyl 5-((2-chloro-4-fluorophenyl)( 1 , 1 -dimethyl ethylsulfinamido)methyl)thiazol-2-ylcarbamate as a yellow solid (2.1 g, 84%) that was used without further purification.
[00224] (S)-ter?-Butyl5-((2-chloro-4-fluorophenyl)(l,l- dimethylethylsulfϊnamido) methyl) thiazol-2-ylcarbamate
Figure imgf000073_0002
[00226] (S)-te/t-Butyl5-((2-chloro-4-fluorophenyl)( 1 , 1 -dimethylethylsulfmamido) methyl) thiazol-2-ylcarbamate was made by the procedure used for (R)-tert-butyl 5-((2-chloro- 4-fluorophenyl)(l,l-dimethylethylsulfinamido)methyl)thiazol-2-ylcarbamate, starting from tert-butyl thiazol-2-ylcarbamate and (S)-N-(2-chloro:4-fluorobenzylidene)-2-methylpropane-2- sulfmamide. The crude product was purified by column chromatography to provide a diasteriomeric mixture of (S)-tert-butyl 5-((2-chloiO-4-fluorophenyi)(l,l- dimethylethylsulfinamido)methyl) thiazol-2-ylcarbamate as an orange-yellow solid (95%) that was used without further purification.
[00227] (R)-te^-Butyl5-((4-chloro-2-fluorophenyl)(l,l- dimethylethylsulfinamido) methyl) thiazol-2-ylcarbamate
Figure imgf000074_0001
[00229] (R)-tert-Butyl5-((4-chloro-2-fluorophenyl)( 1 , 1 -dimethylethylsulfmamido) methyl) thiazol-2-ylcarbamate was made by the procedure used for (K)-tert-butyl 5-((2-chloro- 4-fluorophenyl)(l,l-dimethylethylsulfinamido)methyl)thiazol-2-ylcarbamate, starting from tert-bntyl thiazol-2-ylcarbamate and (R)-N-(4-chloro~2-fluorobenzylidene)-2-methylpropane~ 2-sulfmamide. The cmde product was purified by column chromatography to provide a diasteriomeric mixture of (R)-tert-butyl 5-((4-chloro-2-fluorophenyl)(l,l- dimethylethylsulfinamido)methyl) thiazol-2-ylcarbamate (78%) that was used without further purification.
[00230] (R)-terf-Butyl5-((3,4-dichlorophenyl)(l,l-dimethylethylsulfinamido) methyl)thiazol-2-ylcarbamate
Figure imgf000074_0002
[00232] (R)-ferf-Butyl 5-((3 ,4-dichlorophenyl)( 1 , 1 -dimethylethylsulfmamido) methyl)thiazol-2-ylcarbamate was made by the procedure used for (R)-fert-butyl 5-((2-chloro- 4-fluorophenyl)(l,l-dimethylethylsulfinamido)methyl)thiazol-2-ylcarbamate, starting from tert-butyl thiazol-2-ylcarbamate and (R)-N-(3,4-dichlorobenzylidene)-2-methylpropane-2- sulfinamide. The crude product was purified by column chromatography (excess tert-butyl thiazol-2-ylcarbamate is eluted at 70% EtOAc/hexane, the desired product follows at 0-15% MeOH/EtOAc) to provide a diasteriomeric mixture of (R)-te/t-butyl 5-((3,4- dichlorophenyl)( 1,1 -dimethyl ethylsulfinamido)methyl)thiazol-2-ylcarbamate as a yellow solid (92%) that was used without further purification.
[00233] (R)-tert-Butyl 5-((2-chlorophenyl)(l,l-dimethylethylsulfinamido) methyl)-4-methylthiazol-2-ylcarbamate
Figure imgf000075_0001
[00235] (R)-te/t-Butyl 5-((2-chlorophenyl)( 1 , 1 -dimethylethylsulfmamido)methyl)- 4-methylthiazol-2-ylcarbamate was made by the procedure used for (R)-ter£-butyl 5-((2-chloro- 4-fluorophenyl)( 1 , 1 -dimethylethylsulfinamido)methyl)thiazol-2-ylcai-bamate, starting from tert-butyl 4-methylthiazol-2-ylcarbamate and (R)-N-(2-chlorobenzylidene)-2-methylpropane- 2-sulfinamide. The crude product was adsorbed onto silica gel and purified by column chromatography (20-80% EtOAc/ hexanes) to provide a diastereomeric mixture of (R)-tert- butyl 5-((2-chlorophenyl)( 1 , 1 -dimethylethylsulfinamido)methyl)-4-methylthiazol-2- ylcarbamate as a cream colored solid (90%) that was used without further purification.
[00236] (R)-N-((S)-(2-Aminothiazol-5-yl)(2-chloro-4-fluorophenyl)methyl)-2- methylpropane-2-suIfinamide
Figure imgf000075_0002
[00238] To a solution of of (R)-terf-Butyl 5-((2-chloro-4-fluoroρhenyl)( 1,1- diniethylethylsulfinamido)methyl) thiazol-2-ylcarbamate (1.6 g, 3.5 mmol) in CH2Cl2 (6 mL) was added TFA (6 mL). The reaction was stirred at room temperature for 2 h. The TFA and CH2Cl2 were removed under vacuum. The crude product was re-dissolved in CH2Cl2, washed with aqueous NaHCO3 solution, dried over MgSO4 and concentrated. The crude product was recrystallized from EtOAc to provide (R)-N-((S)-(2-aminothiazol-5-yl)(2-chloro-4- fluorophenyl)methyl)-2-methylpropane-2-sulfinamide as colorless solid ( 672 mg, 53%). 1H NMR (400 MHz, CDCl3) δ 7.56 (dd, J = 8.7, 5.9 Hz, IH), 7.16 (dd, J = 8.4, 2.6 Hz, IH), 7.06 (td, J = 8.2, 2.6 Hz, IH), 6.89 (d, J = 0.8 Hz, IH), 6.07 (d, J = 4.6 Hz, IH), 5.22 (d, J = 2.9 Hz, 2H), 4.06 (d, J = 4.6 Hz, IH), 1.28 (s, 9H); HPLC ret. time 2.28 min, 10-99%CH3CN, 5 min ran; ESI-MS 362.3 m/z (MH+).
[00239] (S)-N-((R)-(2-Aminothiazol-5-yl)(2-chloro-4-fluorophenyl)methyl)-2- methylpropane-2-sulfinamide
Figure imgf000076_0001
[00241] (S)-N-((R)-(2-Aminothiazol-5-yl)(2-chloro-4-fluorophenyl)methyl)-2- methylpropane-2-sulfinamide was made by the procedure used for (R)-N-((S)-(2-aminothiazol- 5-yl)(2-chloro-4-fluorophenyl)methyl)-2-methylpropane-2-sulfinamide, starting from (S)-tert- butyl 5-((4-chloro-2-fluorophenyl)(l , 1 -dimethylethylsulfinamido)methyl) thiazol-2- ylcarbamate. The crude product was purified by column chromatography (0-5% EtOH/EtOAc) to provide the desired product (38%). 1H-NMR (400 MHz, CDCl3) δ 9.14 (br s, 2H), 7.54 (dd, J = 5.7, 8.7 Hz, IH), 7.21 (dd, J = 2.6, 8.1 Hz, IH), 7.13 - 7.08 (m, IH), 6.73 (d, J = 0.6 Hz, IH), 6.00 (d, J = 5.6 Hz, IH), 4.67 (d, J = 5.7 Hz, IH), 1.26 (s, 9H); HPLC ret. time 2.23 min, 10-99% CH3CN, 5 min run; ESI-MS 362.3 m/z (MH+).
[00242] (R)-N-((S)-(2-Aminothiazol-5-yl)(4-chloro-2-fluorophenyl)methyl)-2- methylpropane-2-sulfinamide
Figure imgf000077_0001
[00244] (R)-N-((S)-(2-Aminothiazol-5-yl)(4-chloro-2-fluorophenyl)methyl)-2- methylpropane-2-sulfinamide was made by the procedure used for (R)-N-((S)-(2-aminothiazol- 5-yl)(2-chloro-4-fluorophenyl)methyl)-2-methylpropane-2-sulfinamide, starting from (K)-tert- butyl 5-((4-chloiO-2-fluorophenyl)(l,l-dimethylethylsulfinamido)methyl) thiazol-2- ylcarbamate. The crade product was purified by column chromatography (0-5% EtOH/EtOAc) to provide an orange solid (87%). 1H-NMR (400 MHz, CDCl3) δ 8.62 (br s, 2H), 7.36 (t, J = 8.1 Hz, IH), 7.21 (dd, J = 1.7, 8.3 Hz, IH), 7.16 (dd, J = 1.9, 10.1 Hz, IH), 6.74 (s, IH), 5.81 (d, J = 5.9 Hz, IH), 4.18 (d, J = 5.9 Hz, IH), 1.25 (s, 9H); HPLC ret. time 2.29 min, 10-99% CH3CN, 5 min run; ESI-MS 362.3 m/z (MH+).
[00245] l-(Benzo[rf][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4-fluorophenyl)((R)- l,l-dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide
Figure imgf000077_0002
[00247] To a solution of l-(benzo[<f|[l,3]dioxol-5-yi)cyclopropanecarboxylic acid (618 mg, 3.0 mmol) in anhydrous CH2Cl2 (6 mL) was slowly added (COCl)2 (0.3 mL, 3.4 mmol) at -100C followed by DMF (3 drops). The reaction mixture was stirred at -100C for 0.5 h. The excess (COCl)2 was removed under vacuum. The acid chloride (10.5 mmol) was then dissolved in anhydrous CH2Cl2 (3 mL) and was slowly added to a solution of (R)-N-((S)-(2- aminothiazol-5-yl)(2-chloro-4-fluorophenyl)methyl)-2-methylpropane-2-sulfinamide (648 mg, 1.8 mmol) and Et3N (1.8 mL, 6 mmol) in anhydrous CH2Cl2 (3 mL). The reaction mixture was stirred at room temperature for 1 h, diluted with CH2Cl2 and washed with IN HCl , NaHCO3 and brine. The organic layer was separated from the aqueous layer and dried over MgSO4 and concentrated. The crude product was purified by column chromatography (40-60% EtOAc/Hexane) to provide l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4- fluorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)methyl) thiazol-2- yl)cyclopropanecarboxamide as a colorless solid (680 mg, 69%). 1H-NMR (400 MHz, CDCl3) δ 8.60 (s, IH), 7.60 (dd, J = 8.7, 5.9 Hz, IH), 7.28 (d, J = 2.0 Hz, IH), 7.13 (dd, J = 8.3, 2.6 Hz, IH), 7.05 (td, J = 8.2, 2.6 Hz, IH), 6.90 (td, J = 8.3, 1.7 Hz, 2H), 6.83 (d, J = 7.9 Hz, IH), 6.18 (d, J = 4.3 Hz, IH), 6.04 (s, 2H), 3.90 (d, J = 4.3 Hz, IH), 1.73 (td, J = 5.4, 2.0 Hz, 2H), 1.28 (t, J = 7.1 Hz, 2H), 1.29 (s, 9H). HPLC ret. time 3.65 min, 10-99%CH3CN, 5 min run; ESI-MS 550.5 m/z (MH+).
[00248] N-(5-((S)-(2-Chloro-4-fluorophenyl)((R)-l,l- dimethylethylsulfinaniido)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[rf][l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000078_0001
[00250] N-(5-((S)-(2-Chloro-4-fluorophenyl)((R)- 1,1- dimethylethylsulfinamido)methyl) thiazol-2-yl)-l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)- 1 , 1 -dimethylethylsulfmamido)methyl)thiazol-2- yl)cyclopropanecarboxamide, starting from l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (R)-N-((S)-(2-aminothiazol-5-yl)(2-chloro-4- fluorophenyl)methyl)-2-methylpropane-2-sulfmamide. Yield (77%). 1H-NMR (400 MHz, CDCl3) δ 8.63 (s, IH), 7.59 (dd, J = 8.7, 5.9 Hz, IH), 7.28 (s, IH), 7.21-7.11 (m, 4H), 7.06 (td, J = 8.2, 2.5 Hz, IH), 6.18 (d, J = 4.2 Hz, IH), 3.92 (d, J = 4.3 Hz, IH), 1.82-1.79 (m, 2H), 1.32-1.25 (m, 1 IH); HPLC ret. time 3.90 min, 10-99% CH3CN, 5 min run; ESI-MS 586.3 m/z (MH+). [00251] l-(Benzo[</][l,3]dioxol-5-yl)-N-(5-((R)-(2-chloro-4-fluorophenyl)((S)- l,l-dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide
Figure imgf000079_0001
[00253] l-(Benzo[J][l,3]dioxol-5-yl)-N-(5-((R)-(2-chloro-4-fluorophenyl)((S)- l,l-dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[J][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-I5I- dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from 1- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxylic acid and (S)-N-((R)-(2-aminothiazol-5- yl)(2-cWoro-4-fluorophenyl)methyl)-2-methylpropane-2-sulfinamide. Yield (50%). 1H-NMR (400 MHz, DMSO-J6) δ 11.10 (s, IH), 7.78 (dd, J = 6.3, 8.8 Hz, IH), 7.45 (dd, J = 2.6, 8.8 Hz, IH), 7.35 (td, J = 8.6, 2.7 Hz, IH), 7.03 (s, IH), 6.95 (s, IH), 6.86 (s, 2H), 6.45 (d, J = 6.7 Hz, IH), 6.00 (s, 2H), 5.95 (d, J = 6.5 Hz, IH), 1.46 - 1.43 (m, 2H), 1.25 - 1.24 (m, 2H), 1.14 (s, 9H); HPLC ret. time 3.65 min, 10-99% CH3CN, 5 min run; ESI-MS 550.5 m/z (MH+).
[00254] N-(5-((R)-(2-Chloro-4-fluorophenyl)((S)-l,l- dimethylethyIsulfinamido)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[(/][l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000079_0002
[00256] N-(5~((R)-(2-Chloro-4-fluorophenyrχ(S)-l,l- dimethylethylsulfinamido)methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo[</] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-1 , 1 -dimethylethylsulfmamido)methyl)thiazol-2- yl) cyclopropanecarboxamide, starting from l-(2,2-difluorobenzo[(i][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (S)-N-((R)-(2-aminothiazol-5-yl)(2-chloro-4- fluorophenyl)methyl)-2-methylpropane-2-sulfmamide. Yield (50%). 1H-NMR (400 MHz, DMSO-^6) δ 11.38 (s, IH), 7.78 (dd, J = 6.2, 8.8 Hz, IH), 7.47 - 7.44 (m, 2H), 7.37 - 7.32 (m, 2H), 7.21 (dd, J = 1.6, 8.3 Hz, IH), 7.04 (s, IH), 6.45 (d, J = 6.6 Hz, IH), 5.95 (d, J = 6.5 Hz, IH), 1.54 - 1.50 (m, 2H), 1.22 - 1.21 (m, 2H), 1.14 (s, 9H); HPLC ret. time 3.90 min, 10-99% CH3CN, 5 min run; ESI-MS 586.3 m/z (MH+).
[00257] l-(Benzo[</][l,3]dioxol-5-yl)-N-(5-((S)-(4-chloro-2-fluorophenyl)((R)- l,l-dimethylethylsulfinaraido)methyl)thiazol-2-yl)cyclopropanecarboxamide
Figure imgf000080_0001
[00259] l-(Benzo[<][l,3]dioxol-5-yl)-N-(5-((S)-(4-chloro-2-fiuorophenyl)((R)- l,l-dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-1, 1- dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from 1- (benzo[d][l,3]dioxol-5-yl)cyclopropanecarboxylic acid and (R)-N-((S)-(2-aminothiazol-5- yl)(4-chloro-2-fluorophenyl)methyl)-2-methylpropane-2-sulfinamide. Yield (64%). 1H-NMR (400 MHz, CDCl3) δ 8.56 (s, IH), 7.43 (t, J = 8.1 Hz, IH), 7.18 (s, IH), 7.16 (dd, J = 1.5, 8.3 Hz, IH), 7.08 (dd, J-= 2.0, 10.0 Hz, IH), 6.89 (td, J = 8.0, 1.7 Hz, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 - 5.99 (m, 3H), 3.90 (d, J = 5.0 Hz, IH), 1.73 - 1.70 (m, 2H), 1.28 - 1.23 (m, HH); HPLC ret. time 3.69 min, 10-99% CH3CN, 5 min run; ESI-MS 550.5 m/z (MH+). [00260] N-(5-((S)-(4-Chloro-2-fluorophenyl)((R)-l,l- dimethylethylsulfϊnamido)methyl) thiazol-2-yl)-l-(2,2-difluorobenzo [d\ [1,3] dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000081_0001
[00262] N~(5-((S)-(4-Chloro-2-fluorophenyl)((R)- 1,1- dimethylethylsulfinamido)methyl) thiazol-2-yl)-l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxainide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-I, l-dimethylethylsulfmamido)methyl)thiazol-2- yl)cyclopropanecarboxamide, starting from l-(2,2-difluorobenzo[<i][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (R)-N-((S)-(2-aminothiazol-5-yl)(4-chloro-2- fluorophenyl)methyl)-2-methylpropane-2-sulfinamide. Yield (53%). 1H-NMR (400 MHz, DMSO-J6) δ 11.37 (s, IH), 7.66 (t, J = 8.3 Hz, IH), 7.45 - 7.42 (m, 2H), 7.38 (dd, J = 2.0, 8.4 Hz, IH), 7.34 (d, J = 8.3 Hz, IH), 7.21 (dd, J = 1.5, 8.3 Hz, IH), 7.11 (s, IH), 6.33 (d, J = 6.7 Hz, IH), 5.89 (d, J = 6.5 Hz, IH), 1.55 - 1.52 (m, 2H), 1.24 - 1.22 (m, 2H), 1.13 (d, J = 9.5 Hz, 9H); HPLC ret. time 3.93 min, 10-99% CH3CN, 5 min ran; ESI-MS 586.5 m/z (MH+).
[00263] (S)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)-l- (benzo [d\ [l^dioxol-S-y^cyclopropanecarboxamide
Figure imgf000081_0002
[00265] To a solution of l-(benzo[rf][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4- fiuorophenylX(R)- 1 , 1 -dimethylethylsulfinamido)methyl)thiazol-2- yl)cyclopropanecarboxamide (659 mg, 1.2 mmol) in MeOH (5 mL) was added 4M HCl in dioxane (1.8 mL, 7.2 mmol). The reaction mixture was stirred at room temperature for 1.5 h and evaporated to dryness. The crude product was dissolved in CH2Cl2. The organic layer was washed with aqueous NaHCO3 solution (50 mL x 2), brine (50 mL x 1), dried over MgSO4 and concentrated to provide (S)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)-l- (benzof^fl^Jdioxol-S-y^cyclopropanecarboxamide as a colorless solid that was used without further purification. 1H-NMR (400 MHz, CDCl3) δ 8.48 (br s, IH), 7.63 (dd, J = 6.1, 8.7 Hz, IH), 7.18 (s, IH), 7.08 (dd, J = 2.6, 8.4 Hz, IH), 6.99 (td, J = 8.3, 2.6 Hz, IH), 6.91 - 6.86 (m, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 5.78 (s, IH), 3.80 (s, 2H), 1.74 - 1.67 (m, 2H), 1.30 - 1.22 (m, 2H); HPLC ret. time 2.67 min, 10-99% CH3CN, 5 min ran; ESI-MS 446.3 m/z (MH+).
[00266] (S)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)-l-(2,2- difluorobenzo [d\ [l^Jdioxol-S-y^cyclopropanecarboxamide
Figure imgf000082_0001
[00268] (S)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)- 1 -(2,2- difluorobenzo [J][l,3]dioxol-5-yl)cyclopiOpanecarboxamide was made by the procedure used for (S)-N-(5-(amino(2-chloro-4-fluorophenyl)methyl)tliiazol-2-yl)-l-(benzo [d][l,3]dioxol-5- yl)cyclopropanecarboxamide, starting from N-(5-((S)-(2-chloro-4-fluorophenyl)((R)-l,l- dimethylethylsulfinamido)methyl) thiazol-2-yl)-l-(2,2-difluorobenzo[<f|[l,3]dioxol-5- yl)cyclopropanecarboxamide. The crude product was used without further purification. 1H- NMR (400 MHz, CDCl3) δ 8.35 (s, IH), 7.65 (dd, J = 6.1, 8.7 Hz, IH), 7.22 - 7.17 (m, 3H), 7.12 - 7.10 (m, 2H), 7.02 (td, J = 8.3, 2.6 Hz, IH), 5.80 (s, IH), 3.83 (s, 2H), 1.83 - 1.77 (m, 2H), 1.28 - 1.25 (m, 2H); HPLC ret. time 2.87 min, 10-99% CH3CN, 5 min ran; ESI-MS 482.3 m/z (MH+).
[00269] (R)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)-l- (benzo[rf][l,3]dioxol-5-yl)cycIopropanecarboxamide
Figure imgf000083_0001
[00271] (R)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)- 1 -
(benzo[<f][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for (S)- N-(5-(amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)- 1 -(benzo [d] [ 1 ,3]dioxol-5-yl) cyclopropanecarboxamide, starting from l-(benzo[<f][l,3]dioxol-5-yl)-N-(5-((R)-(2-cliloro-4- fluorophenyl)((S)- 1 , 1 -dimethylethylsulfϊnamido)methyl)thiazol-2-yl) cyclopropane carboxamide. The crude product was purified by column chromatography (0-2.5% Et3MEtOAc) to provide a pale yellow solid (77%). 1H-NMR (400 MHz, DMSO-J6) δ 10.80 (br s, IH), 7.80 (dd, J = 6.4, 8.8 Hz, IH), 7.38 (dd, J = 2.6, 8.8 Hz, IH), 7.27 (td, J = 8.5, 2.7 Hz, IH), 7.07 (d, J = 0.9 Hz, IH), 6.95 (s, IH), 6.86 (d, J = 0.9 Hz, 2H), 6.00 (s, 2H), 5.53 (s, IH), 1.44 - 1.41 (m, 2H), 1.13 - 1.10 (m, 2H); HPLC ret. time 2.67 min, 10-99% CH3CN, 5 min run; ESI-MS 446.3 m/z (MH+).
[00272] (R)-N-(5-(Amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)-l-(2,2- difluorobenzo [d\ [1,3] dioxol-5-yI)cyclopropanecarboxamide
Figure imgf000083_0002
[00274] (R)-N-(5-(Amino(2-chloro-4-fiuorophenyl)methyl)thiazol-2-yl)- 1 -(2,2- difluorobenzo [d][l, 3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for (R)-N-(5-(amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)- 1 -(benzo[<i] [ 1 ,3]dioxol- 5- yl)cyclopropanecarboxamide, starting from N-(5-((R)-(2-chloro-4-fluorophenyl)((S)- 1,1- dimethylethylsulfinamido)methyl) thiazol-2-yl)- 1 -(2,2-difluorobenzo[<f|[ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide (79%). 1H-NMR (400 MHz, DMSO-J6) δ 7.80 (dd, J = 6.4, 8.8 Hz, IH), 7.43 (d, J = 1.7 Hz, IH), 7.38 (dd, J = 2.6, 8.8 Hz, IH), 7.34 (d, J = 8.3 Hz, IH), 7.27 (td, J = 8.5, 2.6 Hz, IH), 7.20 (dd, J = 1.8, 8.3 Hz, IH), 7.07 (d, J = 0.9 Hz, IH), 5.53 (s, IH), 1.52 - 1.49 (m, 2H), 1.21 - 1.19 (m, 2H); HPLC ret. time 2.91 min, 10-99% CH3CN, 5 min ran; ESI-MS 482 m/z (MH4).
[00275] (S)-N-(5-(Amino(4-chloro-2-fluorophenyl)methyl)thiazol-2-yl)-l- (benzo [d] [l^dioxol-S-ylJcyclopropanecarboxamide
Figure imgf000084_0001
[00277] (S)-N-(5-(Amino(4-chloro-2-fluorophenyl)methyl)thiazol-2-yl)- 1 -(benzo [(f|[l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for (R)-N-(5- (amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)- 1 -(benzo[<f| [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide, starting from l-(benzo[J][l,3]dioxol-5-yl)-N-(5-((S)-(4-criloro- 2-fluorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)methyl)thiazol-2- yl)cyclopropanecarboxamide (79%). 1H NMR (400 MHz, CDCl3) δ 8.48 (s, IH), 7.47 (t, J = 8.2 Hz, IH), 7.14 - 7.12 (m, 2H), 7.05 (dd, J = 2.0, 10.1 Hz, IH), 6.91 - 6.87 (m, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 5.61 (s, IH), 1.86 (s, 2H), 1.71 (dd, J = 3.6, 6.7 Hz, 2H), 1.22 - 1.19 (m, 2H); HPLC ret. time 2.71 min, 10-99% CH3CN, 5 min run; ESI-MS 446.3 m/z (MH+).
[00278] (S)-N-(5-(Amino(4-chloro-2-fluorophenyl)methyl)thiazol-2-yl)-l-(2,2- difluorobenzo [d\ [l^dioxol-S-ylJcyclopropanecarboxamide
[00280] (S)-N-(5-(Amino(4-chloro-2-fluorophenyl)methyl)thiazol-2-yl)- 1 -(2,2- difluorobenzo [rf][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for (R)-N-(5-(amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)-l-(benzo[(/|[l,3]dioxol-5- y^cyclopropanecarboxamide, starting from N-(5-((S)-(4-chloro-2-fluorophenyl)((R)-l,l- dimethylethylsulfinamido)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[ιfj[l,3]dioxol-5- yl)cyclopropanecarboxamide (88%). 1H NMR (400 MHz, DMSO-J6) δ 11.20 (br s, IH), 7.66 (t, J = 8.3 Hz, IH), 7.43 (d, J = 1.7 Hz, IH), 7.39 - 7.30 (m, 3H), 7.20 (dd, J = 1.7, 8.3 Hz, IH), 7.09 (s, IH), 5.45 (s, IH), 1.52 - 1.49 (m, 2H), 1.22 - 1.20 (m, 2H); HPLC ret. time 2.94 min, 10-99% CH3CN, 5 min run; ESI-MS 482.3 m/z (MH+).
[00281] l-(Benzo[d] [l,3]dioxol-5-yl)-N-(5-((S)-((R)-3-(tert- butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4-fluorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide
Figure imgf000085_0001
[00283] To a solution of (S)-N-(5-(ammo(2-chloro-4-fluorophenyl)methyl)thiazol-
2-yl)-l-(benzo [(fj[l,3]dioxol-5-yl)cyclopropanecarboxamide (1.2 mmol) in MeOH (10 mL) was added (R)-3-(tert-butyldimethylsilyloxy)-4-chlorobutanal (341 mg, 1.4 mmol). The reaction mixture was stirred at room temperature for 5 min. Then NaBH4 (68 mg, 1.8 mmol) was added and stirring was continued at room temperature for 1 h. The reaction was diluted with H2O and extracted with EtOAc. The combined organic layers were washed with brine and dried over MgSO4. After the removal of solvent, the residue was purified by column chromatography (10-20% EtOAc/Hexane) to afford l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-((S)- ((R)-3-(te7^-butyldimethylsilyloxy)pyiτolidin-l-yl)(2-chloro-4-fluorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide (446 mg, 59% over two steps). 1H NMR (400 MHz, CDCl3) δ 8.45 (s, IH), 7.79 (dd, J = 8.6, 6.3 Hz, IH), 7.25 (d, J = 6.4 Hz, IH), 7.01-6.94 (m, 2H), 6.85 (td, J = 8.3, 1.7 Hz, 2H), 6.78 (d, J = 7.9 Hz, IH), 5.99 (s, 2H), 4.99 (s, IH), 4.35-4.30 (m, IH), 2.77 (dd, J = 9.9, 6.2 Hz, IH), 2.51-2.48 (m, 2H), 2.36 (dd, J = 9.9, 4.3 Hz, IH), 2.06-2.01 (m, IH), 1.71-1.65 (m, 3H), 1.18 (t, J = 3.0 Hz, 2H), 0.85 (s, 9H), -0.01 (d, J = 7.3 Hz, 6H); HPLC ret. time 3.59 min, 10-99%CH3CN, 5 min run; ESI-MS 630.6 m/z (MH+).
[00284] N-(5-((S)-((R)-3-(tert-butyIdimethylsilyloxy)pyrrolidin-l-yl)(2-chloro- 4-fluorophenyl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[</][l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000086_0001
[00286] N-(5-((S)-((R)-3-(ter^butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro~4- fluorophenyl) methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo[β(][ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[<f|[l,3]dioxol-5- yl)-N-(5-((S)-((R)-3-(ter?-butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl) cyclopropanecarboxamide, starting from (S)-N-(5-(amino(2- chloro-4-fluorophenyl) methyl)thiazol-2-yl)-l-(2,2-difluorobenzo [J][1, 3]dioxol-5- yl)cyclopropanecarboxamide and (R)-3-(ter^butyldimethylsilyloxy)-4-chlorobutanal (56% over two steps). 1H NMR (400 MHz, CDCl3) δ 8.31 (s, IH), 7.79 (dd, J = 8.6, 6.3 Hz, IH), 7.25 (d, J = 7.9 Hz, IH), 7.13 (td, J = 8.4, 1.6 Hz, 2H), 7.06 (d, J = 8.1 Hz, IH), 7.01 - 6.95 (m, 2H), 4.99 (s, IH), 4.35-4.30 (m, IH), 2.76 (dd, J = 9.8, 6.2 Hz, IH), 2.50 (t, J = 6.9 Hz, 2H), 2.37 (dd, J = 10.0, 4.2 Hz, IH), 2.08 - 1.98 (m, IH), 1.79-1.64 (m, 3H), 1.24 - 1.19 (m, 2H), 0.85 (s, 9H), -0.01 (d, J = 7.4 Hz, 6H); HPLC ret. time 3.80 min, 10-99% CH3CN, 5 min run; ESI-MS 666.4 m/z (MH+).
[00287] l-(Benzo[J][l,3]dioxol-5-yl)-N-(5-((R)-((R)-3-(te/t- butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4-fluorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide
Figure imgf000087_0001
[00289] l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-((R)-((R)-3-(tert- butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4-fluorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[c(][l,3]dioxol-5- yl)-N-(5-((S)-((R)-3-(teλ^butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from of (R)-N-(5- (amino(2-chloro-4-fluorophenyl)methyl)thiazol-2-yl)- 1 -(benzo [d] [ 1 ,3] dioxol-5-yl) cyclopropanecarboxamide and (R)-3-(fer?-butyldimethylsilyloxy)-4-chlorobutanal (99%). 1H NMR (400 MHz, DMSO-J6) 5 11.01 (s, IH), 7.77 (dd, J = 6.4, 8.8 Hz, IH), 7.38 - 7.36 (m, 2H), 7.29 (td, J = 8.5, 2.7 Hz, IH), 6.94 (s, IH), 6.85 (m, 2H), 5.99 (s, 2H), 4.99 (s, IH), 4.38 - 4.34 (m, IH), 2.83 (dd, J = 6.2, 9.9 Hz, IH), 2.58 - 2.54 (m, IH), 2.46 - 2.42 (m, IH), 2.14 (dd, J = 3.7, 9.9 Hz, IH), 2.05 - 1.99 (m, IH), 1.68 - 1.57 (m, IH), 1.43 - 1.40 (m, 2H), 1.12 - 1.10 (m, 2H), 0.82 (s, 9H), -0.00 (s, 3H), -0.02 (s, 3H); HPLC ret. time 3.60 min, 10-99% CH3CN, 5 min run; ESI-MS 630.5 m/z (MH+).
[00290] N-(5-((R)-((R)-3-(fert-butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro- 4-fluorophenyl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[fif][l,3]dioxol-5-yl) cyclopropanecarboxamide
Figure imgf000087_0002
[00292] N-(5-((R)-((R)-3-(tert-butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro-4- fluorophenyl) methyl)thiazol-2-yl)-l -(2,2-difluorobenzo[<fj [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5- yl)-N-(5-((S)-((R)-3 -(te^butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl) cyclopropanecarboxamide, starting from (R)-N-(5-(amino(2- chloro-4-fluorophenyl) methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo [d] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide and (R)-3-(ter/-butyldimethylsilyloxy)-4-chlorobutanal (92%). 1H NMR (400 MHz, DMSO-J6) δ 11.32 (s, IH), 7.77 (dd, J = 6.4, 8.8 Hz, IH), 7.43 (d, J = 1.4 Hz, IH), 7.39 - 7.30 (m, 4H), 7.20 (dd, J = 1.5, 8.3 Hz, IH), 4.99 (s, IH), 4.40 - 4.35 (m, IH), 2.83 (dd, J = 6.1, 9.9 Hz, IH), 2.60 - 2.52 (m, IH), 2.46 - 2.41 (m, IH), 2.15 (dd, J = 3.7, 9.9 Hz, IH), 2.07 - 1.99 (m, IH), 1.63 - 1.57 (m, IH), 1.51 - 1.48 (m, 2H), 1.25 - 1.24 (m, 2H), 0.83 (s, 9H), 0.01 (s, 3H), -0.02 (s, 3H); HPLC ret. time 3.79 min, 10-99% CH3CN, 5 min ran; ESI-MS 666.3 m/z (MH+).
[00293] l-(Benzo[</] [l,3]dioxol-5-yl)-N-(5-((S)-((R)-3-(te/Y- butyldimethylsilyloxy)pyrrolidin-l-yI)(4-chloro-2-fluorophenyl)methyI)thiazol-2- yl)cyclopropanecarboxamide
Figure imgf000088_0001
[00295] l-(Ben2o[d][l,3]dioxol-5-yl)-N-(5-((S)-((R)-3-(tert- butyldimethylsilyloxy)pynOlidin-l-yl)(4-chloro-2-fluorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[<f|[l,3]dioxol-5- yl)-N-(5-((S)-((R)-3-(tert-butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from of (S)-N-(5- (amino(4-chloro-2-fluorophenyl)methyl)thiazol-2-yl)- 1 -(benzo [d] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide and (R)-3-(ter/-butyldimethylsilyloxy)-4-chlorobutanal (89%). 1U NMR (400 MHz, CDCl3) 5 8.48 (s, IH), 7.64 (t, J = 8.1 Hz, IH), 7.22 (s, IH), 7.11 (dd, J = 1.9, 8.4 Hz, IH), 6.99 (dd, J = 2.0, 9.9 Hz, IH), 6.90 - 6.85 (m, 2H), 6.80 (d, J = 7.9 Hz, IH), 6.00 (s, 2H), 4.91 (s, IH), 4.35 - 4.33 (m, IH), 2.83 (dd, J = 6.2, 9.8 Hz, IH), 2.55 - 2.50 (m, 2H), 2.35 (dd, J = 4.4, 9.8 Hz, IH), 2.07 - 2.02 (m, IH), 1.93 - 1.91 (m, IH), 1.73 - 1.70 (m, 2H), 1.22 - 1.20 (m, 2H), 0.86 (s, 9H), 0.01 (s, 3H)3 0.00 (s, 3H); HPLC ret. time 3.59 min, 10- 99% CH3CN, 5 min run; ESI-MS 630.5 m/z (MH+).
[00296] N-(5-((S)-((R)-3-(teri'-ButyIdimethylsiIyloxy)pyrrolidin-l-yl)(4-chloro- 2-fluorophenyl) methyl)thiazoI-2-yl)-l-(2,2-difluorobenzo[</][l,3]dioxol-5-yI) cyclopropanecarboxamide
Figure imgf000089_0001
[00298] N-(5-((S)-((R)-3-(tert-Butyldimethylsilyloxy)pyπOlidin- 1 -yl)(4-chloro-2- fluorophenyl) methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo[</] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[<f|[l,3]dioxol-5- yl)-N-(5-((S)-((R)-3-(te7^-butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl) cyclopropanecarboxamide, starting from (S)-N-(5-(amino(4- chloro-2 -fluorophenyl) methyl)thiazol-2-yl)-l-(2,2-difluorobenzo [d][l, 3]dioxol-5- yl)cyclopropanecarboxamide and (R)-3-(ter/-butyldimethylsilyloxy)-4-chlorobutanal (90%). 1HNMR (400 MHz, DMSO-^6) δ 11.33 (s, IH), 7.63 (t, J = 8.2 Hz, IH), 7.43 - 7.32 (m, 5H), 7.20 (dd, J = 1.5, 8.3 Hz, IH), 4.93 (s, IH), 4.39 - 4.34 (m, IH), 2.69 (dd, J = 6.1, 9.8 Hz, IH), 2.49 - 2.45 (m, 2H), 2.34 (dd, J = 3.9, 9.9 Hz, IH), 2.10 - 1.99 (m, IH), 1.62 - 1.55 (m, IH), 1.52 - 1.49 (m, 2H), 1.24 - 1.19 (m, 2H), 0.83 (s, 9H), 0.01 (s, 3H), -0.01 (s, 3H); HPLC ret. time 3.79 min, 10-99% CH3CN, 5 min run; ESI-MS 666.3 m/z (MH+). [00299] l-(Benzo[</][l,3]dioxol-5-yI)-N-(5-((S)-(2-chloro-4-fluorophenyl)((R)-3- hydroxypyrrolidin-l-ytymethytythiazoW-ytycyclopropanecarboxamide
Figure imgf000090_0001
[00301] A mixture of l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((S)-((R)-3-(tert- butyldimethylsilyloxy) pyiiOlidin- 1 -yl)(2-chloro-4-fluorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide (365 mg, 0.58 mmol) and TBAF (IM in THF, 2.3 niL, 2.3 mmol) was stirred at room temperature overnight. The reaction was diluted with H2O and extracted with EtOAc. The combined organic layers were washed with brine and dried over MgSO4. After the removal of solvent, the residue was purified by column chromatography (20-50% EtOAc/Hexane) to afford l-(Benzo[φ,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4- fluorophenyl)((R)-3-hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl) cyclopropanecarboxamide (183 mg, 61%, >99% de). 1H-NMR (400 MHz, OMSO-dό) δ 8.41 (s, IH), 7.72 (t, J = 7.1 Hz, IH), 7.20 (d, J = 8.3 Hz, 2H), 6.95 (t, J = 7.2 Hz, 2H), 6.80 (td, J = 8.5, 1.6 Hz, 2H), 6.73 (d, J = 7.9 Hz, IH), 5.94 (s, 2H), 4.95 (s, IH), 4.25 (s, IH), 2.75 (s, IH), 2.58-2.56 (m, IH), 2.42 (s, IH), 2.28-2.27 (m, IH), 2.12-2.11 (m, IH), 1.71-1.61 (m, 3H), 1.19-1.10 (m, 2H); HPLC ret. time 2.68 min, 10-99% CH3CN, 5 min run; ESI-MS 516.2 m/z (MH+).
[00302] N-(5-((S)-(2-Chloro-4-fluorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yI)-l-(2,2-difluorobenzo[</][l,3]dioxol-5-yl)cyclopropanecarboxamide
Figure imgf000091_0001
[00304] N-(5-((S)-(2-chloro-4-fluorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[J][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol-5-yl)~N-(5-((S)-(2-chloro-4- fluorophenyl) ((R)-3-hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from N-(5-((S)-((R)-3-(tert-butyldimethylsilyloxy)pynOlidin-l-yl)(2-chloro-4- fluoiOphenyl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[J][l,3]dioxol-5-yl) cyclopropanecarboxamide (77%). 1H NMR (400 MHz, DMSO-J6) δ 8.36 (s, IH), 7.80 (t, J = 7.2 Hz, IH), 7.30 (d, J = 10.6 Hz, IH), 7.17 (td, J = 8.5, 1.7 Hz, 2H), 7.11-7.01 (m, 4H), 5.05 (s, IH), 4.35-4.33 (m, IH), 2.84-2.83 (m, IH), 2.67-2.64 (m, IH), 2.50 (dd, J = 10.0, 4.9 Hz, IH), 2.38-2.34 (m, IH), 2.20 (dd, J = 12.9, 5.8 Hz, IH), 1.87-1.76 (m, 3H), 1.30-1.23 (m, 2H); HPLC ret. time 2.91 min, 10-99% CH3CN, 5 min run; ESI-MS 552.4 m/z (MH+).
[00305] l-(Benzo [d\ [1,3] dioxol-5-yl)-N-(5-((R)-(2-chloro-4-fluorophenyl)((R)- S-hydroxypyrrolidin-l-ytymethytythiazoI-Z-y^cyclopropanecarboxamide
Figure imgf000091_0002
[00307] l-(Benzo[J][l,3]dioxol-5-yl)-N-(5-((R)-(2-chloro-4-fluorophenyl)((R)-3- hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[J][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-3- hydiOxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecai-boxamide, starting from 1- (benzo[c(][l,3]dioxol-5-yl)-N-(5-((R)-((R)-3-(tot-butyldimethylsilyloxy) pyrrolidin-l-yl)(2- chloro-4-fluorophenyl)methyl)thiazol-2-yl)cyclopropanecarboxamide (61%, >99% de). 1H NMR (400 MHz, DMSO-J6) δ 11.01 (s, IH), 7.80 (dd, J = 6.4, 8.8 Hz, IH), 7.39 - 7.36 (m, 2H), 7.30 (td, J = 8.5, 2.6 Hz, IH), 6.95 (s, IH), 6.85 (s, 2H), 6.00 (s, 2H), 4.94 (s, IH), 4.72 (d, J = 4.3 Hz, IH), 4.19 - 4.18 (m, IH), 2.70 - 2.66 (m, IH), 2.60 - 2.56 (m, IH), 2.34 - 2.30 (m, IH), 2.20 (dd, J = 3.1, 9.9 Hz, IH), 2.00 - 1.95 (m, IH), 1.60 - 1.57 (m, IH), 1.44 - 1.41 (m, 2H), 1.14 - 1.08 (m, 2H); HPLC ret. time 2.72 min, 10-99% CH3CN, 5 min run; ESI-MS 516.3 m/z (MH+).
[00308] N-(5-((R)-(2-Chloro-4-fluorophenyI)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamide
Figure imgf000092_0001
[00310] N-(5-((R)-(2-Chloro-4-fluorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[<i][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4- fluorophenyl) ((R)-3-hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cycloρropanecarboxamide, stalling from N-(5-((R)-((R)-3 -(te7^-butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chloro-4- fluorophenyl)methyl)thiazol-2-yl)- 1 -(2,2-difluorobenzo[J] [ 1 ,3]dioxol-5-yl) cyclopropanecarboxamide (73%, >99% de). 1H NMR (400 MHz, DMSO-J6) δ 11.32 (s, IH), 7.80 (dd, J = 6.4, 8.8 Hz, IH), 7.43 (d, J = 1.4 Hz, IH), 7.39 - 7.28 (m, 4H), 7.20 (dd, J = 1.6, 8.3 Hz, IH), 4.94 (s, IH), 4.72 (d, J = 4.3 Hz, IH), 4.20 - 4.19 (m, IH), 2.71 - 2.67 (m, IH), 2.63 - 2.57 (m, IH), 2.34 - 2.29 (m, IH), 2.20 (dd, J = 3.2, 9.8 Hz, IH), 2.02 - 1.93 (m, IH), 1.62 - 1.54 (m, IH), 1.54 - 1.48 (m, 2H), 1.23 - 1.17 (m, 2H); HPLC ret. time 2.94 min, 10- 99% CH3CN, 5 min run; ESI-MS 552.5 m/z (MH+). [00311] l-(Benzo[</][l,3]dioxol-5-yl)-N-(5-((S)-(4-chloro-2-fluorophenyl)((R)-3- hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide
Figure imgf000093_0001
[00313] l-(Benzo[<][l,3]dioxol-5-yl)-N-(5-((S)-(4-chloro-2-fluoroplienyl)((R)-3- hydroxypyiτolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[(f][l,3]dioxol-5-yl)-N-(5-((S)-(2-chloro-4-fluorophenyl) ((R)-3- hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from 1- (benzo[d] [ 1 ,3] dioxol-5-yl)-N-(5-((S)-((R)-3 -(tøt-butyldimethylsilyloxy) pyrrolidin- 1 -yl)(4- chloro-2-fluorophenyl)methyl)thiazol-2-yl)cyclopropanecarboxamide (37%, >99% de). 1H NMR (400 MHz, CDCl3) δ 8.48 (s, IH), 7.62 (t, J = 8.1 Hz, IH), 7.22 (s, IH), 7.13 (dd, J = 1.9, 8.4 Hz, IH), 7.01 (dd, J = 2.1, 9.9 Hz, IH), 6.90 - 6.85 (m, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 4.92 (s, IH), 4.34 - 4.28 (m, IH), 2.86 - 2.80 (m, IH), 2.63 (d, J = 10.1 Hz, IH), 2.50 - 2.46 (m, IH), 2.34 - 2.23 (m, IH), 2.21 - 2.12 (m, IH), 1.80 - 1.70 (m, 4H), 1.24 - 1.18 (m, 2H); HPLC ret. time 2.77 min, 10-99% CH3CN, 5 min run; ESI-MS 516.3 m/z (MH+).
[00314] N-(5-((S)-(4-chloro-2-fluorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[</][l,3]dioxol-5-yl)cyclopropanecarboxamide
Figure imgf000093_0002
[00316] N-(5-((S)-(4-chloro-2-fluorophenyl)((R)-3-hydroxypyrrolidin- 1 - yl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide was made by the procedure used for l-(benzo[d][l,3]dioxol~5-yl)-N-(5-((S)~(2-chloro-4- fluorophenyl) ((R)-3-hydroxypyrrolidin- 1 -yl)methyl)thiazol-2-yl)cyclopropanecarboxamide, starting from N-(5-((S)-((R)-3-(tert-butyldimethylsilyloxy)pyrrolidin-l-yl)(4-chloro-2- fluorophenyl)methyl)thiazol-2-yl)-l-(2,2-difluorobenzo[rf][l,3]dioxol-5-yl) cyclopropanecarboxamide (78%, >99% de). 1HNMR (400 MHz, DMSO-J6) δ 11.32 (s, IH), 7.66 (t, J = 8.1 Hz, IH), 7.43 (d, J = 1.5 Hz, IH), 7.39 - 7.33 (m, 4H), 7.20 (dd, J = 1.6, 8.3 Hz, IH), 4.88 (s, IH), 4.75 (d, J = 4.4 Hz, IH), 4.21 - 4.16 (m, IH), 2.57 (dd, J = 6.1, 9.8 Hz, IH), 2.51 - 2.44 (m, IH), 2.41 - 2.33 (m, 2H), 2.04 - 1.95 (m, IH), 1.60 - 1.45 (m, 3H), 1.24 - 1.15 (m, 2H); HPLC ret. time 2.97 min, 10-99% CH3CN, 5 min run; ESI-MS 552.5 m/z (MH+).
[00317] (R)-N-((R)-(2-Amino-4-methylthiazol-5-yl)(2-chlorophenyl)methyl)-2- methylpropane-2-sulfϊnamide and (R)-N-((S)-(2-Amino-4-methylthiazol-5-yl)(2- chlorophenyl)methyl)-2-methylpropane-2-sulfinamide
Figure imgf000094_0001
[00319] To a solution of of (R)-tert-Butyl 5-((2-chlorophenyl)(l,l- dimethylethylsulfϊnamido) methyl)-4-methylthiazol-2-ylcarbamate, (19.0 g, 41.6 mmol) in CH2Cl2 (83 mL) was added TFA (83 mL). The reaction was stirred at room temperature for 1 h. The reaction was concentrated and then partitioned between CH2Cl2 and saturated aqueous NaHCO3 solution. The aqueous layer was basified to pH >12 by adding IN NaOH solution and extracted with CH2Cl2. The combined organic layers were dried over MgSO4 and concentrated. The crude product was adsorbed onto silica gel and purified by column chromatography (70 - 100 % EtOAc/ hexanes. The EtOAc contained 2% NH4OH and was stirred to maintain the mixture) to provide (R)-N-((R)-(2-amino-4-methylthiazol-5-yl)(2- chlorophenyl)methyl)-2-methylpropane-2-sulfinamide and (R)-N-((S)-(2-amino-4- methylthiazol-5-yl)(2-chlorophenyl)methyl)-2-methylpropane-2-sulfinamide and a mixture of both diastereomers (7.1 g, 47 %). First eluted product (Isomer A) (white solid, 3.0 g, 20 %, >99 % de); 1H NMR (400 MHz, CDCl3) δ 7.60 (dd, J= 1.6, 7.7 Hz, IH), 7.38 - 7.22 (m, 3H), 6.15 (d, J= 2.5 Hz, IH), 4.94 (s, 2H), 3.87 (d, J= 2.3 Hz, IH), 2.34 (s, 3H), 1.27 (s, 9H); HPLC ret. time 3.08 min, 10-99 % CH3CN, 15 min run; ESI-MS 358.3 m/z (MH+). Second eluted product (Isomer B) (yellow waxy solid, 5.0 g, 33 %. 98 % de); 1H NMR (400 MHz, CDCl3) δ 7.64 (dd, J = 7.7, 1.7 Hz, IH), 7.36 (dd, J = 7.8, 1.4 Hz, IH), 7.32-7.21 (m, 2H), 6.19 (d, J = 1.8 Hz, IH), 4.86 (s, 2H), 3.65 (d, J = 1.2 Hz, IH), 2.33 (s, 3H), 1.26 (s, 9H); HPLC ret. time 3.77 min, 10-99 % CH3CN, 15 min run; ESI-MS 358.3 m/z (MH+).
[00320] (R)-N-((R)-(2-aminothiazol-5-yl)(3,4-dichlorophenyl)methyl)-2- methylpropane-2-sulfinamide and (R)-N-((S)-(2-aminothiazol-5-yl)(3,4- dichlorophenyl)methyl)-2-methylpropane-2-sulfinamide
Figure imgf000095_0001
[00322] (R)-N-(S)- 1 -(2-Aminothiazol-5-yl)- 1 -(3,4-dichlorophenyl)methyl)- 1,1- dimethylethylsulfmamide and (R)-N-(R)- 1 -(2-aminothiazol-5-yl)- 1 -(3 ,4- dichlorophenyl)methyl)-l,l-dimethylethylsulfinamide were made by the procedure for (R)-N- ((R)-(2-amino-4-methylthiazol-5-yl)(2-chlorophenyl)methyl)-2-methylpropane-2-sulfinamide and (R)-N-((S)-(2-amino-4-methylthiazol-5-yl)(2-chlorophenyl)methyl)-2-methylpropane-2- sulfinamide starting from (R)-tert-bntγl 5-((3,4-dichlorophenyl)(l,l- dimethylethylsulfinamido)methyl)thiazol-2-ylcarbamate. The crude product was purified by column chromatography (5% EtOH/EtOAc elutes Isomer A, 20% EtOH/EtOAc elutes Isomer B). Isomer A (yellow solid, 5.67 g, 35 %, >99% de); 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.1 Hz, IH), 7.44 (d, J = 8.3 Hz, IH), 7.25 (dd, J = 2.2, 8.5 Hz, IH), 6.95 (s, IH), 5.63 (d, J = 3.5 Hz, IH), 5.03 (s, 2H), 3.84 (d, J = 3.5 Hz, IH), 1.26 (s, 9H); HPLC ret. time 2.37 min, 10- 99% CH3CN, 5 min run; ESI-MS 378.0 m/z (MH+). Isomer B (yellow solid, 3.64 g, 23 %, 96% de); 1H NMR (400 MHz, CDCl3) D 7.50 (d, J = 2.1 Hz, IH), 7.44 (d, J = 8.3 Hz, IH), 7.25 (dd, J = 2.1, 8.5 Hz, IH), 6.88 (d, J = 0.5 Hz, IH), 5.65 (d, J = 2.5 Hz, IH), 5.02 (s, 2H), 3.88 (d, J = 2.3 Hz, IH), 1.26 (s, 9H); HPLC ret. time 2.50 min, 10-99% CH3CN, 5 min ran; ESI-MS 378.2 m/z (MH+).
[00323] l-(Benzo[</][l,3]dioxol-5-yl)-N-(5-((R)-(2-chIorophenyI)((R)-l,l- dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide and l- (Benzo[i/l[l,3]dioxol-5-yl)-N-(5-((S)-(2-chlorophenyl)((R)-l,l- dimethylethylsuIfinamido)methyl)-4-methylthiazol-2-yI)cyclopropanecarboxamide
Figure imgf000096_0001
[00324] To l-(benzo[<f|[l,3]dioxol-5-yl)cyclopiOpanecarboxylic acid (864 mg, 4.2 mmol) was slowly added SOCl2 (916 μL, 12.6 mmol) followed by DMF (3 drops). The reaction mixture was heated at 60 °C for 0.5 h. The excess SOCl2 was removed under vacuum. The acid chloride was then dissolved in anhydrous CH2Cl2 (6 mL) and was slowly added to a solution of (R)-N-((2-amino-4-methylthiazol-5-yl)(2-chlorophenyl)methyl)-2-methylpropane- 2-sulfϊnamide (Isomer A) (1.35 g, 3.8 mmol) and Et3N (2.92 mL, 21.0 mmol) in anhydrous CH2Cl2 (18 mL). The reaction mixture was stirred at room temperature for 18 h, diluted with CH2Cl2 and washed with IN HCl solution, saturated aqueous NaHCO3 solution and brine. The organic layer was dried over MgSO4 and concentrated to provide l-(benzo[/f|[l,3]dioxol-5-yl)- N-(5-((2-chlorophenyl)((R)- 1 , 1 -dimethylethylsulfmamido)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) as an orange solid (1.54 g, 75%) that was used without further purification. HPLC ret. time 3.59 min, 10-99 % CH3CN, 5 min run; ESI-MS 546.5 m/z (MH+).
[00325] 1 -(Benzo[d][ 1 ,3]dioxol-5-yl)-N-(5-((2-chlorophenyl)((R)- 1,1- dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer B), was made by the procedure used for Isomer A starting from l-(benzo[rf][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (R)-N-((2-amino-4-methylthiazol-5-yl)(2- chlorophenyl)methyl)-2-methylpropane-2-sulfϊnamide (Isomer B). The crude product was adsorbed onto silica gel and purified by column chromatography (25-60% EtOAc/hexanes) to yield the product as light orange solid (62 %). 1U NMR (400 MHz, CDCl3) δ 8.48 (s, IH), 7.70 (dd, J = 7.8, 1.6 Hz, IH), 7.34-7.20 (m, 3H), 6.88-6.79 (m, 3H), 6.26 (d, J = 1.9 Hz, IH), 6.01 (s, 2H), 3.55 (d, J = 1.7 Hz, IH), 2.40 (s, 3H), 1.68 (m, 2H), 1.28-1.18 (m, HH); HPLC ret. time 3.69 min, 10-99 % CH3CN, 5 min run; ESI-MS 546.5 m/z (MH+).
[00326] N-(5-((R)-(2-Chlorophenyl)((R)-l,l- dimethylethylsulfϊnamido)methyl)-4-methylthiazol-2-yl)-l-(2,2- difluorobenzo[«T|[l,3]dioxol-5-yl) cyclopropanecarboxamide and N-(5-((S)-(2- Chlorophenyl)((R)-l,l-dimethylethylsulfinamido)methyl)-4-methyIthiazol-2-yl)-l-(2,2- difluorobenzo^fl^dioxol-S-y^cyclopropanecarboxamide
Figure imgf000097_0001
[00327] N-(5-((2-Chlorophenyl)((R)- 1 , 1 -dimethylethylsulfmamido)methyl)-4- methylthiazol-2-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer A), was made by the procedure used for l-(benzo[<f|[l,3]dioxol-5-yl)-N-(5-((2- chlorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)memyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) starting from l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (R)-N-((2-amino-4-methylthiazol-5-yi)(2- chlorophenyl)methyl)-2-methylpropane-2-sulfinamide (Isomer A). The crude product was adsorbed onto silica gel and purified by column chromatography (25 - 100 % EtOAc/ hexanes) to yield an orange solid (55 %). 1H NMR (400 MHz, CDCl3) δ 8.36 (s, IH), 7.67 (dd, J = 7.7, 1.6 Hz, IH), 7.35-7.21 (m, 3H), 7.17-7.07 (m, 3H), 6.21 (d, J = 2.5 Hz, IH), 3.80 (d, J = 2.4 Hz, IH), 2.41 (s, 3H), 1.80-1.70 (m, 2H), 1.26-1.18 (m, HH); HPLC ret. time 3.81 min, 10-99 % CH3CN, 5 min run; ESI-MS 582.3 m/z (MH+).
[00328] N-(5-((2-Chlorophenyl)((R)- 1 , 1 -dimethylethylsulfmamido)methyl)-4- methylthiazol-2-yl)-l-(2,2-difluorobenzo[ύT|[l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer B), was made by the procedure used for l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((2- chlorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)methyl)-4-memylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) starting from l-(2,2-difluorobenzo[<f|[l,3]dioxol-5- yl)cyclopropanecarboxylic acid and (R)-N-((2-amino-4-methylthiazol-5-yl)(2- chlorophenyl)methyl)-2-methylpropane-2-sulfinamide (Isomer B). The crude product was adsorbed onto silica gel and purified by column chromatography (30 - 80 % EtOAc/ hexanes) to yield an orange solid (37 %) 1H NMR (400 MHz, CDCl3) δ 8.33 (s, IH), 7.70 (dd, J = 7.8, 1.7 Hz, IH), 7.35-7.20 (m, 3H), 7.16-7,07 (m, 3H), 6.26 (d, J = 2.0 Hz, IH), 3.55 (d, J = 1.8 Hz, IH), 2.39 (s, 3H), 1.79-1.71 (m, 2H), 1.28-1.21 (m, HH); HPLC ret. time 3.98 min, 10-99 % CH3CN, 5 min run; ESI-MS 582.3 m/z (MH+).
[00329] l-(Benzo[J][l,3]dioxol-5-yl)-N-(5-((R)-(3,4-dichlorophenyl)((R)-l,l- dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide and 1 -(Benzo [d] [ 1 ,3]dioxol-5-yl)-N-(5-((S)-(3 ,4-dichlorophenyl)((R)- 1,1- dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide
Figure imgf000098_0001
[00331] l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-((3,4-dichlorophenyl)((R)-l,l- dimethylethylsulfinamido)methyl)thiazol-2-yl)cyclopropanecarboxamide (Isomer A), was made by the procedure used for l-(benzo[</][l,3]dioxol-5-yl)-N-(5-((2-chlorophenyl) ((R)- 1,1- dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl) cyclopropanecarboxamide (Isomer A) starting from l-(benzo[J][l,3]dioxol-5-yl) cyclopropanecarboxylic acid, (COCl)2 and (R)-N- ((2-aminothiazol-5-yl)(3 ,4-dichlorophenyl) methyl)-2-methylpropane-2-sulfinamide (Isomer A). The crude product was purified by column chromatography (60-80% EtOAc/Hexane) to provide a yellow solid (2.70 g, 72%). 1H NMR (400 MHz, CDCl3) δ 8.57 (s, IH), 7.49 (d, J = 2.1 Hz, IH), 7.43 (d, J = 8.3 Hz, IH), 7.28 - 7.26 (m, 2H), 6.90 (dd, J = 1.8, 7.9 Hz, IH), 6.87 (d, J = 1.6 Hz, IH), 6.82 (d, J = 7.9 Hz, IH), 6.02 (s, 2H), 5.74 (d, J = 3.1 Hz, IH), 3.73 (d, J = 3.2 Hz, IH), 1.73 - 1.71 (m, 2H), 1.28 - 1.21 (m, HH); HPLC ret. time 3.80 min, 10-99% CH3CN, 5 min run; ESI-MS 566.2 m/z (MH+).
[00332] l-(Benzo[<][l,3]dioxol-5-yl)-N-(5-((3,4-diclilorophenyl)((R)-l,l- dimethylethylsulfϊnamido)methyl)thiazol-2-yl)cyclopropanecarboxamide (Isomer B), was made by the procedure used for l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((2-chlorophenyl) ((R)-1, 1- dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl) cyclopropanecarboxamide (Isomer A) starting from l-(benzo[J][l,3]dioxol-5-yl) cyclopropanecarboxylic acid, (COCl)2 and (R)-N- ((2-aminothiazol-5-yl)(3 ,4-dichlorophenyl) methyl)-2-methylρropane-2-sulfinamide (Isomer B). The crude product was purified by column chromatography (60-100% EtOAc/Hexane) to provide a yellow solid (2.65 g, 71%). 1H NMR (400 MHz, CDCl3) δ 8.59 (s, IH), 7.52 (d, J = 2.1 Hz, IH), 7.42 (d, J = 8.3 Hz, IH), 7.29 - 7.26 (m, 2H), 6.90 - 6.86 (m, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.02 (dd, J = 1.4, 1.9 Hz, 2H), 5.77 (d, J = 1.8 Hz, IH), 3.72 (d, J = 1.9 Hz, IH), 1.72 (dd, J = 3.2, 6.7 Hz, 2H), 1.28 - 1.22 (m, HH); HPLC ret. time 3.91 min, 10-99% CH3CN, 5 min run; ESI-MS 566.4 m/z (MH+). '
[00333] (R)-N-(5-(Amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l- (benzo[d\ [l,3]dioxol-5-yl)cyclopropanecarboxamide and (S)-N-(5-(Amino(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(benzo[rf][l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000099_0001
[00334] To a solution of l-(benzo[</][l,3]dioxol-5-yl)-N-(5-((2-chlorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer A), (1.47 g, 2.69 mmol) in MeOH (13 mL) was added 4 M HCl in dioxane (4 mL,16 mmol). The reaction mixture was stirred at room temperature for 3 h and then concentrated. The crude product was dissolved in CH2Cl2 and washed with saturated aqueous NaHCO3 solution (x 2) and brine, then dried over MgSO4 and concentrated. The crude product was adsorbed onto silica gel and purified by column chromatography (70-100% EtOAc/ hexanes) to provide N- (5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(benzo[J][ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer A), as an orange solid (540 mg, 45 %). 1H NMR (400 MHz, DMSO-Jd) δ 7.80 (d, J = 7.9 Hz, IH), 7.40 - 7.36 (m, 2H), 7.27 (m, IH), 6.94 (s, IH), 6.85 (m, 2H), 6.00 (s, 2H), 5.56 (s, IH), 2.19 (s, 3H), 1.40 (m, 2H), 1.10 (m, 2H); HPLC ret. time 2.65 min, 10-99 % CH3CN, 5 min run; ESI-MS 442.5 m/z (MH+).
[00335] N-(5-(Amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 - (benzofJJfljSjdioxol-S-ytycyclopropanecarboxamide (Isomer B) was made by the procedure used for Isomer A starting from l-(benzo[ύT|[l,3]dioxol-5-yl)-N-(5-((2-chlorophenyl)((R)-l,l- dimethylethylsulfϊnamido)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer B) (90 %). 1H NMR (400 MHz, DMSO-Jd) δ 7.80 (d, J = 7.8 Hz, IH), 7.40 - 7.36 (m, 2H), 7.27 (m, IH), 6.94 (s, IH), 6.85 (m, 2H), 6.00 (s, 2H), 5.56 (s, IH), 2.19 (s, 3H), 1.40 (m, 2H), 1.10 (m, 2H); HPLC ret. time 2.69 min, 10-99 % CH3CN, 5 min run; ESI-MS 442.3 m/z (MH+).
[00336] (R)-N-(5-(Amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(2,2- difluorobenzo[rf] [l^dioxol-S-ytycyclopropanecarboxamide and (S)-N-(5-(Amino(2- chlorophenyI)methyl)-4-methylthiazol-2-yl)-l-(2,2-difluorobenzo[rf][l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000100_0001
[00337] N-(5-(Amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzofJJfl^Jdioxol-S-ytycyclopropanecarboxamide (Isomer A) was made by the procedure used for N-(5~(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l- (benzo[J][l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer A) starting from N-(5-((2- chlorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzo [J][l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer A) (83 %). 1H NMR (400 MHz, DMSO-Jd) δ 7.81 (m, IH), 7.41 - 7.32 (m, 4H), 7.27 (m, IH), 7.18 (dd, J = 1.7, 8.3 Hz, IH), 5.57 (s, IH), 2.20 (s, 3H), 1.48 (m, 2H), 1.17 (m, 2H); HPLC ret. time 2.84 min, 10- 99 % CH3CN, 5 min run; ESI-MS 478.1 m/z (MH+). [00338] N-(5-(Amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(2,2- difluorobenzofffjfljSjdioxol-S-y^cyclopropanecarboxamide (Isomer B) was made by the procedure used for N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l- (benzo[(/j[l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer A) starting from N-(5-((2- chlorophenyl)((R)- 1 , 1 -dimethylethylsulfinamido)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzofifltljSJdioxol-S-yOcyclopropanecarboxamide (Isomer B) (65 %). 1H NMR (400 MHz, DMSO-Λ5) δ 7.81 (m, IH), 7.41 - 7.32 (m, 4H), 7.28 (m, IH), 7.18 (dd, J = 1.7, 8.3 Hz, IH), 5.56 (s, IH), 2.19 (s, 3H), 1.48 (m, 2H), 1.18 (m, 2H); HPLC ret. time 2.84 min, 10-99 % CH3CN, 5 min run; ESI-MS 478.1 m/z (MH+).
[00339] (R)-N-(5-(Amino(3,4-dichlorophenyl)methyl)thiazol-2-yl)-l- (benzo[d] [l^Jdioxol-S-ytycyclopropanecarboxamide and (S)-N-(5-(Amino(3,4- dichlorophenyl)methyl) thiazol-2-yI)-l-(benzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000101_0001
[00340] N-(5-(Amino(3,4-dicmorophenyl)methyl)thiazol-2-yl)-l- (benzo[<f|[l,3]dioxol-5-yi)cyclopropanecarboxamide (Isomer A) was made by the procedure used for N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(benzo[(f][l,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer A) starting from l-(benzo[</][l,3]dioxol-5-yl)-N-(5- ((3 ,4-dichlorophenyl)((R)- 1 , 1 -dimethylethylsulfϊnamido)methyl)thiazol-2- yl)cyclopropanecarboxamide (Isomer A). The crude product was purified by column chromatography (0-20% MeOH/DCM) (98%). 1H NMR (400 MHz, DMSO-d6) δ 10.8 (bs, IH), 7.70 (d, J = 2.0 Hz, IH), 7.58 (d, J = 8.3 Hz, IH), 7.40 (dd, J = 2.0, 8.4 Hz, IH), 7.16 (d, J = 0.8 Hz, IH), 6.96 (s, IH), 6.86 (d, J = 0.9 Hz, 2H), 6.01 (s, 2H), 5.29 (s, IH), 1.44 - 1.42 (m, 2H), 1.13 - 1.10 (m, 2H); HPLC ret. time 2.81 min, 10-99% CH3CN, 5 min run; ESI-MS 462.3 m/z (MH+). [00341] N-(5-(Ammo(3,4-dichlorophenyl)methyl)thiazol-2-yl)-l- (benzo[<f|[l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for (Isomer A) starting from l-(benzo[d][l,3]dioxol-5-yl)-N-(5-((3,4- dichlorophenyl)((R)- 1 , 1 -dimethylethylsulfmamido)methyl)thiazol-2- yl)cyclopropanecarboxamide (Isomer B) (quant.). 1H NMR (400 MHz, DMSOd6) δ 10.8 (bs, IH), 7.70 (d, J = 2.0 Hz, IH), 7.58 (d, J = 8.3 Hz, IH), 7.40 (dd, J = 2.0, 8.4 Hz3 IH), 7.16 (d, J = 0.7 Hz, IH), 6.96 (s, IH), 6.86 (d, J = 0.9 Hz, 2H), 6.01 (s, 2H), 5.29 (s, IH), 1.44 - 1.42 (m, 2H), 1.13 - 1.10 (m, 2H); HPLC ret. time 2.81 min, 10-99% CH3CN, 5 min run; ESI-MS 462.1 m/z (MH+).
[00342] l-(Benzo[</] [l,3]dioxol-5-yl)-N-(5-((R)-((S)-3-(ter/- butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chlorophenyl)methyl)-4-methylthiazoI-2- yl)cyclopropanecarboxamide and l-(Benzo[rf] [l,3]dioxol-5-yl)-N-(5-((S)-((S)-3-(tert- butyIdimethyIsilyloxy)pyrrolidin-l-yl)(2-chlorophenyl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide
Figure imgf000102_0001
[00343] To a solution of N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2- yl)-l-(benzo[cT][l,3]dioxol-5-yl)cyclopiOpanecarboxamide (Isomer A) (450 mg, 1.02 mmol) in MeOH (5 mL) was added (S)-3-(tert-butyldimethylsilyloxy)-4-chlorobutanal (289 mg, 1.22 mmol). The reaction mixture was stirred at room temperature for 20 min before NaBH4 (58 mg, 1.53 mmol) was added. Stirring was continued at room temperature for 3 h. After approximately 1 h some precipitate/ gum started to form in the reaction solution so MeOH (5 mL) and CH2Cl2 (2 mL) were added to keep everything in solution. The reaction was diluted with H2O and extracted with EtOAc. The combined organic layers was washed with brine, dried over MgSO4 and concentrated. The residue was adsorbed onto silica gel and purified by column chromatography (0-25% EtOAc/hexanes) to afford l-(benzo[ιf][l,3]dioxol-5-yl)-N-(5- (((S)-3 -(tert-butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chlorophenyl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) as a pale yellow solid (470 mg, 74 %). 1H NMR (400 MHz, CDCl3) δ 8.40 (s, IH), 7.83 (dd, J = 8.1, 1.6 Hz, IH), 7.28-7.25 (m, 2H), 7.13 (m, IH), 6.88-6.83 (m, 2H), 6.79 (d, J = 7.9 Hz, IH), 6.00 (s, 2H), 5.08 (s, IH), 4.33 (m, IH), 2.94 (dd, J = 9.9, 6.3 Hz, IH), 2.67 (td, J = 8.3, 3.4 Hz, IH), 2.53 (q, J = 8.4 Hz, IH), 2.37 (s, 3H), 2.17 (dd, J = 9.9, 4.7 Hz, IH), 2.00 (m, IH), 1.74-1.61 (m, 3H), 1.17 (m, 2H), 0.86 (m, 9H), 0.01 (s, 3H), -0.01 (s, 3H); HPLC ret. time 3.45 min, 10-99% CH3CN, 5 min run; ESI-MS 626.5 m/z (MH+).
[00344] l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-(((S)-3-(tert- butyldimethylsilyloxy)pyrrolidin-l-yl)(2-clilorophenyl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for (Isomer A) starting from N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 - (benzofd^l^Jdioxol-S-ytycyclopropanecarboxamide (Isomer B) and (S)-3-(tert- butyldimethylsilyloxy)-4-chlorobutanal (81 %). 1H NMR (400 MHz, CDCl3) δ 8.41 (s, IH), 7.86 (dd, J = 7.2, 0.7 Hz, IH), 7.27-7.24 (m, 2H), 7.12 (m, IH), 6.88-6.84 (m, 2H), 6.79 (d, J = 7.9 Hz, IH), 6.00 (s, 2H), 5.05 (s, IH), 4.34 (m, IH), 2.84 (dd, J = 9.7, 6.3 Hz, IH), 2.56-2.46 (m, 2H), 2.37-2.32 (m, 4H), 2.03 (m, IH), 1.74-1.62 (m, 3H), 1.18 (m, 2H), 0.86 (m, 9H), 0.02 (s, 3H), 0.00 (s, 3H); HPLC ret. time 3.54 min, 10-99 % CH3CN, 5 min run; ESI-MS 626.3 m/z (MH+).
[00345] N-(5-((R)-((S)-3-(te^-Butyldimethylsilyloxy)pyrrolidin-l-yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(2,2-difluorobenzo[</l[l,3]dioxol-5- yl)cyclopropanecarboxamide and N-(5-((S)-((S)-3-(terf-Butyldimethylsilyloxy)pyrrolidin- l-yl)(2-chIorophenyl)methyl)-4-methylthiazol-2-yl)-l-(2,2-difluorobenzo[«TI[l,3]dioxol-5- yl)cyclopropanecarboxamide
Figure imgf000104_0001
[00346] N-(5-(((S)-3-(tert-Butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(2,2-difluorobenzo[<f][ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer A) was made by the procedure used for 1- (benzo[<f|[l,3]dioxol-5-yl)-N-(5-(((S)-3-(tert-butyldimethylsilyloxy)pyrrolidin-l-yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer A) starting from N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzo[(f|[l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer A) and (β)-3-(tert- butyldimethylsilyloxy)-4-chlorobutanal (73 %). 1H NMR (400 MHz, CDCl3) δ 8.25 (s, IH), 7.83 (dd, J = 8.1, 1.6 Hz, IH), 7.28-7.25 (m, 2H), 7.16-7.11 (m, 3H), 7.06 (d, J = 8.1 Hz, IH), 5.08 (s, IH), 4.33 (m, IH), 2.94 (dd, J = 9.9, 6.2 Hz, IH), 2.66 (td, J = 8.3, 3.7 Hz, IH), 2.54 (q, J = 8.3 Hz, IH), 2.36 (s, 3H), 2.18 (dd, J = 9.9, 4.7 Hz, IH), 2.02 (m, IH), 1.75 (m, 2H), 1.65 (m, IH), 1.20 (m, 2H), 0.86 (m, 9H), 0.01 (s, 3H), -0.01 (s, 3H); HPLC ret. time 3.69 min, 10-99 % CH3CN, 5 min run; ESI-MS 662.1 m/z (MH+).
[00347] N-(5-(((S)-3 -(tert-Butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)-l-(2,2-difluorobenzo[J][l,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for 1- (benzo[rf][l,3]dioxol-5-yl)-N-(5-(((S)-3-(terf-butyldimethylsilyloxy)pyrrolidin-l-yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer A) starting from N-(5-(amino(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzofdJfl^Jdioxol-S-ytycyclopropanecarboxamide (Isomer B) and (S)-3-(tert- butyldimethylsilyloxy)-4-chlorobutanal (93 %). 1HNMR (400 MHz, CDCl3) δ 8.26 (s, IH), 7.85 (dd, J = 8.1, 1.7 Hz, IH), 7.28-7.24 (m, 2H), 7.16-7.10 (m, 3H), 7.07 (d, J = 8.2 Hz, IH), 5.05 (s, IH), 4.34 (m, IH), 2.83 (dd, J = 9.7, 6.3 Hz, IH), 2.55-2.47 (m, 2H), 2.36-2.33 (m, 4H), 2.04 (m, IH), 1.79-1.63 (m, 3H)5 1.21 (m, 2H), 0.86 (m, 9H), 0.02 (s, 3H), 0.00 (s, 3H); HPLC ret. time 3.73 min, 10-99 % CH3CN, 5 min run; ESI-MS 662.1 m/z (MH+).
[00348] l-(Benzo[tf] [l,3]dioxol-5-yl)-N-(5-((R)-((R)-3-(fejt- butyldimethylsilyloxy)pyrrolidin-l-yl)(3,4-dichlorophenyl)methyI)thiazol-2- yl)cyclopropanecarboxamide and l-(Benzo[</] [l,3]dioxol-5-yl)-N-(5-((S)-((R)-3-(/e^- butyIdimethylsilyloxy)pyrroIidin-l-yl)(3,4-dichlorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide
Figure imgf000105_0001
[00349] l-(Benzo[d][l,3]dioxol-5-yl)-N-(5-(((R)-3-(tert- butyldimethylsilyloxy)pyrrolidin-l-yl)(3,4-dichlorophenyl)methyl)thiazol-2- y^cyclopropanecarboxamide (Isomer A) was made by the procedure used for 1- (benzo[ύT][l,3]dioxol-5-yl)-N-(5-(((S)-3-(tert-butyldimethylsilyloxy)pyrrolidm-l-yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer A) starting fromN-(5-(amino(3,4-dichlorophenyl)methyl)thiazol-2-yl)-l-(benzo[(f][l,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer A) and (R)-3-(tert-butyldimethylsilyloxy)-4- chlorobutanal (85%). 1H NMR (400 MHz, CDCl3) δ 8.47 (s, IH), 7.51 (d, J = 2.0 Hz, IH), 7.35 (d, J = 8.3 Hz, IH), 7.30 (dd, J = 2.0, 8.3 Hz, IH), 7.19 (s, IH), 6.90 - 6.85 (m, 2H), 6.80 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 4.47 (s, IH), 4.34 (m, IH), 2.84 (dd, J = 6.2, 9.8 Hz, IH), 2.55 - 2.44 (m, 2H), 2.31 (dd, J = 4.4, 9.9 Hz, IH), 2.17 (s, IH), 1.73 - 1.64 (m, 3H), 1.26 - 1.19 (m, 2H), 0.91 (s, 3H), 0.86 (s, 6H), 0.02 (s, 6H); HPLC ret. time 3.66 min, 10-99% CH3CN, 5 min run; ESI-MS 646.5 m/z (MH+).
[00350] l-(Benzo[J][l,3]dioxol-5-yl)-N-(5-(((R)-3-(tert- butyldimethylsilyloxy)py1τolidm-l-yl)(3,4-dichlorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for 1- (benzo[<l[l,3]dioxol-5-yl)-N-(5-(((S)-3-(tert-butyldimethylsilyloxy)pyrrolidin-l-yl)(2- chlorophenyl)methyl)-4-methylthiazol-2-yl)cycloproρanecarboxamide (Isomer A) starting from N-(5-(amino(3 ,4-dichlorophenyl)methyl)thiazol-2-yl)- 1 -(benzo[d][ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide (Isomer B) and (R)~3-(fert-butyldimethylsilyloxy)-4- chlorobutanal (70%). 1H NMR (400 MHz, CDCl3) δ 8.47 (s, IH), 7.50 (d, J = 2.0 Hz, IH), 7.36 (d, J = 8.3 Hz, IH), 7.29 (dd, J = 2.0, 8.3 Hz, IH), 7.19 (s, IH), 6.90 - 6.85 (m, 2H), 6.80 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 4.51 (s, IH), 4.34 (m, J = 3.4, 9.4 Hz, IH), 2.88 (dd, J = 6.2, 10.0 Hz, IH), 2.67 - 2.62 (m, IH), 2.53 (dd, J = 8.2, 16.7 Hz, IH), 2.17 (dd, J = 4.4, 10.0 Hz, IH), 2.07 - 1.78 (m, IH), 1.75 - 1.63 (m, 3H), 1.22 - 1.18 (m, 2H), 0.86 (d, J = 2.5 Hz, 9H), 0.01 (m, 6H); HPLC ret. time 3.67 min, 10-99% CH3CN, 5 min run; ESI-MS 646.4 m/z (MH+).
[00351] l-(Benzo[rf][l,3]dioxol-5-yl)-N-(5-((R)-(2-chlorophenyl)((S)-3- hydroxypyrrolidin-l-yl)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide and 1- (Benzo[</j[l,3]dioxol-5-yl)-N-(5-((S)-(2-chlorophenyI)((S)-3-hydroxypyrrolidin-l- yI)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide
Figure imgf000106_0001
[00352] A mixture of l-(benzo[tf][l,3]dioxol-5-yl)-N-(5-(((S)-3-(tert- butyldimethylsilyloxy)pyrrolidin-l-yl)(2-chlorophenyl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) (400 mg, 0.64 mmol) and TBAF (IM in THF, 3.84 mL, 3.84 mmol) was stirred at room temperature for 5 h. The reaction was partitioned between H2O and EtOAc. The combined organic layers were washed with brine, dried over MgSO4 and concentrated. The residue was adsorbed onto silica gel and purified by column chromatography (25-75% EtOAc/ hexanes) to afford l-(benzo[rf][l,3]dioxol-5-yl)-N-(5-((2- chlorophenyl)((S)-3-hydroxypyrrolidin-l-yl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) as a pale yellow solid (245 mg, 75 %, >99% de). 1H NMR (400 MHz, CDCl3) δ 8.41 (s, IH), 7.85 (dd, J = 8.1, 1.7 Hz, IH), 7.29-7.26 (m, 2H), 7.14 (m, IH), 6.88-6.84 (m, 2H), 6.79 (d, J = 7.9 Hz, IH), 6.00 (s, 2H), 5.07 (s, IH), 4.30 (m, IH), 2.79 (td, J = 8.6, 5.8 Hz, IH), 2.63-2.56 (m, 2H), 2.36 (s, 3H), 2.29 (td, J = 9.0, 5.9 Hz, IH), 2.15 (m, IH), 1.85 (d, J = 7.9 Hz, IH), 1.78-1.65 (m, 3H), 1.18 (m, 2H); HPLC ret. time 2.70 min, 10-99 % CH3CN, 5 min ran; ESI-MS 512.5 m/z (MH+).
[00353] l-(Benzo[^[l,3]dioxol-5-yl)-N-(5-((2-cMorophenyl)((S)-3- hydroxypyrrolidin- 1 -yl)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for (Isomer A) starting from l-(benzo[c(|[l,3]dioxol-5-yl)-N- (5-(((S)-3-(ter^-butyldimethylsilyloxy)pyπOlidin-l-yl)(2-chlorophenyl)methyl)-4- methylthiazol-2-yl)cyclopropanecarboxamide (Isomer B) (50 %, >99% de). 1H NMR (400 MHz, CDCl3) δ 8.44 (s, IH), 7.84 (dd, J = 7.8, 1.5 Hz, IH), 7.29-7.25 (m, 2H), 7.14 (td, J = 7.6, 1.7 Hz, IH), 6.88-6.84 (m, 2H), 6.79 (d, J = 7.9 Hz, IH), 6.00 (s, 2H), 5.07 (s, IH), 4.29 (m, IH), 2.83 (td, J = 8.6, 5.0 Hz, IH), 2.61 (d, J = 10.1 Hz, IH), 2.49 (m, IH), 2.36-2.29 (m, 4H), 2.17 (m, IH), 1.89 (d, J = 7.9 Hz, IH), 1.76-1.66 (m, 3H), 1.19 (m, 2H); HPLC ret. time 2.71 min, 10-99 % CH3CN, 5 min run; ESI-MS 512.5 m/z (MH+).
[00354] N-(5-((R)-(2-ChIorophenyl)((S)-3-hydroxypyrrolidin-l-yl)methyl)-4- methylthiazol-2-yl)-l-(2,2-difluorobenzo[</J [1,3] dioxol-S-ytycyclopropanecarboxamide and N-(5-((S)-(2-Chlorophenyl)((S)-3-hydroxypyrrolidin-l-yl)methyl)-4-methylthiazol-2-yl)-l- (2,2-difluorobenzo[</|[l,3]dioxol-5-yl)cycIopropanecarboxamide
Figure imgf000107_0001
[00355] N-(5-((2-Chlorophenyl)((S)-3-hydroxypyrrolidin- 1 -yl)methyl)-4- methylthiazol-2-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer A) was made by the procedure used for l-(benzo[J][l,3]dioxol-5-yl)-N-(5-((2- chlorophenyl)((S)-3 -hydroxypyrrolidin- 1 -yl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) starting from N-(5-(((S)-3-(ter£- Butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzo^lljSJdioxol-S-ytycyclopropanecarboxamide (Isomer A) (72 %). 1H NMR (400 MHz, CDCl3) δ 8.28 (s, IH), 7.84 (dd, J = 8.1, 1.7 Hz, IH), 7.30-7.26 (m, 2H), 7.17-7.12 (m, 3H), 7.07 (d, J = 8.2 Hz, IH), 5.07 (s, IH), 4.30 (m, IH), 2.79 (td, J = 8.6, 5.7 Hz, IH), 2.62- 2.55 (m, 2H), 2.35 (s, 3H), 2.28 (td, J = 9.0, 5.9 Hz, IH), 2.15 (m, IH), 1.86 (d, J = 7.9 Hz, IH), 1.80-1.71 (m, 3H), 1.21 (m, 2H); HPLC ret. time 2.91 min, 10-99 % CH3CN, 5 min run; ESI-MS 548.3 m/z (MH+).
[00356] N-(5-((2-Chlorophenyl)((S)-3-hydroxypyrrolidin- 1 -yl)methyl)-4- methylthiazol-2-yl)- 1 -(2,2-difluorobenzo [d] [ 1 ,3]dioxol-5-yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for l-(benzo[<i][l,3]dioxol-5-yl)-N-(5-((2- chlorophenyl)((S)-3-hydroxypyrrolidin-l-yl)methyl)-4-methylthiazol-2- yl)cyclopropanecarboxamide (Isomer A) starting from N-(5-(((S)-3-(tert- Butyldimethylsilyloxy)pyrrolidin- 1 -yl)(2-chlorophenyl)methyl)-4-methylthiazol-2-yl)- 1 -(2,2- difluorobenzofdJfl^dioxol-S-yrjcyclopropanecarboxamide (Isomer B) (85 %). 1H NMR (400 MHz, CDCl3) δ 8.28 (s, IH), 7.82 (dd, J = 7.7, 1.5 Hz, IH), 7.30-7.25 (m, 2H), 7.14 (m, 3H), 7.07 (d, J = 8.2 Hz, IH), 5.07 (s, IH), 4.29 (m, IH), 2.83 (td, J = 8.7, 5.1 Hz, IH), 2.61 (d, J = 10.0 Hz, IH), 2.50 (dd, J = 10.1, 5.1 Hz, IH), 2.36-2.29 (m, 4H), 2.17 (m, IH), 1.88 (d, J = 7.8 Hz, IH), 1.82-1.70 (m, 3H), 1.22 (m, 2H); HPLC ret. time 2.94 min, 10-99 % CH3CN, 5 min run; ESI-MS 548.3 m/z (MH+).
[00357] l-(Benzo[</[[l,3]dioxol-5-yl)-N-(5-((R)-(3,4-dichIorophenyl)((R)-3- hydroxypyrrolidin-l-ytymethy^thiazol-l-ytycyclopropanecarboxamide and 1- (Benzo[«π[l,3]dioxol-5-yl)-N-(5-((S)-(3,4-dichlorophenyl)((R)-3-hydroxypyrrolidin-l- yl)methyl)thiazol-2-yl)cyclopropanecarboxamide
Figure imgf000108_0001
[00358] l-(Benzo[φ,3]dioxol-5-yl)-N-(5-((3,4-dichlorophenyl)((R)-3- hydroxypyrrolidin-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide (Isomer A) was made by the procedure used for l-(benzo[<fj[l,3]dioxol-5-yl)-N-(5-((2-chlorophenyl)((S)-3- hydroxypyrrolidin- 1 -yl)methyl)-4-methylthiazol-2-yl)cyclopropanecarboxamide (Isomer A) starting from l-(benzo[rf][l,3]dioxol-5-yl)-N-(5-(((R)-3-(fert-butyldimethylsilyloxy)pyrrolidin- l-yl)(3,4-dichlorophenyl)methyl)thiazol-2-yl)cyclopropanecai-boxamide (Isomer A) The crade product was purified by column chromatography (60-90% EtOAc/Hexane) (74%, 98% de). 1H NMR (400 MHz, CDCl3) δ 8.49 (s, IH), 7.50 (d, J = 2.0 Hz, IH), 7.37 (d, J = 8.3 Hz, IH), 7.31 (dd, J = 2.0, 8.3 Hz, IH), 7.20 (s, IH), 6.90 - 6.86 (m, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 4.48 (s, IH), 4.32 (m, IH), 2.82 - 2.76 (m, IH), 2.59 - 2.57 (m, IH), 2.51 (q, J = 5.1 Hz, IH), 2.33 (td, J = 8.9, 6.1 Hz, IH), 2.16 (dd, J = 5.3, 12.5 Hz, IH), 1.81 - 1.69 (m, 4H), 1.22 (dd, J = 5.0, 7.6 Hz, 2H); HPLC ret. time 2.81 min, 10-99% CH3CN, 5 min run; ESI-MS 532.2 m/z (MH+).
[00359] l-(Benzo[J][l,3]dioxol-5-yl)-N-(5-((3,4-dichlorophenyl)((R)-3- hydroxypyiτolidm-l-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide (Isomer B) was made by the procedure used for (Isomer A) starting from l-(benzo[c(][l,3]dioxol-5-yl)-N-(5-(((R)-3- (tert-butyldimethylsilyloxy)pyiτolidin-l-yl)(3,4-dichlorophenyl)methyl)thiazol-2- yl)cyclopropanecarboxamide (Isomer B) (78%, 95% de). 1H NMR (400 MHz, CDCl3) δ 8.49 (s, IH), 7.52 (d, J = 2.0 Hz, IH), 7.37 (d, J = 8.3 Hz, IH), 7.30 (dd, J = 2.0, 8.3 Hz, IH), 7.20 (s, IH), 6.90 - 6.86 (m, 2H), 6.81 (d, J = 7.9 Hz, IH), 6.01 (s, 2H), 4.48 (s, IH), 4.34 - 4.32 (m, IH), 2.76 (td, J = 8.5, 6.0 Hz, IH), 2.57 (m, 2H), 2.29 (m, IH), 2.15 (q, J = 7.2 Hz, IH), 1.81 - 1.68 (m, 4H), 1.25 - 1.20 (m, 2H); HPLC ret. time 2.80 min, 10-99% CH3CN, 5 min run; ESI- MS 532.2 m/z (MH+).
[00360] Assays for Detecting and Measuring ΔF508-CFTR Correction Properties of Compounds
[00361] I) Membrane potential optical methods for assaying ΔF508-CFTR modulation properties of compounds
[00362] The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See,. Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00363] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (V1n) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission were monitored using VIPR™ II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384- well microtiter plates.
[00364] Cell Culture
[00365] NIH3T3 mouse fibroblasts stably expressing ΔF508-CFTR are used for optical measurements of membrane potential. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For all optical assays, the cells were seeded at 30,000/well in 384- well matrigel-coated plates and cultured for 2 hrs at 37 0C before culturing at 27 0C for 24 hrs. for the potentiator assay. For the correction assays, the cells are cultured at 27 0C or 37 0C with and without compounds for 16 - 24 hoursB) Electrophysiological Assays for assaying ΔF508- CFTR modulation properties of compounds
[00367] 1.Ussing Chamber Assay
[00368] Ussing chamber experiments were performed on polarized epithelial cells expressing ΔF508-CFTR to further characterize the ΔF508-CFTR modulators identified in the optical assays. pRrpΔF508-CFTR epithelial cells grown on Costar Snapwell cell culture inserts were mounted in an Ussing chamber (Physiologic Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a Voltage-clamp System (Department of Bioengineering, University of Iowa, IA, and, Physiologic Instruments, Inc., San Diego, CA). Transepithelial resistance was measured by applying a 2-mV pulse. Under these conditions, the FRT epithelia demonstrated resistances of 4 KΩ/ cm2 or more. The solutions were maintained at 27 0C and bubbled with air. The electrode offset potential and fluid resistance were corrected using a cell-free insert. Under these conditions, the current reflects the flow of Cl" through ΔF508-CFTR expressed in the apical membrane. The Isc was digitally acquired using an MPlOOA-CE interface and AcqKnowledge software (V3.2.6; BIOPAC Systems, Santa Barbara, CA).
[00369] Identification of Correction Compounds
[00370] Typical protocol utilized a basolateral to apical membrane Cl" concentration gradient. To set up this gradient, normal ringer was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl" concentration gradient across the epithelium. AU experiments were performed with intact monolayers. To fully activate ΔF508-CFTR, forskolin (10 μM) and the PDE inhibitor, IBMX (100 μM), were applied followed by the addition of the CFTR potentiator, genistein (50 μM).
[00371] As observed in other cell types, incubation at low temperatures of FRT cells stably expressing ΔF508-CFTR increases the functional density of CFTR in the plasma membrane. To determine the activity of correction compounds, the cells were incubated with 10 μM of the test compound for 24 hours at 37°C and were subsequently washed 3X prior to recording. The cAMP- and genistein-mediated Isc in compound-treated cells was normalized to the 270C and 37°C controls and expressed as percentage activity. Preincubation of the cells with the correction compound significantly increased the cAMP- and genistein-mediated Isc compared to the 37°C controls.
[00372] To determine the activity of correction compounds for increasing the density of functional ΔF508-CFTR in the plasma membrane, we used the above-described perforated-patch-recording techniques to measure the current density following 24-hr treatment with the correction compounds. To fully activate ΔF508-CFTR, 10 μM forskolin and 20 μM genistein were added to the cells. Under our recording conditions, the current density following 24-hr incubation at 27°C was higher than that observed following 24-hr incubation at 37 0C. These results are consistent with the known effects of low-temperature incubation on the density of ΔF508-CFTR in the plasma membrane. To determine the effects of correction compounds on CFTR current density, the cells were incubated with 10 μM of the test compound for 24 hours at 37°C and the current density was compared to the 27°C and 37°C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 μM of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37°C controls.
[00179] Table 3 illustrates the EC50 and relative efficacy of exemplary embodiments of the present invention. In Table 3, the following meanings apply:
EC50: "+++" means <2 uM; "++" means between 2uM to 20 uM; "+" means between 25 uM to 6OuM.
% Efficacy: "+" means < 25%; "-H-" means between 25% to 100%; "+++" means > 100%.
Table 3
Figure imgf000112_0001
As illustrated in Table 3 above, the compounds of the present invention exhibit unexpectedly better correction activity as measured by the assays above.
- Il l -

Claims

Claims
1. A compound of formula I or formula II:
Figure imgf000113_0001
or a pharmaceutically acceptable salt thereof, wherein: each Rx is independently hydrogen, halo, CF3, C1-C4 alkyl, or -OC1-C4 alkyl; provided that both Rx are not simultaneously hydrogen; or the two Rx, taken together form ring (a):
Figure imgf000113_0002
X is CH2, CF2, CH2-CH2, or CF2-CF2; ring A is 3-7 membered monocyclic cycloalkyl ring;
RAA and RBB, taken together with the nitrogen atom, form a pyrrolidinyl ring substituted with OR';
R' is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -O-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, NRSO2-, or -NRSO2NR-;
R is hydrogen or C1-C6 aliphatic;
Z is an electron withdrawing substituent; and q is 0-3.
2. The compound according to claim 1, wherein two Rx taken together form ring (a) and X is CH2.
3. The compound according to claim 1, wherein wherein two Rx taken together form ring (a) and X is CF2.
4. The compound according to claim 1, wherein one Rx is hydrogen and the other Rx is halo, CF3, C1-C4 alkyl, or -OC1-C4 alkyl.
5. The compound according to claim 1, wherein one Rx is hydrogen and the other R is 4-methoxy.
6. The compound according to any one of claims 1-5, wherein ring A is cyclopropyl, cyclopentyl, or cyclohexyl.
7. The compound according to claim 6, wherein ring A is cyclopropyl or cyclopentyl.
8. The compound according to claim 6, wherein ring A is cyclopropyl.
9. The compound according to any one of claims 1-8, wherein R' is hydrogen.
10. The compound according to any one of claims 1-8, wherein R' is Ci-6 alkyl.
11. The compound according to any one of claims 1-10, wherein RΛA and RBB, taken together, form a pyrrolidinyl with an OH substituent.
12. The compound according to any one of claims 1-11, wherein Z is selected from halo, CF3, or difluoromethylenedioxy.
13. The compound according to any one of claims 1-12, wherein q is 0.
14. The compound according to any one of claims 1-12, wherein q is 1.
15. The compound according to any one of claims 1-14, wherein R is hydrogen.
16. The compound according to any one of claims 1-12 or 14, wherein compounds of formula I or formula II comprise one or more, and preferably all, of the following features: two Rx taken together form ring (a);
X is CH2; ring A is cyclopropyl;
R is hydrogen; q is 1; and
Z is halo, CF3, or difluoromethylenedioxy.
17. The compound according to any one of claims 1-16, wherein R^ and RBB in formula I, taken together with the nitrogen atom, form the following ring (i):
Figure imgf000115_0001
18. The compound according to any one of claims 1-16, wherein RAA and RBB in formula I, taken together with the nitrogen atom, form the following ring (ii):
Figure imgf000116_0001
19. A compound selected from Table 1.
20. A pharmaceutical composition comprising:
(i) a compound according to any one of claims 1-19; and (ii) a pharmaceutically acceptable carrier.
21. The composition of claim 20, optionally further comprising an additional agent selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, CFTR potentiator or a CFTR corrector other than a compound of the present invention, or a nutritional agent.
22. A method of increasing the number of functional CFTR in a membrane of a cell, comprising the step of contacting said cell with a compound according to any one of claims 1-19
23. A kit for use in measuring the activity of CFTR or a fragment thereof in a biological sample in vitro or in vivo, comprising:
(i) a first composition comprising a compound according to any one of claims 1-19; and (ii) instructions for: a) contacting the composition with the biological sample; b) measuring activity of said CFTR or a fragment thereof.
24. The kit according to claim 23, further comprising instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the CFTR in the presence of the additional compound with the density of the CFTR in the presence of said first composition.
25. The kit according to clcaim 24, wherein the kit is used to measure the density of CFTR.
26. A method of treating a condition, disease, or disorder in a patient implicated by CFTR, comprising the step of administering to said patient a compound according to any one of claims 1-19.
27. The method according to claim 26, wherein said condition, disease, or disorder is selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as amilial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, hereditary emphysema, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, Huntington, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to Prion protein processing defect), Fabry disease, Straussler-Scheinker disease, secretory diarrhea, polycystic kidney disease, chronic obstructive pulmonary disease (COPD), dry eye disease, or Sjogren's syndrome.
28. A compound having formula I' or formula II':
Figure imgf000118_0001
wherein:
Rx, ring A, Z, and q are as defined in claim 1 ; L is a linker selected from C(O) or SO2; p is 0 or 1 ; CA is a suitable chiral auxiliary.
29. The compound according to claim 28, wherein CA, L, p, and the oxygen atom linked thereto, taken together, is (+)-10-camphorsulfonate, (IS, 4i?)-(-)-ω-camphanic ester, (IR, 2S, 5R)-(-) mentholcarbonate, (IS, 2R, 55)-(+)-mentholcarbonate, (Ii?, 2i?)~l-phenyl-2- cyclopropylester, or (3i?)-tetrahydrofuran-3-carbonate.
30. A method of producing a compound of formula I or formula II:
Figure imgf000118_0002
comprising the step of reacting under a first suitable conditions a compound of formula R-I with either a compound of formula I-A to produce said compound of formula I, or a compound of formula H-A to produce said compound of formula II:
Figure imgf000119_0001
I-A H-A
R' \
O O
LG-
H
R-I; wherein: each Rx is independently hydrogen, halo, CF3, C1-C4 alkyl, or -OC1-C4 alkyl; provided that both Rx are not simultaneously hydrogen; or the two Rx, taken together form ring (a):
Figure imgf000119_0002
X is CH2, CF2, CH2-CH2, or CF2-CF2; ring A is 3-7 membered monocyclic cycloalkyl ring;
RAA and RBB, taken together with the nitrogen atom, form a pyrrolidinyl ring substituted with OR';
R' is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR-, -CONRNR-, -CO2-, -OCO-, -NRCO2-, -0-, -NRCONR-, -OCONR-, -NRNR, -NRNRCO-, -NRCO-, -S-, -SO, -SO2-, -NR-, -SO2NR-, NRSO2-, or -NRSO2NR-;
R is hydrogen or C1-C6 aliphatic;
Z is an electron withdrawing substituent; and q is 0-3; and LGi is a first suitable leaving group
31. The method according to claim 30, wherein LGi is selected from alkyl sulfonate, aryl sulfonate, halide, alkyl carboxylate.
32. The method according to claim 30, wherein said first suitable conditions comprises a first suitable solvent, a first suitable temperature, and a suitable reducing agent.
33. The method according to claim 32, wherein said first suitable solvent is a polar or apolar, protic or aprotic solvent.
34. The method according to claim 33 wherein said solvent is selected from methanol, ethanol, propanol, isopropanol, tert-butanol, dichloromethane, dichloroethane, toluene, tetrahydrofurane, dioxane, diethylether, dimethylether, acetonitrile, DMF, DMAC, or NMP.
35. The method according to claim 32, wherein said first suitable temperature is between about 0 0C to about 110 0C.
36. The method according to claim 32, wherein said suitable reducing agent is a metallo-borohydride or an agent capable of catalytic hydrogenation.
37. The method according to claim 36, wherein said suitable reducing agent is selected from sodium borohydride, sodium cyanoborohydride, lithium borohydride, sodium triacetoxyborohydride, calcium borohydride, hydrogen in the presence of a suitable metal catalyst.
38. The method according to claim 30, wherein said compound of formula I- A and formula II-A is produced from formula I-B formula H-B, respectively:
Figure imgf000120_0001
I-B H-B; wherein [CA] is a suitable chiral auxiliary; said method comprising the step of removing said chiral auxilary under a second suitable conditions.
39. The method according to claim 38, wherein said suitable chiral auxiliary is an alkylsulfoxyl group.
40. The method according to claim 38, wherein said suitable second conditions comprises a suitable protic acid and a suitable second solvent.
41. The method according to claim 40, wherein said suitable second solvent is selected from a polar aprotic solvent or a protic solvent.
42. The method according to claim 41, wherein said suitable second solvent is a polar aprotic solvent.
43. The method according to claim 42, wherein said polar aprotic solvent is selected from dioxane, tetrahydrofurane, diethyl ether, or dichloromethane.
44. The method according to claim 38, wherein said compound of formula I-B and formula H-B is produced by reacting, respectively, a compound of formula I-C or formula II-C with a compound of formula R-2 under a third suitable conditions:
Figure imgf000121_0001
R-2 wherein: R1 is hydrogen or a first suitable protecting group; [CA] is a suitable chiral auxiliary; and LG2 is a second suitable leaving group.
45. The method according to claim 44, wherein LG2 is selected from halide, OC(O)alkyl, pentafluorophenoxy, alkoxy, OCO2alkyl or hydroxy.
46. The method according to claim 44, wherein R1 is hydrogen.
47. The method according to claim 44, wherein said third suitable conditions comprises a suitable a third suitable coupling agent and a third suitable solvent.
48. The method according to claim 47, wherein said suitable coupling agent is selected from triethyl amine, pyridine, DIEA, lutidine, HATU, TCPH, or HBTU.
49. The method according to claim 47, wherein said third suitable solvent is selected from dichloromethane, dioxane, DMF, dichloroethane, or tetrahydrofuran.
50. The method according to claim 44, wherein said compound of formula I-C or formula H-C is produced from an isomeric mixture of a compound of formula R-3:
Figure imgf000122_0001
R-3; wherein:
PGi is a second suitable protecting group; and [CA] is a suitable chiral auxiliary; said method comprising two steps, wherein one of said two steps is separating said isomeric mixture using suitable separation means, and the other of said two steps is the conversion OfPG1 to R1 in a fourth suitable conditions.
51. The method according to claim 50, wherein said suitable separation means comprises suitable chromatographic means.
52. The method according to claim 51, wherein said suitable chromatographic means is selected from column chromatography or thin layer chromatography.
53. The method according to claim 50, wherein said suitable separation means comprises crystallization methods.
54. The method according to claim 50, wherein said fourth suitable conditions comprises a suitable deprotecting reagent and a fourth suitable solvent.
55. The method according to claim 54, wherein said suitable deprotecting reagent is trifluoroacetic acid.
56. The method according to claim 54, wherein said fourth suitable solvent is a apolar aprotic solvent.
57. The method according to claim 56, wherein said polar aprotic solvent is dichloromethane.
58. The method according to claim 50, wherein said compound of formula R-3 is produced from a compound of formula R-4 and a compound of formula R-5:
Figure imgf000123_0001
R-4 R-5; wherein:
PG1 is a second suitable protecting group;
M is a suitable metal cation; and
[CA] is a suitable chiral auxiliary; said method comprising the steps of reacting said compound of formula R-4 with said compound of formula R-5 in a fifth suitable conditions.
59. The method according to claim 58, wherein said M is selected from Li , Na or Mg -H-
60. The method according to claim 58, wherein PG1 is selected from an alkylcarbamate, trifiuoroacetyl, trialkylsilyl, or pivaloyl.
61. The method according to claim 60, wherein said PGi is BOC or trimethylsilyl.
62. The method according to claim 58, wherein said fifth suitable conditions comprises a fifth suitable solvent and a fifth suitable temperature.
63. The method according to claim 62, wherein said suitable temperature is about -78 degrees C.
64. The method according to claim 62, wherein said fifth suitable solvent is- tetrahydrofuran.
65. The method according to claim 30, wherein said compound of formula R-I is
Figure imgf000124_0001
66. The method according to claim 30, wherein said compound of formula I or formula II is selected from Table 1.
PCT/US2006/031457 2005-08-11 2006-08-11 Modulators of cystic fibrosis transmembrane conductance regulator WO2007021982A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT06801307T ATE512145T1 (en) 2005-08-11 2006-08-11 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS
NZ566208A NZ566208A (en) 2005-08-11 2006-08-11 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators
JP2008526246A JP5143738B2 (en) 2005-08-11 2006-08-11 Modulator of cystic fibrosis membrane conductance regulator
EP06801307A EP1912983B1 (en) 2005-08-11 2006-08-11 Modulators of cystic fibrosis transmembrane conductance regulator
AU2006279810A AU2006279810B2 (en) 2005-08-11 2006-08-11 Modulators of cystic fibrosis transmembrane conductance regulator
CA002618057A CA2618057A1 (en) 2005-08-11 2006-08-11 Modulators of cystic fibrosis transmembrane conductance regulator
MX2008002019A MX2008002019A (en) 2005-08-11 2006-08-11 Modulators of cystic fibrosis transmembrane conductance regulator.
IL189178A IL189178A0 (en) 2005-08-11 2008-02-03 Thiazolyl derivatives and pharmaceutical compositions containing the same
NO20081280A NO20081280L (en) 2005-08-11 2008-03-11 Modulators of systemic transmembrane conductance regulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70738005P 2005-08-11 2005-08-11
US60/707,380 2005-08-11
US73247605P 2005-11-02 2005-11-02
US60/732,476 2005-11-02

Publications (2)

Publication Number Publication Date
WO2007021982A2 true WO2007021982A2 (en) 2007-02-22
WO2007021982A3 WO2007021982A3 (en) 2007-05-03

Family

ID=37663354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/031457 WO2007021982A2 (en) 2005-08-11 2006-08-11 Modulators of cystic fibrosis transmembrane conductance regulator

Country Status (13)

Country Link
US (5) US7999113B2 (en)
EP (1) EP1912983B1 (en)
JP (4) JP5143738B2 (en)
KR (1) KR20080053297A (en)
AT (1) ATE512145T1 (en)
AU (1) AU2006279810B2 (en)
CA (1) CA2618057A1 (en)
IL (1) IL189178A0 (en)
MX (1) MX2008002019A (en)
NO (1) NO20081280L (en)
NZ (1) NZ566208A (en)
RU (1) RU2008109031A (en)
WO (1) WO2007021982A2 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US7713965B2 (en) 2008-02-29 2010-05-11 Vetoquinol Sa 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
US8071590B2 (en) 2008-07-09 2011-12-06 Vetoquinol Sa 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
WO2012035158A1 (en) 2010-09-17 2012-03-22 Novartis Ag Pyrazine derivatives as enac blockers
EP2444120A1 (en) 2007-12-10 2012-04-25 Novartis AG Spirocyclic amiloride analogues as ENac blockers
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2013093812A2 (en) 2011-12-19 2013-06-27 Umc Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2013140319A1 (en) 2012-03-19 2013-09-26 Novartis Ag Crystalline form of a succinate salt
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
WO2014086687A1 (en) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova A cftr corrector for the teatment of genetic disorders affecting striated muscle
US9642831B2 (en) 2014-10-31 2017-05-09 Abbvie S.Á.R.L. Substituted chromanes and method of use
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9725440B2 (en) 2007-05-09 2017-08-08 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9751890B2 (en) 2008-02-28 2017-09-05 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9776968B2 (en) 2007-12-07 2017-10-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2017173274A1 (en) * 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US9840499B2 (en) 2007-12-07 2017-12-12 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10076513B2 (en) 2010-04-07 2018-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US10258624B2 (en) 2014-10-06 2019-04-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020049189A1 (en) 2018-09-09 2020-03-12 Qanatpharma Gmbh Use of cftr modulators for treating cerebrovascular conditions
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
US11591350B2 (en) 2019-08-14 2023-02-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
ATE437640T1 (en) * 2003-11-14 2009-08-15 Vertex Pharma THIAZOLES AND OXAZOLES AS MODULATORS OF ATP BINDING CASSETTE TRANSPORTERS
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8759335B2 (en) * 2004-01-30 2014-06-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1912983B1 (en) * 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
AU2006336504C9 (en) * 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
PT2217572E (en) 2007-11-16 2014-02-17 Vertex Pharma Isoquinoline modulators of atp-binding cassette transporters
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CN101998854A (en) * 2007-12-07 2011-03-30 沃泰克斯药物股份有限公司 Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2009231993B2 (en) 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
JP2012504143A (en) 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid dosage unit
ES2483690T3 (en) * 2008-10-23 2014-08-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BR112012026257A2 (en) 2010-04-07 2017-03-14 Vertex Pharma solid forms of 3- (6- (1- (2-, 2-difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
TWI535712B (en) * 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
IN2014KN00885A (en) 2011-11-08 2015-10-02 Vertex Pharma
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN107746834A (en) * 2013-03-27 2018-03-02 辉瑞爱尔兰制药公司 For preparing the method and intermediate of Pregabalin
KR101721029B1 (en) 2014-10-16 2017-03-29 연세대학교 산학협력단 Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient
AU2022265718A1 (en) 2021-04-29 2023-11-02 Novartis Ag Deubiquitinase-targeting chimeras and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426331B1 (en) * 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
PT1394150E (en) * 1999-02-24 2011-02-17 Hoffmann La Roche 4-phenylpyridine derivatives and their use as nk-1 receptor antagonists
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2005520171A (en) * 2001-04-10 2005-07-07 トランス テック ファーマ,インコーポレイテッド Probes, systems, and methods for drug discovery
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004080972A1 (en) 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
DE602004022819D1 (en) * 2003-06-06 2009-10-08 Vertex Pharma TRANSPORTER OF ATP-BINDING CASSETTE
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1680411A2 (en) 2003-10-08 2006-07-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
ATE437640T1 (en) 2003-11-14 2009-08-15 Vertex Pharma THIAZOLES AND OXAZOLES AS MODULATORS OF ATP BINDING CASSETTE TRANSPORTERS
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8759335B2 (en) * 2004-01-30 2014-06-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP1773816B1 (en) * 2004-06-24 2015-01-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US8242149B2 (en) * 2005-03-11 2012-08-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8822451B2 (en) * 2005-05-24 2014-09-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1912983B1 (en) * 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
RU2008118001A (en) 2005-10-06 2009-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATF-DEPENDENT TRANSPORTERS
JP5317184B2 (en) 2005-11-08 2013-10-16 バーテックス ファーマシューティカルズ インコーポレイテッド ATP binding cassette transporter modulator
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
AU2006331614A1 (en) 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of ABC transporters
CA2635214A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
LT1993360T (en) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
CN101460489A (en) 2006-04-07 2009-06-17 弗特克斯药品有限公司 Modulators of ATP-binding cassette transporters
US7553855B2 (en) * 2006-05-12 2009-06-30 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2789606B1 (en) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008147952A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
EP2222304A2 (en) * 2007-09-14 2010-09-01 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
PT2217572E (en) 2007-11-16 2014-02-17 Vertex Pharma Isoquinoline modulators of atp-binding cassette transporters
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
LT2639223T (en) * 2007-12-07 2017-06-26 Vertex Pharmaceuticals Incorporated Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
CN101998854A (en) * 2007-12-07 2011-03-30 沃泰克斯药物股份有限公司 Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP2011506330A (en) 2007-12-07 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド Solid form of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
WO2009076593A1 (en) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8299099B2 (en) 2008-02-28 2012-10-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
AU2009231993B2 (en) 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
BRPI0916877A2 (en) 2008-08-13 2016-02-10 Vertex Pharma pharmaceutical composition and administration thereof
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2012504143A (en) 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid dosage unit
JP5645835B2 (en) 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated N- (4- (7-azabicyclo [2.2.1] heptane-7-yl) -2- (trifluoromethyl) phenyl) -4-oxo-5- (trifluoromethyl) -1,4-dihydro Solid form of quinoline-3-carboxamide
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
ES2483690T3 (en) * 2008-10-23 2014-08-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2009308232B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010078103A1 (en) 2008-12-30 2010-07-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
HUE038854T2 (en) 2009-03-20 2018-12-28 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2010108162A1 (en) * 2009-03-20 2010-09-23 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
JP5793496B2 (en) 2009-09-17 2015-10-14 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Process for preparing azabicyclic compounds
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
CA2778493A1 (en) 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
KR20120104554A (en) 2009-10-23 2012-09-21 버텍스 파마슈티칼스 인코포레이티드 Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
EP2547658A1 (en) 2010-03-19 2013-01-23 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PL2826776T3 (en) 2010-03-25 2021-05-31 Vertex Pharmaceuticals Incorporated Solid dispersion of amorphous form of (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012026257A2 (en) 2010-04-07 2017-03-14 Vertex Pharma solid forms of 3- (6- (1- (2-, 2-difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
BR112012026255A2 (en) 2010-04-07 2017-03-14 Vertex Pharma 3- (6- (1- (2-, 2-Difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid pharmaceutical compositions and administration thereof
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
CN105130948A (en) 2010-04-22 2015-12-09 弗特克斯药品有限公司 Pharmaceutical compositions and administrations thereof
AU2011242457A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2560650A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US20110288122A1 (en) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Pharmaceutical Compositions and Administrations Thereof
US8404849B2 (en) 2010-05-20 2013-03-26 Vertex Pharmaceuticals Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
IN2014KN00885A (en) 2011-11-08 2015-10-02 Vertex Pharma
ME03464B (en) 2012-01-25 2020-01-20 Vertex Pharma Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
AR092857A1 (en) 2012-07-16 2015-05-06 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF (R) -1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) -N- (1- (2,3-DIHYDROXIPROPIL) -6-FLUORO-2- ( 1-HYDROXI-2-METHYLPROPAN-2-IL) -1H-INDOL-5-IL) CYCLOPROPANCARBOXAMIDE AND ADMINISTRATION OF THE SAME
SG11201503365YA (en) 2012-11-02 2015-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
SG11201702817SA (en) 2014-10-06 2017-05-30 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Handbook of Chemistry and Physics"
"March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS
ARIDOR M ET AL., NATURE MED., vol. 5, no. 7, 1999, pages 745 - 751
BROSS P. ET AL., HUMAN MUT., vol. 14, 1999, pages 186 - 198
CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369
DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528
DEAN, M. ET AL., CELL, vol. 61, 1990
E. L. ELIEL, S. H. WILEN: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, pages: 868 - 870
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO.
GONZALEZ, J. E., K. OADES ET AL.: "Cell-based assays and instrumentation for screening ion-channel targets", DRUG DISCOV TODAY, vol. 4, no. 9, 1999, pages 431 - 439
GONZALEZ, J. E., R. Y. TSIEN: "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer", CHEM BIOL, vol. 4, no. 4, 1997, pages 269 - 77
GONZALEZ, J. E., R. Y. TSIEN: "Voltage sensing by fluorescence resonance energy transfer in single cells", BIOPHYS J, vol. 69, no. 4, 1995, pages 1272 - 80
GREGORY, R. J. ET AL., NATURE, vol. 347, 1990, pages 382 - 386
J. JACQUES ET AL.: "Enantiomers, Racemates And Resolutions", 1981, JOHN WILEY & SONS, pages: 251 - 369
J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
JERRY MARCH: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 1992, JOHN WILEY & SONS, pages: 14 - 16,18-19
JERRY MARCH: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 1992, JOHN WILEY & SONS, pages: 339 - 357
KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451
KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080
MORELLO, JP ET AL., TIPS, vol. 21, 2000, pages 466 - 469
PASYK, FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50
QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727
RICH, D. P. ET AL., NATURE, vol. 347, 1990, pages 358 - 362
RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1066 - 1073
RUTISHAUSER, J. ET AL., SWISS MED WKLY, vol. 132, 2002, pages 211 - 222
SHASTRY, B.S. ET AL., NEUROCHEM. INTERNATIONAL, vol. 43, 2003, pages 1 - 7
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11084804B2 (en) 2005-11-08 2021-08-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10987348B2 (en) 2006-04-07 2021-04-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10239867B2 (en) 2006-04-07 2019-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
US9725440B2 (en) 2007-05-09 2017-08-08 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US9776968B2 (en) 2007-12-07 2017-10-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US12065432B2 (en) 2007-12-07 2024-08-20 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US10597384B2 (en) 2007-12-07 2020-03-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9840499B2 (en) 2007-12-07 2017-12-12 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2444120A1 (en) 2007-12-10 2012-04-25 Novartis AG Spirocyclic amiloride analogues as ENac blockers
EP2520574A1 (en) 2007-12-10 2012-11-07 Novartis AG Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases
US9751890B2 (en) 2008-02-28 2017-09-05 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
US7713965B2 (en) 2008-02-29 2010-05-11 Vetoquinol Sa 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US8071590B2 (en) 2008-07-09 2011-12-06 Vetoquinol Sa 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US11052075B2 (en) 2010-04-07 2021-07-06 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10076513B2 (en) 2010-04-07 2018-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2012035158A1 (en) 2010-09-17 2012-03-22 Novartis Ag Pyrazine derivatives as enac blockers
EP3045912A1 (en) 2011-12-19 2016-07-20 UMC Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
US11035852B2 (en) 2011-12-19 2021-06-15 Umc Utrecht Holding, B.V. Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells
WO2013093812A2 (en) 2011-12-19 2013-06-27 Umc Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
US11988661B2 (en) 2011-12-19 2024-05-21 Umc Utrecht Holding, B.V. Rapid quantitative test to diagnose polycystic kidney disease
US10006904B2 (en) 2011-12-19 2018-06-26 Umc Utrecht Holding B.V. Rapid quantitative assay to measure CFTR function in a primary intestinal culture model
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2013140319A1 (en) 2012-03-19 2013-09-26 Novartis Ag Crystalline form of a succinate salt
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
WO2014086687A1 (en) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova A cftr corrector for the teatment of genetic disorders affecting striated muscle
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10758534B2 (en) 2014-10-06 2020-09-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10258624B2 (en) 2014-10-06 2019-04-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9642831B2 (en) 2014-10-31 2017-05-09 Abbvie S.Á.R.L. Substituted chromanes and method of use
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
WO2017173274A1 (en) * 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2017240685B2 (en) * 2016-03-31 2021-08-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11186566B2 (en) 2016-09-30 2021-11-30 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11866450B2 (en) 2018-02-15 2024-01-09 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020049189A1 (en) 2018-09-09 2020-03-12 Qanatpharma Gmbh Use of cftr modulators for treating cerebrovascular conditions
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
US11591350B2 (en) 2019-08-14 2023-02-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
US12122788B2 (en) 2019-08-14 2024-10-22 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators

Also Published As

Publication number Publication date
US20140121381A1 (en) 2014-05-01
KR20080053297A (en) 2008-06-12
JP2014156494A (en) 2014-08-28
EP1912983A2 (en) 2008-04-23
AU2006279810B2 (en) 2011-10-27
IL189178A0 (en) 2008-06-05
CA2618057A1 (en) 2007-02-22
JP2009504670A (en) 2009-02-05
ATE512145T1 (en) 2011-06-15
MX2008002019A (en) 2008-04-16
US20150126566A1 (en) 2015-05-07
JP5850983B2 (en) 2016-02-03
AU2006279810A1 (en) 2007-02-22
RU2008109031A (en) 2009-09-20
NZ566208A (en) 2010-09-30
US8962856B2 (en) 2015-02-24
WO2007021982A3 (en) 2007-05-03
US8586615B2 (en) 2013-11-19
US20120010257A1 (en) 2012-01-12
US7999113B2 (en) 2011-08-16
US20080161371A1 (en) 2008-07-03
US9351962B2 (en) 2016-05-31
JP2015127347A (en) 2015-07-09
JP2013018795A (en) 2013-01-31
US9856248B2 (en) 2018-01-02
EP1912983B1 (en) 2011-06-08
NO20081280L (en) 2008-05-09
US20170174675A9 (en) 2017-06-22
US20160237079A1 (en) 2016-08-18
JP5143738B2 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
US9856248B2 (en) Modulators of cystic fibrosis transmembrane conductance regulator
US7407976B2 (en) Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
ES2367844T3 (en) MODULATORS OF THE REGULATOR OF THE TRANSMEMBRANE CONDUCTANCE OF THE CHYSICAL FIBROSIS.
KR20110082188A (en) Modulators of atp-binding cassette transporters
EP1680411A2 (en) Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
AU2015228930B2 (en) Heteroaryl derivatives as CFTR modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680037556.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 189178

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2618057

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006801307

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 540/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008526246

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/002019

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006279810

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 566208

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008109031

Country of ref document: RU

Ref document number: KR

ENP Entry into the national phase

Ref document number: 2006279810

Country of ref document: AU

Date of ref document: 20060811

Kind code of ref document: A